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ABSTRACT 
Previous studies of molecular prognostic markers following resection for exocrine pancreatic 
cancer have produced conflicting results.  The aim of this study was to undertake a 
comprehensive analysis of potentially useful markers in a large multicentre patient population 
and compare these markers with standard pathological prognostic variables.  Formalin fixed, 
paraffin-embedded specimens of pancreatic ductal adenocarcinoma were analysed from 157 
patients (100 men and 57 women with a median [range] age of 60 [33-77] years) who had 
undergone pancreatectomy.  Immunhistochemistry was used to detect expression of p16INK4, 
p53, p21WAF1, cyclin D1, c-erbB-2 and c-erbB-3.  In a selected number of p53 positive and 
negative staining cases, mutational analysis was undertaken using DNA obtained from 
microdissected specimens.   Mutations in codons 12 and 13 of the K-ras oncogene were 
detected by SSCP and sequencing following DNA extraction and amplification by PCR.  The 
median [range] survival post-resection was 12.5 [3-83] months.  Abnormalities of p16INK4, 
p53, p21WAF1, cyclin D1, c-erbB-2 and c-erbB-3 expression were found in 87%, 41%, 75%, 
72%, 33% and 57% of cases, respectively.  There was no significant correlation between 
expression of any of these markers and patient survival.  K-ras mutations were found in 73 
(75%) out of 97% cases with amplifiable DNA.  The presence of K-ras mutation alone did 
not correlate with survival, but there were significant differences in survival according to the 
type of K-ras mutation (p=0.0007).  Reduced survival was found in patients with GaT, cGT 
and GcT K-ras mutations compared to GtT, aGT and GaC mutations.  In conclusion survival 
was associated with the type of K-ras mutation but not the expression of p16INK4, p53, p21 
WAF1, cyclinD1, c-erbB-2 and c-erbB3.  
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1.1     Introduction 
Pancreatic cancer is often a symptomatically silent disease and commonly presents at an 
advanced stage.  The lack of currently available methods for cure emphasises the need to 
identify the risk factors that in turn may lead to a clue to the aetiology of this disease. 
 
1.2   Incidence 
Pancreatic Ductal Adenocarcinoma (PDAC) is the fourth commonest cause of cancer related 
death in the USA, accounting for just over 40,000 cases and an almost equal number of 
deaths (Jemal, A et al, 2009).  In the USA the age adjusted mortality rate for PDAC between 
200-2010 was 12.2 in a population of 100,000 in both sexes (SEER Cancer Statistics Review, 
1975-2010, November, 2012).  In 2008, the tumour accounted for about 8,000 deaths in 
England and Wales (Office For National Statistics, 2010).   In a large epidemiological study 
of pancreatic cancer in the West Midlands between 1980 and 1984, Bramhall et al found the 
incidence was 10.1 per 105 population in men and 8.4 per 105 in women (Bramhall SR et al 
(1995). In Europe, about 30,000 cases of pancreatic cancer occur each year representing the 
sixth commonest cause of cancer related death (Parkin DM et al, 1999; Pisani P et al, 1999,).  
The incidence in the other developed countries is similar (Ahlgren JD, 1996; Swedish 
National Board of Health and Welfare (SNBHW), 1998; Kleeff J et al, 2000).  World-wide 
approximately 185,000 new cases are reported annually but it is important to take into 
account that the percentage of cases lacking a histological confirmation varies widely, up to 
85% in some areas (Parkin DM et al 1993, Porta M et al, 2000).   
 
 
1.3  Risk factors for pancreatic cancer 
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Currently, there are no screening tests for the disease but there are a number of environmental 
and genetic risk factors that have been identified.  Smoking has been reported to be 
associated with pancreatic cancer in about a third of cases in the United Kingdom (Parkin 
DM, 2010).   Additionally, smokers have been reported to acquire the disease about ten years 
younger than smokers (Parkin DM, 2011).  N-nitroso compounds in tobacco are postulated to 
be carried in the blood stream and then affect the pancreas gland (Iodice S et al, 2008).  
Hereditary Pancreatitis is associated with an earlier onset of PADC and where a family 
history also exists, the risk ratio has been reported at about fifty (Lowenfals AB, 2000).  
Other risk factors identified are pancreatitis (Lowenfels AB, 2000, Rebours V, 2011)), 
diabetes mellitus (Stolzenburg-Solomon, RZ, 2005), obesity (Aune, D et al, 2012), alcohol 
consumption (Michaud DSet al, 2001) and diet (Table 1.5; Larsson SC et al, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.1  Genetic syndromes associated with pancreatic cancer 
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1.4.1.1  Familial pancreatic cancer (FPC) 
This is rare, but inheritance may play a small part in its etiology.  Studies have shown that 
about 10 per cent of patients with pancreatic cancer have a family history of the disease (Shi 
C et al, 2009; Permute-Wey J et al, 2009).  The increased risk of pancreatic cancer in 
pancreatic cancer prone families is associated either as part of a known syndrome, where 
predisposition to pancreatic cancer is a one part of the cancer spectrum that these families 
develop. Alternatively it can occur as the only type of cancer that is inherited.  To make a 
diagnosis of this syndrome, the following is required; At least two first degree relatives 
(parents or siblings) with the disease; One first degree relative found with the cancer at 
50years or less and at least two or more second degree relatives with PDAC (Finch M et al, 
1997; Bretnall TA et al, 2000; Klein AP et al, 2004).  Klein and colleagues used this criteria 
and other data to develop a risk assessment model called PancPro (Wang et al, 2007) to 
assess an individual’s risk. 
 
1.4.1.2  Hereditary pancreatitis (HP) and pancreatic cancer 
This is an autosomal dominant disorder with similar gender prevalence. Usually recurring 
abdominal pain in childhood is perhaps ignored or not fully investigated until chronic 
pancreatitis is diagnosed in early teens or even later in life (Finch M et al, 1997; Paolini O et 
al, 1998; Whitcomb DC et al, 1996).  According to one report, individuals with chronic 
pancreatitis are many times more likely to develop pancreatic cancer when compared to the 
normal population (Chowdhury P and Rayford PL, 2000).  In a French study from a single 
centre, a risk of 13.7 was reported (Madeura J et al, 1998) while an American study found a 
risk of 4 (Bansal P and Sonnenberg A, 1995) and a Swedish study found this to be 8 
(Karlsson BM et al, 1997). There is no consensus, however with Bansal et al expressing 
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doubts as to whether there could be  misdiagnosis of pancreatitis for  cancer could  (Bansal, P 
et al, 1995).   
A lot of interest was generated when Whitcomb et al, reported a mutation in the cationic 
trypsinogen gene PRSS1 associated with hereditary pancreatitis with the hope that a better 
understanding of the disease could be explained (Whitcomb DC et al, 1996).  Whitcomb et al 
suggested that the mutation appears to make the protein resistant to trypsin cleavage.  The 
consequence of this process is a protein that is auto activated with inappropriate intracellular 
accumulation of the proteolytic enzyme trypsin and leading to digestion of the pancreatic 
tissue. The probable risk of developing cancer in one’s lifetime has been suggested to be 
about 40% in elderly never smoking individuals (Lowenfels AB et al, 1997).  In those 
individuals with non-hereditary pancreatitis, the risk of developing pancreatic cancer to the 
surprise of some investigators appears to be higher [4% at 20 years from the diagnosis of 
chronic pancreatitis (Lowenfels AB et al, 1993].  An added diagnostic problem is that 
inability to identify mutations in the PRSS1 gene in clinically suspected individuals does not 
in itself eliminate the diagnosis.  In fact at least one report has stated that about a third of 
hereditary pancreatitis families test negative for the known mutations (Steinberg WM et al, 
1999).  
 
1.4.1.3  BRCA2 gene germline mutation and pancreatic cancer      
Carriers of this mutation have a ten-fold higher risk of developing pancreatic cancer than the 
general population (Bretnall TA et al, 2000; Liede A et al, 2004).   Mutations appear to occur 
often in Ashkenazi Jews (McClain, MR et al, 2005).  The estimated risk of acquiring 
pancreatic cancer by the age of 75 is 7% in the carriers as compared to 0.85% in the general 
population (Ozcelik H et al, 1997).  Bretnall et al have reported that loss of heterozygosity in 
the BRACA 2 gene is a later event in tumourigenesis.  They explained this by the observation 
 16 
that the pancreatic intraepithelial neoplasia lesions showed minimal to no loss of 
heterozygosity alone the different grades of the lesions (Bretnall TA et al, 2001).     
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1.5   Familial Cancer Syndromes  
1.5.1  Familial atypical multiple mole melanoma syndrome (FAMMM) and 
CDKN2A/p16 germline mutations 
This is a rare autosomal dominant inherited disorder associated with multiple atypical naevi, 
malignant melanomas (cutaneous or ocular) and caused by germline mutations in p16 
Pancreatic adenocarcinoma is probably the second most common cancer in FAMMM 
families. In several chromosome 9p-linked FAMMM families, a mutation in the cell cycle 
inhibitor gene CDKN2A//p16/MTS1 has been found to co segregate with both melanoma and 
pancreatic cancer (BorgA et al, 2000).  In a study among 200 members from nine Dutch   
families with FAMMM, the observed/expected ratio for pancreatic cancer was 13.4 to 1.0 
(Bergmann W et al, 1990).   Affected family members had an incidence of pancreatic cancer 
29 times that of the general population.  Using an in vitro assay, Goldstein et al made a 
distinction between FAMMM kindreds with a functionally defective p16 protein and the 
FAMMM kindreds without a defective p16 gene product (Goldstein AM et al, 2000).  A 22-
fold excess risk of pancreatic cancer (standardised incidence ratio 21.8; 95% CI, 8.7-44.8) 
was restricted to FAMMM families with impaired p16 function.  Other reports which 
confirmed an increased risk of pancreatic cancer in melanoma-prone kindreds have also 
identified CDKN2A/p16/MTS1 germline mutations (Whelan AJ et al, 1995; Lal G et al, 
2000).  Not all patients with the germline CDKN2/p16/MTS1 mutations come from the 
classic FAMMM families.  Twenty-one kindreds with familial pancreatic cancer without the 
FAMMM syndrome were screened for germline mutations in CDKN2A/p16/MTS1 and in 
the related CDK4 gene.  A germline CDKN2/p16/MTS1 mutation was identified in only one 
family (5% of kindreds) and one of the affected carries also had a melanoma (Platz A et al, 
1997). 
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1.5.2  Hereditary non-polyposis colorectal carcinoma (HNPCC):  Lynch    syndrome  
11 and pancreatic cancer 
The genetic abnormality in this disorder is that of inability to repair damaged DNA usually 
performed by the mismatch repair genes; hMSH2, hMLH1, nPMS1 and 2.  Individuals with 
this condition are at risk of developing colon cancers, usually on the right side as well pelvic 
cancers in females and pancreatic cancer (Goggins M et al, 1998). Bretnall et al have reported 
that the actual number of hereditary pancreatic cancers that occur in this autosomal 
dominantly inherited tumours is less than that seen with mutations occurring  in other genes, 
for example from the  p16 and BRACA2 genes (Bretnall TA, 2000).  
 
 
 
 
1.5.3  LKB1/STK11 and Peutz- Jeghers syndrome (PJS)  
Peutz-Jeghers syndrome is rare and associated with numerous polyps in the gastrointestinal 
tract and pigmented lesions in and around the mouth. Implicated in this condition is an 
aberration in the LKB1/SK11 gene (Hemminki A et al, 1998, Hearle, N et al, 2006). 
Pancreatic cancer is also known to occur with this genetic abnormality (Hizawa K et al, 1993; 
Hearle et al, 2006).   A review of 210 patients with Peutz-Jeghers syndrome reported that the 
risk of pancreatic cancer was increased 132 fold when compared with the general population 
(Giardiello FM et al, 2000).     The exact risk of patients with PJS patients for pancreatic 
cancer development is unclear (Bretnall TA, 2000), however, in the report by Su et al, 53 PJS 
patients reported in four independent studies, averaged an 11% lifetime risk of developing 
pancreatic tumors (Su GH et al, 1999). 
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1.5.4  Ataxia telangectasia 
This is an autosomal recessive condition with loss of function of the ATM gene.  The ATM 
protein is essential for the signaling of DNA damage to p53 and loss may be associated with 
an increased risk of PDAC (Taylor AM, 1992). 
 
1.5.5   Li-Fraumeni Syndrome (LFS) 
LFS is a rare condition in which the genetic abnormality is a mutation in the p53 gene and 
has been reported to predispose to pancreatic adenocarcinoma (Hisada M et al, 1998). 
 
 
 
 
 
 
 
1.6  Diabetes mellitus 
The case for diabetes mellitus as a cause of pancreatic cancer has been debated since Marallie 
first reported this association in the late nineteenth century (Marallie et al, 1893).  It is still 
not known whether diabetes is a true aetiologic factor or an early manifestation of the tumour 
(Warshaw AL et al, 1992; Anderson KE et al, 1996).   Gullo et al have found that diabetes 
mellitus predates the diagnosis of pancreatic cancer by up to two years in more than 20% of 
patients (Gullo L et al, 1994) and it has also been reported that impaired glucose tolerance is 
present in up to 75% of patients with pancreatic cancer at diagnosis (Permert J et al, 1993).  
In these patients impaired glucose tolerance is characterised by peripheral resistance to high 
circulating levels of insulin (Permert J et al, 1993) and in cases where the primary tumour is 
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resected glucose tolerance improves despite a reduction in serum insulin levels (Permert J et 
al, 1993).  The case that long standing diabetes is a risk factor for pancreatic cancer is 
supported by two large cohort studies analysing the association between diabetes and 
pancreatic cancer over 10 or more years (Chow WH et al, 1995; Calle EE et al, 1998).  After 
an initial hospitalisation for diabetes mellitus, the patients had an increased risk of developing 
pancreatic cancer and this risk persisted for more than 10 years (Chow WH et al, 1995).  This 
increased risk however was only seen in patients with non-insulin dependent diabetes or in 
those patients whose diabetes was diagnosed after the age of 40 years.  Gapstur   has recently 
reported on evidence for a positive dose-response relationship between post load glycaemia 
and pancreatic cancer mortality among individuals who were initially not diabetic (Gapstur 
SM et al, 2000).  
 
 
1.7  Diet 
Numerous studies have looked at various diets that may be implicated in pancreatic cancer 
but, these are varied and report a weak association (see Table 1.5).  
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1.8  Summary 
The incidence of pancreatic cancer is rising and has a devastating mortality that almost equals 
its incidence.   Older age groups are mainly affected uncommon below the age of 40 years 
and rare in children.  Wide geographical and racial variations in incidence are seen.  The 
highest rates age-adjusted rates are found in Western countries, in those of Polynesian extract 
and USA blacks, whilst the lowest incidences are found in India.  The roles of alcohol and 
coffee in the pathogenesis of pancreatic cancer are controversial.  The relation between 
diabetes mellitus and pancreatic cancer is also controversial and possibly may reflect 
pancreatic endocrine insufficiency secondary to the cancer rather than the other way round.  
Hereditary factors do play a role in pancreatic carcinogenesis and the extent of this 
contribution is under intense investigation.  There is strong evidence implicating cigarette 
smoking and pancreatic cancer with a relative risk of about 2.0:1.0.  Those who stop smoking 
for many years may have their risk of developing pancreatic cancer reduced so that this is 
comparable to non-smokers.  Dietary habits may play a role in pancreatic cancer.  Whereas a 
western type diet rich in animal protein, saturated and unsaturated fats increases the relative 
risk, a vegetarian type diet high in fruits, vegetables and pulses appears to exert a protective 
effect.  Occupational exposure to carcinogens may play a small role in the aetiology of 
pancreatic cancer. The management of individuals with inherited predisposition for 
pancreatic cancer is controversial and is still not clear but options range from close 
observation to aggressive surgery.   Some have suggested that screening should start at least 
ten years before the earliest age of onset of pancreatic cancer or when suspicious symptoms 
are found (Brentnall TA et al, 2000).   Given the lack of more than a few hard aetiological 
factors that can explain the development of pancreatic cancer the future in its understanding 
lie in the identification of prognostic molecular markers with potential for screening, early 
diagnosis and the development of chemotherapeutic agents.  
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Table 1.1.   Five-year survival rates from single institution 
 Institution Authors Year published Overall 5-year 
survival rate (%) 
Sloan Kettering Geer, RJ et al 1993 24 
Mannheim Trede, M et al 1990 24 
Johns Hopkins Yeo, CJ et al 1995 21 
Kyoto, Japan Manabe, T et al 1990 14 
Erlangen Declore, R et al 1996 13 
Padua Declore, R et al 1996 12 
Erlangen Gall, FP et 1991 11 
Mayo Clinic Nitecki, SS et al 1995 6.8 
Munich Roder, JD et al 1992 6 
Amsterdam Allema, JH et al 1995 0 
 
Adapted from Finch MD et al (1999) in “ Pancreatic Diseases: towards the year 2000”. C.D 
Johnson and C.W. Imrie (Eds). 
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Table 1.2.   Pancreatic cancer statistics per 100,00  (Cancer  Research 2010) 
 
Pancreatic 
cancer sta 
males females Persons  Country year 
New cases  
A year 
4189 4274 8463 UK 2010 
Incidence  rate 
per 100,000 
10.6 8.4 9.4 UK 
 
 
Number of 
deaths per year 
3875 4029 7901  2010 
Mortality rate 
per 100,000 
9.8 7.7 8.6 UK  
One year 
survival 
17.4% 19.1% 18.2% England  2005-9 
5 year survival 3.6% 3.8% 3.7% England  and 
Wales 
2007 
10 year survival 2.9% 2.7% 2.8% England  and 
Wales 
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Table 1.3. SEER 2002-10 Age - adjusted incidence rate per 100,000 population (USA) 
Race/Ethnicity Male    Female 
All races            13.9    10.9 
White   13.8    10.7 
Black   17.6    14.3 
Asian/pacific  10.4    8.9 
American Indian 11.4    10.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25 
Table 1.4   Genetic conditions associated with pancreatic adenocarcinoma 
 
Disease      (chromosome)    
Familial Pancreatic cancer    (4q32 -34) Lowenfels AB et al, 2000 
Hereditary Nonpolyposis colon cancer  (2, 3)  Tersmette, AC et al 2001 
Familial adenomatous polyposis    (5q12-21) Murphy , KM et al,2002  
Hereditary pancreatitis    (7q35) Ghadirian, P et al, 2003 
Familial atypical malignant melanoma  (9p21)  Vasen, HF et al, 2000 
BRACA 2      (13)  Murphy KM et al, 2002 
Peutz- Jeghers syndrome    (19q)  Su, GH et al 1999 
Ataxia telangiectasia     (11q)  Maisonneuve, P et al, 2003 
Li – Fraumeni syndrome    (17p13.1) 
 
Adapted from (Jpn J Clin Oncol 2004; 34(5).   All these diseases are associated with the 
formation of pancreatic cancer to a varying degree. 
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Table 1.5.   Cigarette smoking and pancreatic cancer  
Reference 
 
Year Cohort Study  Mortality ratio 
Falk et al 1988 Louisiana whites males 
1 to 5 cigarettes/day 
16-25 per day 
>25 per day     
 
1.5 
1.9 
2.03 
Gold et al 1985 Baltimore both sexes 
ever smoked 
never quit smoking 
 
1.2 to 1.4 
1.7 to 2.7 
Heuch et al 1983 Norwegian males 1.13to 2.13 
Hirayama et al 1977 both sexes 1.83 
Doll and Peto 1976 British male physicians 1.6 
Cedarlof et al 1975 Swedish males 
Swedish females 
3.1 
2.5 
Hammond et al 1966 US men (age 45- 64 yrs.) 
US men (age 65 -79yrs) 
2.69 
2.17 
Wynder et al 1973 US Hospital-based 
 Males 
 Females 
 
2.67 
2.1 
Best  1966 Canadian veterans 2.1 
Kahn et al 1966 US veterans 1.83 
 
 Significant at p<0.05 Adapted from Ahlgren, JD (1996).  
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Table 1.6.    Possible protective foods for pancreatic cancer         
Reference Diet 
Fernandez, E et al, 1996 
Gold EB, 1995 
Shibata, S et al, 1994 
Thouez JP et al, 1990 
Ohaba, S, et al, 1996 
Ji, BT, et al, 1991 
Lyon, JL, et al, 1993 
Bueno de Mesquita, HB, et al, 1990 
Falk, RT et al, 1988 
Ghadirian, P, et al, 1991 
Olsen, GW, et al, 1991 
Mills, PK, et al, 1993 
 
 
 
Fruits and vegetables 
 
  
Watanapa, P, et al, 1997 
Muscat.JE, et al, 1996 
Adlercreutz ,H et al, 1996 
Stephens, FO, 1997 
Japanese foods 
Plant protein 
Soy 
Other Legumes 
 
 
 
 
 
 
  
 28 
Chapter 2         Pathology of pancreatic cancer 
 
 
 2.1 Introduction 
Pancreatic tumours were first reported by Bigsby (1835) and later by Mondiere (1836).  
Malignant epithelial tumours account for over 90% of primary non-endocrine pancreatic 
tumours (Cubilla AL and Fitzgerald PF, 1978).  Benign neoplasms are usually of the islet cell 
variety and are uncommon. Primary pancreatic sarcomas and lymphomas are occasionally 
reported (Kloppel G, 1984).   Ductal adenocarcinoma has an extremely poor prognosis even 
in the resected cases, however an accurate histological diagnosis is important because there 
are rare types of tumours that have a good prognosis following resection.  The histological 
type and stage of pancreatic tumours must be established at presentation to allow for the 
assessment of prognosis and appropriate treatment. Pre-malignant lesions are now classified 
by the term “pancreatic intraepithelial neoplasia” (Pan IN), mucinous cystic neoplasia (M 
CN) and intraduct pancreatic mucinous neoplasia (IPMN). 
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Anatomy of Pancreas gland 
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Pancreatic Intraepithelial Neoplasia (Pan IN) 
The better understanding of the progression of precursor lesions to invasive neoplasia in 
several organs has resulted in a number of standard classification systems (Haggitt RC, 1994; 
Ellis IO, 1999).  For example, a histologic classification system for dysplasia arising in 
inflammatory bowel disease established a basis for a number of clinical, pathologic and 
molecular studies that in turn have led to a better understanding of neoplastic progression in 
these patients (Rabinovitch PS et al, 1999).  Knowledge of well-defined premalignant lesions 
of some tumours has resulted in screening of several tumours with improved outcome (Boyes 
DA et al, 1970; Kronborg O et al, 1996).    Precursor lesions of the pancreas have previously 
been reported by different names e.g. lesions, metaplasia, hyperplasia, dysplasia and 
neoplasia (Bretnall TA et al, 1994; Brockie E et al, 1998; Klimstra D and Longneker DS, 
1994).  To address this problem a group of pathologists with an interest in pancreatic disease 
met in Utah, USA in 1999 (Kern SE et al, 2001).  A modification of the Pan IN terminology 
originally proposed by Klimstra and Longnecker (Klimsrta D and Longnecker, 1994) was 
agreed upon (Figure 2.1).  This new terminology took into account the growing evidence to 
support a progression model for pancreatic cancer.  The classification system is based on 
clinical and morphologic observations and the evidence available from molecular genetic 
studies of duct lesions and their associated infiltrating adenocarcinomas (Caldas C et al, 
1994; Digiuseppe JA et al, 1994; Day JD et al, 1996; Goggins M et al, 2000).  The stepwise 
nature of the grading system correlates with mutational events found in duct lesions such that 
the genetic alterations in the higher grades of Pan IN approach those found in the infiltrating 
adenocarcinomas (Hruban RH et al, 2000, Hruban , RH et al, 2004, Singh, M et al, 2007)).  
The system also applies to duct lesions that involve the smaller calibre ducts and takes into 
account that some ducts may have changes of more than one Pan IN grade.  In these cases, it 
was agreed that the lesions should be graded on the highest component of the lesion.   
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Figure 2.1.   Progression model for pancreatic cancer (Wilentz RE et al, 2000).  The 
progression from low grade Pan IN to a higher grade Pan IN is associated with acquisition of 
genetic changes. 
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2.3  Classification of pancreatic cancer 
Human pancreatic tumours are classified as exocrine or endocrine with the former further 
classified according to the UICC/TNM classification (Sobin LH and Wittekind Ch, 1997).   
 
2.3.1  Ductal carcinoma of the pancreas 
PDAC is believed to arise from the ductal epithelium of the pancreas (Cubilla AL et al 
(1976); Kozuka S et al (1982), although some studies suggest a possible origin from 
transdifferentiated pancreatic acinar cells (Longnecker DS et al, 1980).  Alternatively, a 
hamster model has suggested that the cell of origin may actually derive from the endocrine 
portion of the pancreas, or even multipotent stem cells (ref).  Carcinoma of duct cell origin is 
the most common malignant tumour of the pancreas and the general term ‘carcinoma of the 
pancreas’ refers to this.  Sixty-five percent of carcinomas are located within the head of 
pancreas.  The remaining tumours are situated within the body (15%), tail (10%) or multiple 
subsites within the pancreas (10%).  Tumours of the body and tail are usually clinically silent 
until large and usually present late with severe back pain, anorexia and dramatic weight loss.  
When they typically obstruct the common bile duct and present with obstructive jaundice 
often before distant spread has occurred.   
Macroscopically, the tumour is usually a grey white, schirrous, nodular growth that is poorly 
demarcated with irregular edges.  The cut surface may show scattered red or brown areas of 
necrosis or haemorrhage and locules of turbid grey or brown liquid may be present.  In most 
cases, obstruction and dilatation of proximal main pancreatic duct is present resulting in 
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secondary chronic pancreatitis with atrophy in the remainder of the gland.  In such cases the 
tumour margins can be indistinguishable and it is often difficult to differentiate between a 
carcinoma and chronic pancreatitis.  Mucinous non-cystic adenocarcinoma of the pancreas 
appears grossly mucinous and sometimes the tumour may form a papillary mass within an 
extremely dilated main pancreatic duct presenting as an intraductal carcinoma. 
 
2.3.2     Histological features 
Over 80% of exocrine pancreatic cancers show ductal differentiation and are termed 
pancreatic ductal adenocarcinoma (PDAC).  They are characterised by the presence of 
glandular structures or in poorly differentiated cases, a cord-like or diffuse pattern.  Glands 
are of a variable size and shape with columnar epithelium and irregular nuclei.  Mucin is 
produced in a variable amount.  With poorly differentiated carcinomas signet-ring cells with 
intracytoplasmic lumina occur and a sarcomatous pattern may be seen.  Frequently there is an 
intense desmoplastic stromal reaction.  They must be distinguished from carcinomas of the 
intrapancreatic bile duct, ampulla of Vater or duodenal mucosa that are frequently resectable 
and tend to have a better prognosis.  
 
2.3.3   Variants of pancreatic ductal adenocarcinoma (PDA) 
There are several uncommon tumour types, which may be considered to be variants of 
PDAC.  
2.3.3.1   Squamous and adenosquamous cell carcinomas  
 These tumours account for 1% and 2% of cases respectively and contain purely squamous or 
a mixture of adenocarcinoma and squamous components. Both types are generally more 
aggressive than PDAC.   
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2.3.3.2  Small cell carcinomas 
Occur in approximately 1% of cases and are composed of sheets of small basophilic cells, 
which may result in this tumour being mistaken for lymphoma.  Small cell carcinoma cells 
however, demonstrate typical neuroendocrine features including positive staining for 
calcitonin and chromogranin a similar to that seen in small cell carcinomas of the lung.  
These tumours have an extremely poor prognosis. 
 
2.3.3.4   Pancreaticoblastoma /Infantile tumours 
These tumours are an extremely rare variant of PDAC seen predominantly in infants and 
children under the age of seven years.  Macroscopically, cystic changes may be observed.  
This tumour is composed of epithelial tissue with acinar cell differentiation, squamoid cell 
nests and occasional neuroendocrine cells, sometimes with a pronounced mesenchymal 
component and has a more favourable prognosis.  
 
2.3.3.5     Acinar cell carcinoma of the pancreas 
Acinar cell carcinomas are most commonly seen in elderly patients and are rare accounting 
for 1-2% of cases.  Grossly, they are large, soft tumours with areas of necrosis.  
Microscopically, they are characterised by typical groups of polygonal acinar cells with 
abundant eosinophilic granular cytoplasm in which 1-amylase, lipase, trypsin and 
chymotrypsin can be demonstrated by immunohistochemistry.  High serum lipase levels may 
be seen and may result in subcutaneous fat necrosis.  In poorly differentiated tumours, poorly 
formed acini can be misdiagnosed as endocrine tumours.  Very rarely, cystic appearances are 
observed known as acinar cell cystadenocarcinoma.  Some cases are associated with the 
paraneoplastic syndrome characterised by polyarthralgia, subcutaneous and interosseous fat 
necrosis and eosinophilia associated with an extremely poor prognosis. 
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2.4    Peri-Ampullary Tumours 
Ampullary epithelial neoplasms include benign (5%) and malignant (95%) tumours and 
account for up to 36% of surgically resectable pancreaticoduodenal tumours (Yamaguchi K 
and Enjoji M 1987).    Peri-ampullary tumours include tumours of the ampulla of Vater the 
intra-pancreatic bile duct, duodenal tumours involving the papilla and tumours of the head of 
the pancreas involving the ampulla.  It is very important to distinguish peri-ampullary cancers 
from carcinomas of the pancreas as a larger proportion are resectable and the prognosis tends 
to be better (Yamaguchi K and Enjoji M 1987, Talbot I et al 1988).    
Macroscopically, tumours may be classified as; intramural protruding, exposed protruding 
and ulcerated (Yamaguchi and Enjoji 1987).  Initially peri-ampullary tumours spread locally 
and are often small when diagnosed as early compression of the distal bile duct results in 
jaundice.  Resectability rates are therefore much higher, approximately 80% when compared 
with ductal carcinoma of the pancreas (Ihse I et al, 1993).  Histologically, adenomatous areas 
are often observed in the majority of malignant tumours and similarly foci of carcinoma 
frequently observed within adenomas, which has led to hypothesis that an adenoma-
carcinoma sequence may exist (Scarpa A et al 1994).  Kimura and Ohtsubo (1988) however 
suggest alternative pathogenetic mechanisms for the development of benign and malignant 
ampullary tumours as a proportion of cancers do not show any detectable adenomatous areas.   
 
2.5    Cystic tumours of the Pancreas     
There are four different types of these tumours with relatively similar features on the cell of 
origin, biology and on imaging.  The tumour arises in any part of the gland and is slow 
growing usually attaining a large size before detection.  Cystic tumours represent a particular 
diagnostic problem and the differentiation between pseudocysts, serous (usually benign) and 
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mucinous (potentially malignant) tumours is difficult but very important, as their 
management is different.  Patients usually present with an abdominal mass although they may 
present with pressure effects for example obstructive jaundice.  Management is by surgical 
exploration and resection if technically feasible.  
2.5.1      Serous cystadenomas 
Serous cystadenomas are glycogen rich microcystic adenomas that are usually benign.  They 
may be associated with other neoplasms and chronic disorders, the best recognised of which 
is the Von-Hippel Lindau syndrome.  Histologically they are well-circumscribed multicystic 
tumours most commonly seen in the proximal pancreas, which have a mean diameter of 7 
centimetres and a range of 2-25 centimetres.  Macroscopically serous cystadenomas consist 
of a collection of small cysts sometimes microscopic in size, lined by a low cuboidal 
epithelium.  Microcystic areas are separated by vascular fibrous stroma, which may be 
calcified producing a sunburst or stellate pattern on CT.  The epithelial cells are rich in 
glycogen and no mitotic activity, cellular atypia or dysplasia is observed within the 
epithelium.  Routine staining for mucin, chromogranin, neuropeptides, enteroendocrine 
peptides and carcinoembryonic antigen (CEA) are all routinely negative (Sarr MG et al, 
2001).  Almost all serous cystadenomas are benign and follow a benign course over many 
years although malignant change is occasionally seen (Pyke et al 1992; Kamei et al 1992).  
They are composed of multiple small (<2cm) cystic areas that resemble a bunch of small 
grapes and appear like a honeycomb-like appearance grossly and on imaging.  A starburst 
appearance with a centrally located calcified scar caused by a calcification of the central 
fibrous stroma is virtually pathognomonic but occurs in only about a third of patients.  The 
characteristic findings of stromal hypervascularity with predominance of small cystic areas, 
combined with an indolent course, lack of metastases or local invasion and an appropriate 
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clinical setting, allows the diagnosis of serous adenoma to be made with 95% accuracy.  
There are few reported cases and management should be conservative in most cases.   
 
 
 
 
2.5.2      Mucinous Cystic Neoplasms 
 Mucinous cystic neoplasms are very rare and represent a broad spectrum of related 
neoplasms ranging from benign cystadenomas with a real potential for malignant 
transformation to cystadenocarcinomas with an aggressive metastatic potential (Sarr MG et 
al, 2000).     A fifth of patients may have a history of pancreatitis while the rest are found 
during investigation for non-specific abdominal symptoms that usually are from a local mass 
effect.  It is important to differentiate this tumour from other cystic disorders because of its 
premalignant potential.  The presence of papillary fronds or septae with the cystic structures 
or an eccentric solid component within the wall of the cystic mass on ultrasonography or CT 
scanning is pathognomonic.  When present, calcification is peripheral unlike the central 
location with serous cystadenomas.   
Macroscopically, mucinous cystic neoplasms are different from their benign serous 
counterparts as cystic areas are often larger (>2cm) and contain less than six separate cysts.  
Most mucinous cystic neoplasms appear as multilocular tumours with smooth glistening 
surfaces that vary from a few centimetres to 25cm in diameter with a mean size of 8-10 cm. 
The cyst lumen often contains a thick sometimes-bloodstained mucoid material. Some are 
unilocular and some may contain large whitish nodules, which project into the lumen.  The 
malignant tumours are usually larger than the benign ones; show a marked female 
preponderance and approximately two-thirds are located within the body and tail of the 
pancreas.  
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Microscopic examination of the wall of the cyst reveals three distinct layers: an inner 
epithelium, a middle zone of mesenchymal stroma and an outer layer of hyaline connective 
tissue.  They are lined by a tall mucin secreting columnar epithelium, the cells of which often 
stain positive for CEA and somatostatin supporting their origin from ductal or stem cells.  
These neoplasms are notorious for containing multiple areas of discontinuous epithelium and 
differing degrees of differentiation and dysplasia within the mucinous epithelium.  Within the 
same tumour, variations within the spectrum of cystic neoplasms may be seen with areas of 
atypia, dysplasia, carcinoma in situ and overt invasive carcinoma (Warshaw A et al 1990).  
Albores-Saavedra et al (1990) considered true benign mucinous tumours to be very rare, but 
difficulties in interpretation arose as the tumour may have a single focus of malignant 
invasive epithelium with the remaining areas appearing benign.  Therefore a simple biopsy of 
the wall of a presumed mucinous cystic neoplasm may not be adequate to make the diagnosis 
or to exclude malignant transformation.  
Some reports from the Mayo Clinic (Sarr et al, 2000) and Johns Hopkins Hospital (Wilentz 
RS et al, 1999) support an aggressive resection approach to tumours and more importantly 
shed new light on the natural history of mucinous cystic neoplasms suggesting that they are 
premalignant conditions, but this has not gained wide acceptance (Sarr et al, 2000).  Sarr et al 
(2000) have proposed three groups of these tumours.  Mucinous cystadenoma (65%) that are 
benign, proliferative cystic mucinous neoplasms (30%) with some dysplasia and mucinous 
cystadenoma (<10%) that have stromal invasion.   
 
2.6      Intraductal  papillary mucinous tumour (IPMT) 
IPMT represents a spectrum, which varies from a generalised dilatation of the main 
pancreatic duct to a more segmental dilatation of the pancreatic ducts (Hruban et al, 2004).  
This tumour has been referred to by various names including mucin hypersecreting tumour 
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(Furukawa T et al 1992), intraductal mucin hypersecreting neoplasm (Rickaert F et al, 1991), 
mucin producing tumour (Yamada M et al 1991), intraductal papillary neoplasm (Conley CR 
et al 1987), intraductal mucinous papillary tumour (Nagai et al, 1995) and duct ectatic 
mucinous cystadenoma (Itai Yet al, 1986).   The incidence appears to be rising as reported in 
some series and this may be due to an increased awareness of the condition (Sugiyama M et 
al, 1998; Traverso LW et al, 1998).   
This tumour is found most commonly occurs within the head of the pancreas and produces 
thick viscid mucus resulting in dilatation of the main pancreatic duct.  Approximately 30-
50% of patients have associated malignancy within the areas of mucinous ductal ectasia 
strongly suggesting that mucinous dysplasia is premalignant in a similar way to mucinous 
cystic neoplasms of the pancreas.  The tumour grows along the duct before invading the 
parenchyma of the gland and distant metastases may occur.  Microscopically IPMT consists 
of mucinous cell dysplasia of the dilated ductal segment but a spectrum of changes from 
mucinous hyperplasia to severe dysplasia to carcinoma in situ to invasive cancer may be 
observed in different segments of columnar epithelial cells.  Lesions of IPMT cause pain 
probably because the mucin that is produced or papillary growth results in ductal obstruction.    
Clinically, IPMT usually presents with symptoms suggestive of idiopathic chronic 
pancreatitis but in an older age group (mean, 68 years) and usually with the similar risk 
factors (Sugiyama M et al, 1998; Traverso LW et al, 1998).   Jaundice secondary to ductal 
obstruction and pancreatitis are common in mucinous papillary tumours of the pancreas and 
prompt surgical treatment results in good results (Tibayan F et al, 2000).  In a study of 33 
cases, Traverso et al (1998) found that malignancy is common (42%) and there was an 
association with alcohol abuse and jaundice.   The prognosis was found to be better than in 
pancreatic cancer but about a fifth of patients developed recurrence of symptoms in residual 
pancreatic remnants and this was in both benign and malignant cases.  
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2.7     Grading of pancreatic tumours 
Tumour grading is a histological method for determining the tumour’s inherent biology and 
predicting its aggressiveness.  A major problem in grading pancreatic tumours is that the 
degree of differentiation is often variable in different parts of the tumour. The amount of 
gland (duct) formation and mucin production is the basis of grading (Kloppel G et al, 1982) 
but this is subjective.  Well-differentiated tumours display a high degree of gland formation 
while poorly differentiated tumours show little.  Several studies have shown a correlation 
between histologic grade and survival by both univariate analysis and multivariate analysis 
(Eskelinen M et al, 1991).   
 A semi quantitative system for the histological grading of pancreatic ductal adenocarcinoma 
was described by Kloppel et al (1985) in which the entire neoplasm was classified according 
to the highest grade of its components, regardless of their prevalence (Table 2.2).  Most 
recently, Luttges J et al (2000) studied the possibility of supplementing tumour grade with 
proliferative activity as assessed by immunohistochemistry.   They found that either the 
number of mitoses or the growth fraction do not seem to discriminate tumours of varying 
prognosis.  The traditional cellular or structural differentiation appears to be superior 
particular on low power magnification over irregular glands (Lutteges J et al, 2000). 
The Japanese grade tumors according to the most predominant structures histologically 
(Japanese General Rules for Surgical and Pathological Studies in Cancer of the Pancreas 
(1996).  In contrast however, the UICC recommends that PDA should be assigned the least 
favourable grade of G1-G4 (Table 2.4) and includes carcinomas with undifferentiated areas 
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next to areas of glandular differentiation.  The International Pancreatic Cancer Study Group, 
(IPCSG) recommends that in addition to the predominant grade observed, any additional 
grades present should also be stated and it is therefore essential that sections from different 
parts of the tumour be examined to enable an accurate assessment of tumour grade (Pour P et 
al 1994).  Histologically well-differentiated tumours have small acini and a fibrous stroma 
and may be difficult to distinguish from chronic pancreatitis.  Perineural and vascular 
invasion are common, diagnostic of malignancy and associated with a poorer outcome.   
Although there is a case for a more objective grading system, grading itself is of relatively 
low prognostic value compared with other predictors of outcome such as stage 
 
 2.8     Staging of Pancreatic Tumours 
Staging is classification of the anatomical extent of a tumour (Sobin LH, 2001).   After the 
tumour is removed this assessment is further extended by considering the observed (R0) or 
the extent (R1/R2) of the residual tumour (Hermanek P and Wittekind C, 1994) as shown in 
(Table 2.3).  Clinical stage and the individual staging variables e.g. tumour size and lymph 
node status have also been separately associated with prognosis (Eskelian MJ et al, 1999).   In 
most specialist units pre-operative staging is routinely carried out by spiral CT scanning, 
endoscopic ultrasonography, diagnostic laparoscopy and laparoscopic ultrasound (Durup-
Scheel-Hincke J et al, 1999).  Pierre Denoix working at the Institute Gustave Roussy in 
France introduced the TNM classification between 1943 -1952.  In pancreatic cancer, the 
TNM classification relies on tumour size (T), lymph node involvement (N) and the presence 
of distant metastases (M).  This staging system has since has undergone several 
modifications.  The present UICC TNM classification of adenocarcinoma of the pancreas 
(Sobin LA and Fleming ID, 1997) comprises four stages.  Stage I represents tumours with no 
extra pancreatic spread (T1, N0, M0); stage II those tumours with direct extension into 
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surrounding structures (T2 or T3, N0, M0); stage III any tumour with regional lymph node 
metastases (N1-3, N1, M0); and stage IV those tumours with distant metastases (T1-3, N0-1, 
M1).   
The UICC T category considers tumour size, peripancreatic extension and venous invasion 
while the Japanese T considers tumour size only.  The latter is supplemented by a separate S 
(serosal invasion), Rp (retro peritoneal invasion), and V (venous invasion) classifications.  In 
the UICC system the first and second lymph node stations only are considered as regional 
lymph nodes while the Japanese include other intra-abdominal nodes.  This staging system 
emphasises lymph node involvement causing a tumour of whatever size and degree of loco-
regional infiltration to be classified as stage II.  Loco-regional infiltration of the tumour is 
underestimated, classifying a tumour as stage II even when it invades adjacent organs or large 
vessels.  A further problem is that correlation of stage-prognosis in this system reveals no 
statistical difference between patients in stage II and II (Kawarada Y and Isaji S, 1998).  
 
2.8.1  TNM residual tumour classification (R classification) 
The absence or presence of residual tumour after treatment influences prognosis and may be 
described by the symbol R.  The definitions of the R classification are (RX- presence of 
residual tumour; R0- No residual tumour; R1- microscopic residual tumour and R2- 
macroscopic residual tumour).    Following surgical treatment there are three areas that 
should be considered before definition of the R classification: distant metastases following 
adequate staging for example liver metastases and peritoneal deposits; macroscopic local or 
regional tumour remaining following resection; histological assessment of resection margins. 
In a series of 130 resections for pancreatic ductal adenocarcinoma 76 were considered R0 
resections and 54 R1 or R2.  None of the patients with R1 or R2 disease were alive at two 
years but the five-year survival in the patients staged as R0 was 36% (Trede M et al, 1990).   
An acceptable long-term prognosis can be expected in R0 patients only.  Although there is a 
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correlation between stage and R classification, the differences cannot be explained in stage 
alone (Hermanek P and Wittekind C, 1994).  
The Japanese Pancreatic Society system considers a larger number of distinctly more refined 
parameters and stresses involvement of the adjacent structures to the pancreas [(other organs, 
large vessels and retroperitoneal tissue, playing down the role of lymph node invasion 
(Japanese Pancreas Society, 1982)].   Kobari et al (1996) compared the two major systems in 
over 1600 patients who underwent resection and reported that the Japanese system may offer 
improvements over the UICC system.  The JPS system showed better survival for each 
individual stage compared to the UICC system when applied to the identical groups of 
patients.  This paradoxical effect needs to be kept in mind when considering survival data 
from the Japanese since a direct stage-for stage is inappropriate due to this paradoxical effect.  
The two major staging systems are poor at describing early lesions of the pancreas.  Early 
carcinoma of the pancreas is variously defined as “small carcinoma”, “early carcinoma” or 
T1a/pT1a.  All define the tumour as being less than or equal to 2 cm in size and most limit 
the tumour to the boundaries of the pancreas (Tsuchiya R et al, 1986).  This definition of 
early carcinoma excludes lymph node and distant metastases yet lymph node metastases and 
spread beyond the pancreas may have occurred in more than 40-80% of such “early” tumours 
(Tsuchiya R et al; 1986, Nagakawa T et al, 1993).  Consequently only about 49% of small 
ductal adenocarcinomas fit the pT1aN0Mo classification and small carcinomas make up only 
about 10% of all resected tumours and early lesions only about 5% (Moosa AR and Levin B, 
1981). The two staging systems are unsatisfactory in determining prognosis in pancreatic 
cancer.   
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2.9     Benign tumours of the exocrine pancreas      
 
2.9.1     Intraductal Papilloma 
These are rare tumours of the pancreas which occur within the pancreatic duct in the head or 
body of the pancreas.  They may be multiple and usually present in patients over 50 years of 
age with symptoms resembling pancreatitis.  Macroscopically they are intraductal masses 
which may obstruct the main pancreatic duct.  Histologically, they are papillary neoplasms 
lined by mucus-secreting epithelium which may contain foci of dysplasia but the tumours are 
benign (Morohoshi T et al 1989). 
 
2.9.2  Tumours of the endocrine pancreas 
These tumours account for approximately 5% of pancreatic tumours..  They have been known 
by a variety of names including carcinoid tumours, APUD cell tumours, APUDOMAS, islet 
cell tumours or endocrine cell tumours but it is now believed that they are derived from a 
common bipotential cell.  Insulinomas are the commonest variety accounting for up to 50%, 
whilst gastrinomas account for 20% and the rarer functioning tumours only 5%; the 
remaining 25% are non-functioning tumours.  About 25% of islet cell tumours are associated 
with the multiple endocrine neoplasia type 1 (MEN-1) syndrome of which half are malignant.  
The remaining 75% are sporadic and of these, 70% are malignant.  Tumours may be derived 
from any one component of the pancreatic islets including alpha cells (glucagon-secreting); 
beta cells (insulin-secreting); delta cells (somatostatin-secreting); PP cells (pancreatic 
polypeptide-secreting); G cells (gastrin-secreting) and VIP (vasoactive intestinal peptide) 
derived from nerve fibres.  Several hormones may be produced by a tumour but symptoms 
 45 
are invariable due to one dominant hormone.  They run an unpredictable course and only 
curative resection has been shown to alter the outcome of the disease (O`Shea D et al, 1996).  
Neuroendocrine tumours of the pancreas are evenly distributed throughout the gland, affect 
males and females equally and present most commonly in the fifth or sixth decade.  They are 
usually encapsulated, firm and normally compress the surrounding tissue rather than infiltrate 
it.  Malignant neuroendocrine tumours however, invade the normal pancreatic tissue and may 
show lymph node metastases.  Gastrinomas and glucagonomas are more likely (60%) to be 
malignant than insulinomas (10%).   Histologically, tumours may be divided into four 
categories.  Type A is the carcinoid pattern consisting of typical nests and cords of cells; type 
B tumours show ribbons of cells; type C appear histologically as tumour cells in tubular and 
rosette formations and type D are undifferentiated tumours which form sheets of cells with no 
characteristic pattern.  Many tumours however, show combinations of these histological 
types.  Benign and malignant tumours are difficult to distinguish histologically as malignant 
tumours may show little anaplasia and benign tumours are not always encapsulated.  Larger 
tumours are more likely to be malignant but the only absolute indicators of malignancy are 
invasion of the normal surrounding pancreas or the presence of metastases.  Local 
complications include gastrointestinal bleeding and obstruction and involvement of the 
superior mesenteric and portal veins.  Adenocarcinoma of the islets generally follows a more 
indolent course than adenocarcinoma of the exocrine pancreas and although half the patients 
have liver metastasis at the time of diagnosis, the median survival time is 3.5 years compared 
to 4-6 months in unresected PADC. A classification system based on clinicopathological 
features has been suggested but its clinical value has yet to be seen (Schind IM et al, 2000).  
The non-functioning tumours are not associated with an obvious hormonal syndrome.  Most 
of them are found in the head of the pancreas and are malignant (Cheslyn-Curtis S et al, 
1993; Eckhauser FE, 1986).  They are identical to the functional tumours but usually present 
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at an advanced stage. Selective angiography and CT scanning are the main localisation 
methods (Geoghegan JG et al, 1994). 
  Results from medical and surgical treatment are encouraging, showing reduction of 
hormonal excess and increased survival (Hellman P et al, 2000). 
 
2.10    Primary pancreatic  lymphoma 
Primary pancreatic lymphoma is a rare form of extra nodal lymphoma (less than 0.5% of 
pancreatic cancers) that arises from the pancreatic parenchyma (Boni L et al, 2002).    They 
may present as primary or secondary lymphomas.  The tumour is often bulky on CT with an 
average diameter of eight centimeters and surrounding peripancreatic lymphadenopathy often 
with involvement of adjacent organs.  Primary pancreatic lymphoma includes only those 
patients with stage I or II disease according to the modified Ann Arbor staging system.  The 
diagnosis must be confirmed by CT or USS guided biopsy or cytology of pancreatic juice 
obtained at ERCP.   Most of the patients present with abdominal pain, and CT guided 
percutaneous biopsy may be useful in making the diagnosis (Bouvert M et al, 1998).  The 
tumour appears to have some response to adjuvant treatment.   Berhns et al (1994), in a small 
series found that the mean survival following chemotherapy was 13 months (n=2), 22 months 
with radiotherapy (n=5) and 26 months for those who had chemotherapy.    
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2.11  Summary 
It is important to define a tumour, classify it and assess whether it is one of the entities that 
have a more optimistic outlook.  Even amongst the common tumours there is a difference in 
prognosis according to cell type, whilst in the unusual types of tumours there is an entirely 
different pattern of prognosis.  The clinician needs to be aware of these variants in order to 
avoid failing to treat a patient with a potentially curable lesion for whom a simple surgical 
procedure can be life saving.  Histological typing and sub typing of primary pancreatic 
cancers, in addition to staging and grading, should form the basis for treatment selection and 
prognostic assessment.   The two major staging systems do not accurately predict prognosis 
in pancreatic cancer and they are likely to be replaced by other systems, possibly related to 
the genetic changes of this aggressive tumour.  The chapter explored the different 
pathological entities of some precursor lesions with different names referring to the same 
condition.  Since 2004, clarity has now established three main precursor lesion; pancreatic 
intraepithelial neoplasia (Pan IN), which is the commonest, mucinous cystic neoplasia 
(MCN) and intraductal pancreatic mucinous neoplasia (IPMN).  This will inevitably 
standardize reporting and the development of appropriate treatment strategies. 
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Table 2.1.  Histological classification of tumours of the pancreas 
 
 
 
Origin 
 
Frequency 
 
Histological Type 
 
 
Clinical Features 
 
 
Exocrine 
(95%) 
 
 
80% 
2% 
<1% 
2% 
5% 
3% 
<1% 
rare 
1% 
(5%) 
 
DuctalAdenocarcinoma (PDA) 
Mucinous non cystic 
Squamous Cell Carcinoma 
Adenosquamous Carcinoma 
Anaplastic (Undifferentiated)  
Mucinous  
Intraductal (Papillary)- 
Pancreatoblastoma 
Small Cell Carcinoma  
Acinar cell carcinoma 
 
long term survival rare 
prognosis worsens with content of signet rings 
generally more aggressive than PDA 
Generally more aggressive than PDA 
worse prognosis 
female preponderance, more favourable prognosis than PDA 
more favourable prognosis than PDA 
childhood, more favourable prognosis than PDA 
extremely poor prognosis 
may be associated paraneoplastic syndrome, poor prognosis 
 
Endocrine 
(2.5%) 
 
 
 
 
 
 
 
 
 
 
Insulinoma 
VIPoma 
Gastrinoma 
Glucagonoma 
non-functioning 
 
10% malignant 
50% malignant 
60% malignant 
60% malignant 
60% malignant 
 
Other (2.5%) 
  
Lymphoma 
 
responsive to chemotherapy 
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Table 2.2.   UICC TNM clinical classification of exocrine pancreatic 
carcinoma  (Sobin LH and Wittekind Ch, 2003) 
 
T – Primary Tumour 
 TX   Primary tumour cannot be assessed 
 T0    No evidence of primary tumour 
 Tis   Carcinoma in situ 
 T1    Tumour limited to the pancreas, 2cm or less in greatest dimension 
 T2    Tumour limited to the pancreas, more than 2cm in greatest dimension 
T3    Tumour extends directly into any of the following: duodenum, bile duct. 
Peripancreatic tissues1 
T4   Tumour extends directly into any of the following: stomach, spleen, colon, and 
adjacent large vessles2 
   
N – Regional Lymph Nodes 
 
 NX Regional lymph nodes cannot be assessed 
 N0 No regional lymph node metastases 
 N1 Regional lymph node metastases 
   N1a Metastases in a single regional lymph node 
   N1b Metastases in multiple regional lymph nodes  
 
M – Distant Metastasis 
 
 MX Distant metastasis cannot be assessed 
 M0 No distant metastasis 
 M1 Distant metastasis 
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Table 2.3.        R classification 
 
 
RX  Presence of residual tumour cannot be assessed 
 
R0   No residual tumour 
 
R1   Microscopic residual tumour 
 
R2   Macroscopic residual tumour 
 
 
 
TNM 7 
 
Table 2.4.    Histopathological Grading 
 
 
GX  Grade of differentiation cannot be assessed 
 
G1  Well differentiated 
 
G2  Moderately differentiated 
 
G3  Poorly differentiated 
 
G4  Undifferentiated 
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Chapter 3   Molecular biology of pancreatic cancer 
 
3.1     Introduction 
Cancer is caused by uncontrolled cell division leading ultimately to the formation of a tumour 
and this has been shown to be a multi-step process requiring the accumulation of several 
genetic changes.  When a cell experiences stress e.g. chemical, heat or DNA damage it can 
respond in several ways to counteract any damage incurred.  Inhibitory factors are produced 
at the appropriate checkpoint, which can cause arrest of the cell cycle allowing the damage to 
be repaired and cell cycle to resume or, if the damage is too great cause the onset of apoptosis 
(programmed cell death).  Cancer can be considered to be a result of numerous failed 
attempts to adequately control the cell cycle process and/or instigate apoptosis.   
Genetic alterations predispose an individual to cancer and can be inherited or acquired.  In 
inherited predisposition the individual already has a genetic lesion e.g. point mutation and 
because cancer is due to the accumulation of genetic lesions, the individual is at an increased 
risk of developing cancer as fewer additional steps are required for cancer formation and 
progression.  Acquired genetic alterations can be attributed to environmental carcinogen 
factors (Soussi T, 1996). Two main categories of genes whose alteration or change may lead 
to cancer are oncogenes and tumour suppressor genes, (Steele RJ et al, 1998).  An oncogene 
is a gene whose overexpression can predispose a cell to transformation.  Proto-oncogenes, the 
wild type of the gene encode proteins that respond to cellular growth or survival factors (e.g. 
growth factors and growth receptors) and are involved in cell cycle progression.  Mutations 
within these genes can confer malignant properties on the cell that can enhance cell 
proliferation and survival.  The oncogenic genotype is dominant; therefore mutations arising 
in just one of the alleles can be sufficient for the onset of overexpression.  In a few cases 
mutations in oncogenes are inherited, but more frequently they are acquired (Steele RJ et al, 
1998).  Tumour suppressor genes in their wild state suppress uncontrolled or unregulated 
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growth and are associated with the cell cycle check points.  For a mutant gene to become 
apparent both alleles need to be altered either by mutation or loss. The molecular biology of 
pancreatic cancer is becoming clearer. The disease is caused by inherited and acquired 
mutations in cancer related genes. A study of premalignant genetic lesions has led to the now 
accepted Pan IN (Pancreatic intraepithelial neoplasia) classification to explain the tumour 
progression model (Hruban RH et al, 2001, Singh, M et al, 2007)).  The premalignant 
changes seen in colorectal cancer seem to be similar to carcinogenesis in pancreatic cancer 
and this adeno-carcinoma sequence has led to a better understanding of pancreatic cancer 
formation (Hruban RH et al, 2000).  The stepwise accumulation of mutations in a number of 
genes leads to a disturbance of the cell cycle.  In pancreatic cancer there is over expression of 
growth factors and growth factor receptors including EGF, TGF, EGFR, amphiregulin, c-
erbB 2-4, αFGF, βFGF, TGFR, TGFsl-3 and TGFβRs.  Inactivation of the tumour 
suppressor genes (TS) p53, p16, SMAD4 (Hahn SA et al, 1995) and activation of dominant 
oncogenes K-ras and cyclin D1 all play a role in tumourigenesis.  Most recently, global 
genomic sequencing for genetic changes in pancreatic cancer has been carried out by Jones, S 
et al (2008).  More than twenty thousand genes were screened in 24 different pancreatic 
specimens and about sixty mutations were found in each sample and mainly affecting 12 
overlapping signalling pathways (Carter, H et al, 2010).   The five pathways were; apoptosis, 
DNA damage repair, G1/S phase cell cycle progression, cell-cell adhesion and invasion.  
Other pathways include the signalling cascades; embryonic. MAPkinase and TGF-B 
signalling (Jones, S, et al, 2010 
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Figure 3.1:   The cell cycle: Normal cell division is checked at numerous stages before it is 
allowed to continue. 
 
M: mitosis 
G1: Gap1 
G2: Gap2 
S: DNA synthesis 
 
 
 
 
 
 
 
3.2         Growth Factors and their Receptors 
 
Epidermal growth factor receptor (EGFR) and the erb-B family of growth factor receptors (c-
erbB-2, c-erbB-3 and c-erbB-4) are all frequently overexpressed in pancreatic cancer and in 
epithelial proliferative states such as chronic pancreatitis.  They are all transmembrane 
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tyrosine kinase receptors with a similar sequence.   The action of these oncogenes is shown in 
Figure 3.2. (Magee et al, 2001)  There are essentially 3 different types of actions that can 
occur.  Initially in the autocrine phase, cancer cells appear to release substances that act on its 
own cell surface. In the paracrine type of action, factors produced from the surrounding area 
of a normal or malignant cell appear to stimulate surrounding or distant cells.  In Proxicrine 
action, substances from islet cells of the pancreas are transported via the portal system where 
translocation takes place upon contact. Translocation is where the growth factor couples itself 
to the nucleus and is able to influence DNA synthesis or change of genetic function (Raper 
SE et, 1987). How the cells respond to these stimuli is dependent on a number of factors.   
Clearly the quantity of the ligand substrate which may be under or overexpressed as well as 
the receptor is crucial, adequate function of these ligands, effectiveness of downstream 
signalling pathways and finally the feedback loop to all these responses 
 
Figure 3.2   Signalling pathways 
 
 
 
 
 
 
 
 
 
 
 
 
AUTOCRINE SIGNALLING 
 
EGF/EGF-R 
FGF/FGFR 
PDGF/PDGF-R  platelet derived growth factor 
HGF/MET hepatocyte growth factor 
VEGF   vascular endothelial growth factor 
KGF/KGFR  keratinocyte growth factor 
PARACRINE SIGNALLING 
 
TGF-/ TR-I, TR-II 
PROXICRINE SIGNALLING 
 
Insulin, IGF-I, IGF-II/IGF-IR, IGF-IIR 
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3.2.1     Epidermal growth factor (EGFR) family 
 
This family of type 1 growth factor receptors comprises four transmembrane tyrosine kinases: 
the epidermal growth factor receptor (EGFR), c-erbB-2, 3 and 4 (Carraway KL and Hartley 
LC, 1994).   EGFR is activated by a family of peptide ligands that includes EGF, TGFα, 
heparin-binding EGF-like growth factor, betacellulin and amphiregulin (Prigent SA and 
Lemoine NR 1992).  EGF is a polypeptide of 53 amino acids which stimulates proliferation 
and differentiation of a wide variety of cell types through the EGFR (Ullrich A and 
Schlessinger J, 1990).  The EGFR is encoded by c-erbB-1 proto-oncogene activity.  In the 
normal pancreas, EGFR is only expressed in the islets of Langerhans.  The EGFR gene 
however is overexpressed in 95% of ductal adenocarcinomas and human pancreatic cell lines 
due to an increase in gene transcription (Barton CM et al, 1991a).  EGFR binds EGF and 
TGFα with high affinity and both of these ligands are overexpressed in pancreatic cancer 
(Yamanaka Y et al, 1992). The overexpression of EGFR has been shown to increase the 
production of EGF and TGFa promoting autocrine and paracrine loops that promote cell 
proliferation (Korc M et al, 1992).  TGFα is expressed at low levels in the ductal epithelium 
of the normal human pancreas but is overexpressed at high levels in 95% of ductal 
adenocarcinomas (Barton CM et al, 1991b).  Whilst EGF is not detectable in the normal 
pancreas, it is found in 12% of pancreatic cancers (Barton CM et al, 1991).  High levels of 
EGFR, EGF and or TGFα correlated with reduced patient survival which is also associated 
with overexpression of amphiregulin (Yokayama M et al, 1995). 
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3.2.2 c-erbB-2  
The c-erbB-2 proto-oncogene encodes a 185-kDa transmembrane glycoprotein (Akiyama T et 
al, 1986).  There are a number of ligands for the c-erbB-2 receptor, including heregulin, gp30 
and NEU-differentiation factor (NDF) but the full contribution of the c-erbB-2 to growth 
stimulation in pancreatic cancer remains unknown (Leung HY and Lemoine NR et al, 1992a).  
c-erbB-2 is overexpressed in bladder, breast, oesophageal and gastric cancers where it 
appears to have a role in lymph node metastases (Mellon JK et al, 1996; Hardwick RH et al, 
1997).   In invasive ductal adenocarcinomas of the pancreas and ampullary tumours c-erbB-2 
are overexpressed in 20% and are usually due to c-erbB-2 gene amplification (Hall PA et al, 
1990).   
 
3.2.3    c-erbB-3  
This is the third member of the EGF receptor-related family of growth factor receptors (Kraus 
MH et al, 1989).  The c-erbB-3 gene encodes a Mr 180,000 transmembrane polypeptide 
which shares close structural similarity with the EGF receptor and c-erbB-2 but it has no 
known natural ligands.  In the normal pancreas c-erbB-3 is expressed in the islets of 
Langerhans but has been detected in up to 90% of pancreatic and ampullary cancers 
(Thangarajan R et al, 1993; Lemoine NR et al, 1992b). 
  
3.2.4     c-erbB-4 
This is a 180 kDa transmembrane tyrosine kinase whose extracellular domain is similar to 
that of c-erbB-3.  The cytoplasmic kinase domain exhibits a high degree of similarity with 
EGFR and c-erbB-2 (Plowman GD et al, 1993).  The heregulins and betacellulin can all 
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activate c-erbB-4 (Tzahar et al, 1994; Riese DJ et al, 1996).  c-erb B-4 is predominately 
expressed in normal skeletal muscle, heart, pituitary, brain and cerebellum as well as breast 
cancer cell lines.  In a recent study of c-erbB-4 expression in pancreatic cancer using 
quantitative RT-PCR and immunohistochemistry, no significant difference was found 
between patients with c-erbB-4 positive tumours and those with C-erb-4 negative tumours 
(Graber HU et al, 1999). 
 
3.2.5    TGFs and TGF receptors 
The Transforming growth factor- family of cytokines actively influence cell division, 
cellular differentiation and cell death (Heldin C et al, 1997; Massague J, 1998).  Members 
include TGF-β s; bone morphogenetic (BMPs) and activins, all of which are found in PDAC 
(Li CY et al, 1995).  TGF β normally exists in the extracellular space as a complex with the 
latency-associated protein (LAP) and the latent TGF-β binding protein (LTBP).  Once 
released from this complex, TGF-B binds to a teterodimeric transmembrane receptor 
consisting of 2 components – TBR-1 and TBR-11.  Binding of TGF- β to TBR-11 forms a 
complex that binds to TBR-1.  This enables phosphorylation and activation of TBR-1 by 
TBR-11.  TBR-1 phosphorylates the cytoplasmic proteins Smad2 and Smad3, which are 
termed receptor regulated or R- Smads.  These R-Smads associate with Smad4 (common 
mediator Smad or Co-Smad) as shown in figure 3.3.  The co-smad/R-Smad heterocomplex 
translocates to the nucleus where it can co-operate with a host of co-factors leading to the up- 
or down-regulation of transcriptional activity.  This transcriptional regulation appears to be 
mediated by chromatin remodelling by histone acetylases (HATs) and histone deacetylases 
(HDACs).  Evidence has shown that TGF- β signalling through Smad4 upregulates 
p21cip1/waf1 (Li cy et al, 1995) thereby arresting the cell in G1 and that TGF- β mediated 
growth inhibition is mediated through pRb-E2F trans repression (Kleeef J et al, 1999).  There 
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are also inhibitory SMAD proteins (1-Smads, Smads6 and Smads7) that abrogate Smad 
pathway signalling and these have been shown to be elevated in pancreatic cancer samples 
when compared to normal pancreatic tissue and such overexpression may confer TGF- β 
resistance and enhanced tumorigenicity (Kleef J et al, 1999; Kleef J et al, 1999).  They bind 
to specific cell surface receptors and are able to down regulate transcription factors, decrease 
phosphorylation of target proteins and inactivate cell cycle regulatory enzymes. The end 
targets are the G1 cyclins and cyclin dependent kinases.  The presence of mutant p53 has 
been correlated with the loss of TGF-1 responsiveness in malignant epithelial cell lines.  
TGF-1 may also induce the universal cyclin inhibitor p21 by a p53 independent pathway 
(Bladydes JP et al, 1995, Datto MB et al, 1995).  The three isoforms TGF β -1-3 have been 
shown to be overexpressed in pancreatic cancer.  Survival data from 60 patients with 
pancreatic cancer showed significantly decreased survival time with the overexpression of 
these isoforms (Friess H et al, 1993; Lu Z et al, 1997).  In a more recent study, however, TGF 
β -1, which was expressed in 31% of cancers, was significantly associated with increased 
survival (Friess H et al, 1993; Lu Z et al, 1997).  These contradictory findings deserve further 
investigation.  The TGF β receptors 1-3 are all found in normal pancreas, but in cancer there 
is overexpression of TGF β -2 receptor only (Friess H et al, 1993)  
 
3.2.6    Fibroblast growth factors 
Fibroblast growth factors (FGFs) belong to a large group of polypeptide growth factors that 
include the two main groups, FGF (αFGF) and FGF (βFGF).  These growth factors are highly 
abundant in the basement membrane and extracellular matrix of a variety of tissues.  FGFs 
influence cell differentiation, tissue homeostasis, regeneration and repair, cell migration and 
growth.  Binding to specific transmembrane receptors (which have intracellular tyrosine 
kinase activity) is dependent on the presence of heparin sulphate proteoglycans (on the cell 
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surface or in the extracellular matrix) for which they have a high affinity.  The intense 
desmoplastic stromal reaction that is seen in pancreatic cancer and the histological prevalence 
of perineural invasion supports the role of FGFs in the progression of this tumour.   
 
3.3  Insulin-Like Growth Factor-1 and its Receptor  
This is a polypeptide that binds and activates both the IGF-I and Insulin receptors (Frosch RG 
et al, 1985).   Additionally, both receptors appear to promote cell division in different cells 
but it has been reported that it is the latter receptor that is mainly involved (Frosch RG et al, 
1985).  Both receptors activate insulin receptor substrate-1, an important regulatory protein 
that mediates the growth promoting and metabolic effects of the IGF-I and insulin (Myers 
MG et al, 1994).  IGF-I acts in a paracrine and autocrine manner to enhance pancreatic cancer 
cell growth in vivo. 
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3.4  Tumour suppressor genes 
Tumour-suppressor genes are genes that, when activated, convey transforming properties.  
The genes are inactivated either by homozygous deletion (deletion of both copies of the gene) 
or by loss of one allele (one copy of the gene).  Loss of function can be associated with 
uncontrolled cell growth and proliferation, decreased apoptosis, and malignant 
transformation. 
 
3.4.1  p53 
 
The p53 gene is 21Kb in length and is located on the short arm of chromosome 17 (17p).  It 
spans 11 exons and a 2.8Kb mRNA encodes a 393 amino acid protein.  The protein is 
comprised of four functional domains.  (1) a transcriptional activation domain in the acidic 
terminus (0-80aa); (2) a DNA- binding domain (80-150aa); 3) an oligomerisation domain 
(150-300) and 4) a basic C terminus. 
 
3.4.1.1 p53 in normal cells 
 
The normal p53 protein referred to as the wild type has a short half-life and is found in the 
nucleus of cells.    Karstan et al postulated a form of feedback loop with the MDM2 protein 
that is itself stimulated by normal p53 resulting in the destruction of the latter. Additionally, 
he suggested that the p53 protein is like a gatekeeper for the entry of cells into the cell cycle 
at the G1/S transition and is implicated in the repair of DNA that has been damaged prior to 
its entry in the replication process (Kastan MB et al, 1991).  During times of damage to DNA, 
the cell increases the concentration of p53 protein which in turn forms bonds with DNA 
leading to the production of other genes responsible for aborting cell growth and destruction 
of damaged cells also known as apoptosis.  Additional functions of the p53 protein include its 
role as a transcription factor, cell growth and normal function of the cell by regulation of 
other genes.  The timing and combination of these functions results in a controlled cell cycle.   
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P53 upregulates p21cip1/waf1 (El Diery WS et al, 1993) that acts upon the retinoblastoma 
pathway to inhibit retinoblastoma phosphorylation thus arresting the cell cycle in G1 and Bax 
(Miyashita T et al, 1994) that promotes apoptosis.   
 
3.4.1.2 p53 and cancer 
Mutations that occur in the p53 protein prevent binding of the protein to DNA and as a result 
the up regulation of the MDM protein does not occur with the mutated p53 protein has a 
much longer half-life than wild-type p53 protein.    Accumulation of p53 protein is used as a 
surrogate marker for the presence of mutant p53, although an increase of the protein may also 
be found in stressful conditions.  More than half of tumours in have mutations in the p53 gene 
(Lane DP et al, 1991; Hollstein M et al, 1994).  Early work by Barton et al, found that In 
PADC the gene is inactivated in approximately 65% of cases usually by missense point 
mutations (Barton CM et al, 1991).  Other work by Apple et al suggested that the genetic 
aberrations demonstrate loss of the wild type allele and appears to be a late event in cancer 
formation (Apple SK et al, 1999).  Additional reports that mutation in the gene shows an in 
exact number of chromosomes referred to as aneuploidy makes the case that normal p53 is 
important for normal cell function. (Harada T et al, 2002; Gorunova L et al, 1998).    
Germline mutations in p53 have been described as Li Fraumeni syndrome, predisposing to 
many cancers but pancreatic cancers are a rare finding (Strong LC et al, 1987; Li FP et al 
1988).   The majority of mutations are found in exons5, 6 and 8 which is the location for 
DNA binding. This so called hot-spot region was subsequently shown to be the DNA binding 
region of the molecule.  Mutations in this region of the molecule, by disrupting DNA binding, 
affect the ability of the p53 protein to regulate genes involved in cell cycle arrest.  Hence the 
high proportion of tumours with mutations in this region of the gene.  Generally, because p53 
is a tumour suppressor gene both copies of the allele need to be lost or their function altered 
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in order for its suppression role to be lost.  Many tumours therefore as well as possessing 
point mutations in the p53 gene also show loss of heterozygosity (LOH) i.e. the other, wild 
type allele of the gene has been lost through chromosomal changes.  Mutant p53 however can 
exert harmful effects on the cell even when there is still one remaining wild-type allele 
present.  This function of the mutant allele is exerted either through a transdominant effect of 
the mutant over wild type when tetramerisation of mutant p53 molecules alongside wild-type 
molecules causes inactivation of the wild-type functions.  In addition, it has been shown that 
mutant p53 molecules can exhibit gain of function that may lead to increased oncogenic 
potential.  
 
3.4.1.3 p53 and adjuvant treatment 
When cells are exposed to either radiation or cytotoxic agents the levels of wild type p53 
protein rise 5-60 fold (due to increased stability of the protein rather than increased protein 
synthesis).  It follows that tumours with functioning p53 may carry a better prognosis than 
those expressing the mutant protein when exposed to radiation or DNA damaging agents.   
 
 
 
3.4.2     p16 
 
The p16 (MTS1/INK4A/CDKN2) tumour suppressor gene is found on the short arm of 
chromosome 9 (9p21) and encodes for a 16-kDa protein (Serrano M et al, 1993) that plays a 
key role in controlling the G1 checkpoint (or restriction point, R) of the cell cycle (Figure 
3.1). The retinoblastoma gene product (pRb) is an active transcriptional repressor when 
bound to transcription factors such as the E2F family.  Inactivation of the pRb by 
phosphorylation (mediated by the complex formed by CDK4, 6 and cyclin D) causes release 
of E2F and subsequent transcription of genes important for DNA synthesis. The p16 protein 
prevents the association of CDK4 and 6 with cyclin D and the subsequent phosphorylation of 
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pRb. This growth suppression by p16 requires functional retinoblastoma protein (Medema R 
et al, 1995).  Loss of p16 expression occurs in up to 85% of pancreatic cancer cell lines and 
xenografts (Caldas C et al, 1994) due to homozygous or heterozygous deletion (Naumann M 
et al, 1996) and usually occurs late in the tumour progression model (Caldas C et al, 1994; 
Rozenblum E et al, 1997; Wilentz RE et al, 1998).   The p16INK4A locus also encodes the 
tumour suppressor ARF (alternative reading frame).  Both p16INK4A and p19ARF share a 
common exon 2, however ARF has a different frame resulting in a non-identical protein 
product.  ARF’s role as a tumour suppressor is dependent on its ability to sequester MDM2 in 
the nucleolus thereby potentiating p53 mediated G1 arrest (Weber JD et al, 1999).  Loss of 
the p16INK4A locus in pancreatic cancer is inevitably accompanied by loss of the ARF 
reading frame.  This loss of heterozygosity is often followed by hypermethylation and 
inactivation of the p16INK4A promoter on the remaining allele.  ARF does not share the 
same promoter as p16INK4A, potentially allowing ARF to still be produced.  The exact role 
of ARF in pancreatic cancer is not fully understood. 
  
 
3.4.3        SMAD4 (DPC4) and the TGF-β signaling pathway 
Previously, the DPC4 gene was named after the finding of mutations in hepato-biliary –
pancreatic tumours (Hahn HA et al, 1996).  The name has since changed to SMAD4 which is 
named after the protein family Drosophila melanogaster MAD (mothers against 
decapentaplegic) protein and the Caenorrhabditis elegans protein SMA (small body size).  
Loss of an allele at chromosome 18q in has been observed with high frequency, about 90% of 
PADC and in approximately half of these tumours, homozygous deletions are located at 
chromosome 18q21.1 (Hahn SA et al, 1995).    DPC4 has not been reported in early lesions 
such as flat, papillary or atypical intraduct neoplasias but is inactivated at a high frequency in 
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severely atypical neoplastic lesions and from this, it can be concluded that its influence on 
tumourigenesis is a late event (Biankin AV et al; 2001Wilentz et al, 2000).   The protein 
product is believed to play a role in signal transduction from the transforming factor- B 
(TGF-β) superfamily of cell surface receptors (Hahn SA et al, 1995; Dai JL et al, 1998; 
Wilentz JP e al, 2000).   Smad proteins interact with these receptors, become phosphorylated 
and then complex with the DPC4 (Smad4) (Montgomery E et al, 2001).  Activated SMAD 
complexes are then translocated to the nucleus where binding to DNA stimulates the 
transcription of nearby genes (Montgomery E et al, 2001).  Immunohistochemical labelling 
for the DPC4 gene product has been reported to correlate with gene expression (Wilentz et al, 
2000).  The 3′ end of the gene is highly conserved and reports of mutations within this region 
support the idea that the C-terminus region is important for tumour suppressor function 
(Hahn SA, 1995).   There is an 85% homology in amino acid sequence between the SMAD4 
protein and the Drosophila melanogaster (Mad) protein in exons 1, 2 and 11 and a 75% 
homology in exons 8, 9 and 10.  Drosophila that have homozygous mutations in the Mad 
gene exhibit defects in midgut morphogenesis with a similar phenotype being produced with 
mutations in the dpp gene which codes for a member of the TGF-β superfamily (Massague J, 
1996).  TGF-β is a potent inhibitor of cellular proliferation and many cancer cells show a 
diminished responsiveness to TGF- β induced growth inhibition which could be explained 
by the loss of the SMAD4 gene (Kloppel G et al, 2000).  Similarity with the Caenorhabditas 
elegans proteins sma-2, sma-3 and sma-4 has also been reported.  These proteins form part of 
the post-receptor transforming growth factor beta (TGF-β) signalling pathway and it is 
suggested that SMAD4-induced tumour suppression acts along a TGFB-like signalling 
pathway.   Most recently Kloppel et al (2000) studied the restoration of the SMAD4 gene in 
human pancreatic carcinoma cells in vivo and found that it did not restore sensitivity to TGF-
β.  Inspite of this finding, the SMAD4 gene has an important function in angiogenesis and in 
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decreasing expression of vascular endothelial growth factor.  The results of Koppel’s work 
suggest an angiogenic switch pathway previously unknown in the SMAD4 gene.   Finally, the 
SMAD4 (protein) has only been reported in mammals in  (Cook T et al, 2000) and mutations 
in pancreatic cancer occur with high frequency (Jones, S et al, 2008).   
 
 
 
 
 
 
 
 
  
3.4.4    p21 WAF1 
p21 WAF1 is a cyclin-dependent kinase inhibitor and a downstream target and effector of p53 
which is overexpressed in pancreatic cancer.  The 21-kDa product of the WAF1 gene forms 
part of a quaternary complex along with cyclin/CDKs and the proliferating cell nuclear 
antigen (PCNA) in normal cells but not transformed cells and is a universal inhibitor of CDK 
activity (Xiong Y et al, 1993).  One consequence of p21 binding to and inhibiting CDKs is to 
prevent CDK-dependent phosphorylation and subsequent inactivation of the Rb protein, 
which is essential for cell cycle progression at both G1 and G2 checkpoints.  The negative 
regulatory action of p21WAF1 on the cell cycle permits sufficient time for repair to extensive 
DNA damage to be completed.  Functional p21 is essential for p53-mediated G1 arrest due to 
WAF1 inhibition of both CDK activity and PCNA-dependent DNA replication (Xiong Y et 
al, 1993).  Thus p21 overexpression causes growth suppression consistent with its role as an 
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inhibitor of CDKs and a tumour suppressor gene. Induced expression of p21 WAF1 by p53 
directly or by p53-independent mechanisms results in as much as 20 to 100 fold increase 
depending on the cell type and mode of induction.  In preneoplastic lesions of the pancreas 
p21 overexpression occurs early (Biankin AV et al, 2001).   In pancreatic cancer p21 has 
been reported to be overexpressed with increased frequency (Biankin AV et al, 2001).  
Kinetic analysis of p53-dependent induction indicates that p21 WAF1 expression begins to rise 
coincident with the accumulation of p53 in response to DNA damage.  Failure to do so is 
associated with failure of G1 arrest and with inappropriate onset of apoptosis (Agarwal ML et 
al, 1995).  Overexpression of p21WAF1 is an early event in the development of pancreatic 
intraepithelial neoplasia      
 
 
 
3.4.5  BRCA2    
BRCA2 is a tumour suppressor gene that has been identified on chromosome 13q12, which 
along with BRCA1 has been implicated in the pathogenesis of carcinoma of the breast 
(Wooster R et al 1994).  Its role is that of regulation of repair mechanisms for DNA. 
(Venktaraman AR, 2002).  Inherited mutations have been reported to increase the risk of 
pancreatic cancer (Ozcelik H et al, 1997).    In the non-hereditary pancreatic cancers, the 
BRCA2 gene has been estimated to occur in just fewer than 10 percent is (Goggins M et al, 
1996).  Schutte reported a single case of a homozygous deletion in pancreatic cancer within 
the region of the BRC2 locus suggesting that a tumour suppressor gene might be located 
within this region (Schutte M et al, 1995).   
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3.4.6  APC (Adenomatous Polyposis Coli gene) 
This gene is located at chromosome 5q21 and was first identified in patients with familial 
adenomatous polyposis.  At present there is a discrepancy of the results between Western 
groups that have found no evidence of gene mutations or loss of protein expression of the 
APC gene (McKie AB et al, 1993) and those of some Japanese authors who reported 
inactivating mutations in a small number of cases, predicting a truncation of the gene product 
(Horii A et al, 1992).  The significance of this discrepancy has not been explained yet and 
whether it represents some form of ethnic variation remains to be seen.  Studies with 
pancreatic cancer cell lines support the absence of APC gene mutations in pancreatic cancer 
as all had a full length of the APC protein (Smith KJ et al, 1993). 
 
 
3.5         Oncogenes 
 
These are genes that, when activated by mutation or overexpression, possess transforming 
properties. 
 
3.5.1  K-ras      
The Ras family of proto-oncogenes include three human genes, Harvey (H-ras), Kirsten-ras 
(K-ras) and N-ras in which the highest incidences of mutations are found in the early genesis 
of pancreatic cancer (Caldas C and Kern SE, 1995).  The Ras proteins are located on 
chromosome 12p and encode for small GTP-binding proteins that are involved in cell 
proliferation, survival and migration (Shields JM et al, 2000).  
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3.5.1.1   K-ras in normal cells 
K-ras responds to chemical substances that encourage division of cells by firstly binding to 
GTP.  This creates an environment for further stimulation of other substances which cascade 
information further downstream and one of these being the RAF/MAPK pathway (Magee et 
al 2001).  A number of complex processes occur culminating in the eventual activation of the 
of molecular translocation to the cell membrane and in part phosphorylation of RAF. Upon 
completion of the signalling process, the GTP is destroyed and therefore switching off the 
signalling pathway of K-Ras (Maggee et al, 2001; Figure 3.3)     
  
3.5.1.2    K-ras in cancer 
Most of the commonly reported mutations in the K-ras gene are found in codon 12 and range 
from being very uncommon N-ras and H-ras genes (about 20%) and almost in all cases in the 
K-ras gene (Smit V et al, 1988; Lemoine NR et al, 1992; Caldas C and Kern SE, 1995; 
Maruta H and Burgess AW, 1994).  Fewer mutations are also seen in other codons, usually in 
13 and 61.  Finkelstein et al have described the location of these mutations; the aspartic acid 
mutation (GAT), valine (GTT), arginine (CGT) and cysteine (TGT) (Finkelstein SD et al, 
1994). K-ras mutations affect the ability of the K-RAS protein to metabolise GTP by 
hydrolysis.  The result of this process is that K-Ras protein is activated with constant 
stimulation of other targets in a cascading manner.      
  In general, human epithelial cells are not sensitive to oncogene transformation by mutated 
Ras while this is not the case with mice fibroblasts which are readily activated with the 
addition of other either a tumour suppressor gene or an additional oncogene (Serrano M et al, 
1997).   This senescence is thought to be a defence mechanism against oncogenic stress.  
Whether the observed expression of p21CIP1, whose frequency mirrors that of K-Ras mutation 
in the pancreatic cancer model is part of this defense mechanism or directly linked to the cell 
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cycle by working as an assembly factor for the cyclin D1/CDk4 complex, is unclear (Biankin 
AV et al, 2001).   These mutations are well defined and reliably detected by DNA assays.   K-
ras mutations can be detected in cancer tissue, blood, pancreatic secretions and stool.  In 
benign and premalignant diseases of the pancreas, mutations are seen in a very small 
proportion of cases but the risk of progression to malignancy is low in the absence of other 
genetic events (Tada M et al, 1996; Moskaluk CA et al, 1997).   Inspite of the high mutation 
frequency in human pancreatic cancer, mice which harbour a latent allele of K-ras, G12D 
which is capable of spontaneous activation in vivo, develop multiple onset lung tumours but 
not PADC.  This further demonstrates the species differences of Ras functions (Johnson L et 
al, 2001) 
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3.5.2   Cyclin D1 
 
Cyclin D1 is a cell cycle regulator, which may act as an oncoprotein and is overexpressed in 
ductal pancreatic cancer.  It forms part of the enzyme complexes that are active in G1 phase 
of the cell cycle and inactivate pRb by phosphorylation. These enzyme complexes (CDKs) 
contain two components, a regulatory subunit- the cyclin and the catalytic subunit the cyclin 
dependent kinase (cdk) (Kato JY et al, 1993).  The CDKs can be activated by binding a 
cyclin and the phosphorylation of a conserved threonine by the CDK-activating kinase 
(CAK).  Inactivation of the active cdk-cyclin complex can occur by binding of the CDK 
inhibitory subunits (CKIs) (Scher CJ et al, 1995).  There are two classes of CKIs; the INK4 
kinase inhibitors, p15, p16, p18, and p19 which specifically regulate complexes of cyclin D1, 
D2 and D3 with CDK4 and 6 and a second group p21, p27 and p57 inhibit all G1 cyclin/cdk 
complexes.  The primary regulator of CDK activity is the cyclin subunit whose levels 
oscillate during cell cycle.  The G1 cyclin complexes consist of D-type cyclins (D1, D2 and 
D3) complexed with either cdk4 or 6, cyclin E is complexed with cdk2 and cyclin A is 
complexed with cdk2.  The appearance of D type cyclins is tightly linked to growth factor 
exposure and their downstream cell cycle effects are due to inactivation of pRb by 
phosphorylation. Cyclin D1 has been implicated in the pathogenesis of a number of cancers 
including oesophageal, lung, head and neck, bladder and also sarcomas.   Overexpression of 
cyclin D1 leads to phosphorylation of pRb and thus deregulated (and increased) E2F activity.  
Also activation mutations of cdk4 have been identified in certain tumours such as melanoma.  
Thus both cyclin D1 and cdk4 can act as oncoproteins by inactivating pRb.  
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3.5.3  DCC (Deleted in Colorectal Carcinoma)    
This is a complex gene consisting of 29 exons spanning 1.4 megabases and is situated on 
chromosome 18q close to SMAD4.   Some early reports found abnormalities in the 
expression of the DCC gene in pancreatic cancer (Simon B et al, 1994; Hohne MW et al, 
1992) but subsequent work found that deletion of the DCC locus was uncommon (Barton CM 
et al, 1995).  More work is needed and in particular the definitive sequence has yet to be 
carried out. 
 
 
 
 
3.6  DNA Mutation Mismatch Repair (MMR) genes 
The DNA mismatch repair genes code for proteins that ensure the smooth DNA replication.   
Single base pair mutations that occur during division of DNA are identified and then repaired 
(Goggins M et al, 1998; Wilentz RE et al, 2000).   Inherited mutations in DNA mismatch 
repair genes are associated with an increased risk of cancer (Goggins M et al, 1998; Wilentz 
RE et al, 2000).  Moreover, there is an association with Lynch syndrome, as discussed 
elsewhere in the thesis which is characterised by an increased risk of developing colorectal, 
breast and about 4% in pancreatic cancer (Aarnio M et al, 1995; Goggins M et al, 1998).   
 
3.7  Apoptotic factors 
Apoptosis is a central regulator of homeostasis in normal tissue. Damaged cells are removed 
without an immune response and apoptosis balances cell proliferation under normal 
physiological conditions.  There are numerous apoptotic pathways; proapoptotic (Bcl-2, Bcl-
xl and Mcl-1) and anti-apoptotic (Bax, Bcl-xs) proteins have been reported in pancreatic 
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cancer (Miyamoto Y et al, 1999).   The bcl-2 family of apoptotic genes includes bcl-2, bcl-x, 
bax and bak plus others, most having four conserved domains. The first two domains are 
important for homo- and hetero-dimerisation and the fourth is important for normal function. 
Bcl-2 is an anti-apoptotic factor and sometimes is referred to as a cooperating oncogene. By 
itself it is unable to transform cells, but when activated in the presence of the oncogenes, bcl-
2 is vital to malignant transformation.  Bcl-x exists as two isoforms: bcl-xL is the longer form 
and functions as an apoptotic inhibitor (Boise LH et al, 1993) and bcl-xS functions as an 
apoptosis promoter.   Bax is a promoter of apoptosis and it has been shown that the ratio 
between bax and bcl-2 can be important in determining cell survival.  An excess of bax 
homodimers promotes cell death whereas an excess of bcl-2 homodimers will inhibit 
apoptosis.    
 
 
 
3.7.1   Tumour angiogenesis            
Angiogenesis is essential for tumour growth and metastasis.  Angiogenic factors include FGF 
and FGF, which stimulate locomotion and proliferation of endothelial cells and TGF, which 
has an effect on endothelial cell proliferation.  These and other angiogenic factors can be 
produced by the tumour as well as by endothelial and stromal cells. 
 
 
 
3.7.2    Angiogenin 
 
Angiogenin (ANG), an inducer of vascularisation is a 14,000MW polypeptide.  ANG may 
interact with endothelial cells via a cell surface receptor and extracellular matrix (ECM) such 
as proteoglycans (Hu G F et al, 1994).  ANG has been shown to bind to actin on the 
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endothelial cell surface and this complex may lead to the activation of several protease 
cascades. In patients with pancreatic cancer high levels of mRNS expression and high levels 
of serum ANG were significantly associated with poorer survival (Shimoyama S et al, 1996). 
 
3.7.3      Vascular Endothelial Growth Factor (VEGF) Platelet derived 
Endothelial Cell Growth Factor (PD ECGF) 
VEGF is a very potent and selective endothelial cell mitogen on the surface of pancreatic 
cells (Korc M, 2003), which has been shown to be associated with tumour progression and 
metastases in a variety of gastrointestinal malignancies. VEGF is a 38-46 kDa dimeric N-
glycoprotein which is chemotactic as well as mitogenic for endothelial cells in vitro, induces 
angiogenesis in vivo and increases the permeability of the vascular endothelium.  In humans 
four different isoforms have been identified (VEGF121, VEGF165, VEGF189, and VEGF206). In 
pancreatic cancer the predominant species are VEGF121 and VEGF165 (Fujimoto K et al, 
1998). 
PG-ECGF is a 55kDa polypeptide, which exists in vivo as a homodimer. PD-ECGF 
stimulates chemotaxis of endothelial cells and therefore indirectly induces angiogenesis 
(Kuniyasi H et al, 1999).   
 
 3.8       Stromal factors and adhesion molecules 
3.8.1   Urokinase plasminogen activator (uPA) and its receptor (uPAR) 
Plasminogen is an inactive proenzyme that can be converted to plasmin by urinary or tissue 
plasminogen activator (uPA and tPA). This has been implicated in pericellular proteolysis 
during cell migration and tissue remodeling.  This enzyme is initially released from cells as 
an inactive proenzyme (pro-uPA) that can be cleaved by and activated by protease (Schmitt 
M et al, 1992).  Pro-uPA and uPA bind to a specific cell surface receptor and following 
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ligand binding the uPA receptor increases the enzymatic activity of uPA itself.  Plasminogen 
is converted to plasmin by uPA leading to degradation of fibrin, type IV collagen, fibronectin 
and laminin. Plasmin also activates latent collagenases such as procollagenase (matrix 
metalloproteinase – MMP1) and pro-stromelysin (MMP3) (Lim YT et al, 1996; Baramova 
EN et al, 1997).  The activation of several growth factors such as hepatocyte growth factor, 
TGF, FGF and VEGF is mediated by uPA, uPAR and plasmin.  The resultant cellular 
activation and ECM proteolysis enhance the ability of pancreatic cancer cells to invade and 
metastasise.  As in other tumours, a concomitant overexpression of uPA and uPAR was 
associated with significantly worse survival times compared to those patients with no tumour 
expression of either uPA or uPAR or neither (Cantero D et al, 1997).    
 
 
 
 
3.8.2     E-cadherins and matrix metalloproteinases (MMPs) 
E-cadherin is a transmembrane glycoprotein responsible for homotypic binding and 
morphogenesis of epithelial tissues, which is localised to the epithelial junction complex.  In 
cancer decreased or absent expression of E-cadherin is associated with a decrease in cellular 
and tissue differentiation and higher metastatic potential.  Transfection of E-cadherin has 
been shown to inhibit motility and invasiveness of cancer cells and the imbalance with the 
expression of the natural inhibitions of MMP`s (TIMPs) is weakly associated with pancreatic 
cancer progression. 
The MMPs are a family of zinc-containing proteolytic enzymes that breakdown extracellular 
matrix proteins. One of the first steps of cancer invasion is the breakdown of the basement 
membrane, which is composed of predominately type IV collagen.  The level of MMP 
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enzyme activity has been shown to correspond to tumour grade, regional lymph node 
metastases and distant metastases. MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are type 
1V collagenases and are overexpressed in pancreatic cancer (Bramhall SR et al, 1996; 
Bramhall SR et al, 1997).  The expression of these metalloproteinases has been shown to 
directly correlate with invasion and metastasis in pancreatic cancer. A recent study assessed 
the expression of E-cadherin and MMP-2 and MMP-9 using in-situ hybridisation in 
pancreatic cancer (Kuniyasi H et al, 1999).  Expression of E-cadherin in pancreatic cancer 
was inversely correlated with tumour progression and the development of metastases.  
Patients with cancers that had an expression ratio of MMP: E-cad 3 had a significantly 
better prognosis than those with ratio of 3.  Inactivation of the adenomatous polyposis coli 
(APC) is observed at early stages of intestinal tumour formation, whereas loss of E-cadherin 
is usually associated with tumour progression.  Smit has demonstrated in an Apc mouse 
model that because both proteins compete for the binding to beta-catenin, an essential 
component of the Wnt signalling pathway, and a reduction of E-cadherin levels could 
influence both tumour initiation and progression (Smits R et al, 2000).   
 
3.8.3  Expression profiling 
It is well known that preoperative diagnosis for pancreatic cancer does not usually have the 
luxury of histological diagnosis as compared to other tumours.  Resections for chronic 
pancreatic may sometimes turn out to be malignant on postoperative histology and the 
collorary is the same for pancreatic cancer resections.   This then raises the question as to the 
need for accurate pre-operative diagnosis particularly given the high risk nature of these 
major operations.  It was with these concerns in mind that Young et al suggested that perhaps  
genetic  markers could be useful in the differentiation  of these different disease states by the 
introduction of “expression profiling” (Young RA, 2000).  The transcriptional profile or 
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transcriptome represents the entire mRNA population of a cell at a single time point.  From 
this transcriptome a “DNA microarray” can be made.  DNA microarrays can be stored on 
glass slides or nylon membranes.  It is then possible to analyse the relative up- or down-
regulation of genes in a particular disease state compared to normal.  The hope is that this 
knowledge may be used in diagnosis and possibly outcome of disease (Golub TR et al, 1999; 
Alizadeh A A et al, 2000).   
 
 
 
 
 
 
 
3.9    Summary 
Several genetic alterations have now been identified in the causation of pancreatic 
adenocarcinoma.  These fall broadly into oncogenes e.g. K-ras, tumour suppressor genes e.g. 
p53, p21, p16, SMAD4, growth factor receptors e.g. c-erb family and other genes responsible 
for maintenance of the genome e.g. BRCA2, microsatellite instability. Given this knowledge, 
it has been possible to postulate the cancer progression model with the potential for early 
diagnosis, screening and perhaps selection for chemotherapeutic agents. It has now been 
shown that K-ras mutations frequently occur early, whereas changes in the expression of the 
p16 gene appear in intermediate lesions.  The inactivation of the p53, DPC4 genes occur late 
in the neoplastic progression model.   
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Table 3.1.    Frequency of major genetic alterations in pancreatic cancer 
 
Gene (ref)       Normal  PanIN1A PanIN1B PanIN2  PanIN3     Carcinoma
         
K-ras (1)   0%  38%  44%  87%  _ 
 
 (2) 3%  30%  31%  73%  _         90-
100 
 
 
INK4a (3)  0%  30%  27%  55%  71% 
 100% 
 
P53 (3) 0%  _  _  _  12%  40% 
 
 (4) 0%  _  35%  _  36%  40% 
  
 (5) 0%  0%  0%  20%  57%  47% 
 
DPC4 (6) _  0%  0%  0%  31%  55% 
 
 (1)Terhune PG et al, 1998, (2) Biankin AV et al, 2001, (3) Moskaluk CA et al, 1997, (4) Apple SK et al, 1999, 
(5) DiGiuseppe JA et al, 1994, (6) Wilentz RE et al, 1998. 
Adapted from Schneider G and Schmid RM (2003) “Genetic alterations in pancreatic 
carcinoma”.  Molecular Cancer; 2:15.  
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Chapter 4       Prognostic molecular markers in Pancreatic cancer 
 
   4.1    Introduction 
Pancreatic cancer is a very aggressive tumour with the majority of patients presenting with 
unresectable disease.    The minority who undergo resection have a longer median survival 
of 18-24 months with a 5-year survival rate of less than 10% (Gudjonsson B et al, 1987; 
Bramhall SR et al, 1995). Resectability rates of pancreatic cancer have steadily improved, 
mainly because of improved postoperative care and the concentration of pancreatic 
resections in experienced centres (Neoptolemos JP et al, 2001, Riall TS et al, 2005). 
Moreover, the currently available chemotherapy and radiotherapy have not shown improved 
survival in advanced disease but a number of trials studying the efficacy of various forms of 
adjuvant therapy are in progress (Ghaneh et al, 2001, Abbott, DE et al, 2010).  It is 
important therefore to have reliable prognostic factors to assess the efficacy of the 
increasingly numerous surgical and adjuvant therapies advocated in an attempt to improve 
survival rates in patients with pancreatic cancer.  Prognostic factors are used to assess the 
risk of systemic disease, recurrence or death after primary treatment and as a guide to the 
use of adjuvant therapy.  
 Clinical prognostic variables used in many staging systems of solid tumours include tumour 
stage, tumour size, grade and lymph node involvement. Current staging systems in use 
include the UICC/TNM classification in the West and the JPS system in Japan but as 
discussed in chapter 2, they are not comparable.  This causes difficulties when comparing 
survival data due to ‘stage system migration’.  The serum concentrations of tumour markers 
such as CA19-9, CA242 and MUC1 may have prognostic significance in advanced disease 
but not in patients with small tumours.   Biological factors provide further prognostic 
information but although not effectively used in a routine clinical setting, they improve 
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understanding of cancer and development of new treatments.  The clinical factors that have 
been studied as shown in this chapter are unsatisfactory in clinical the management of this 
lethal tumour and the two major staging systems are inadequate.   The molecular biology of 
pancreatic cancer is now better understood and consistent genetic changes include 
overexpression of growth factors and growth factor receptors (EGF, TGF alpha, 
amphiregulin, c-erbBs 2-4,aFGF, βFGF, TGFR, TGFβRs); inactivation of tumour 
suppressor genes (TS), p53, p16, p21, SMAD4 and activation of dominant oncogenes (K-ras 
and cyclin D1).  The possible use of these molecular markers for prognosis in pancreatic 
cancer has been suggested. 
   
4.2     Tumour suppressor genes 
4.2.1   p53 
Mutations in the tumour suppressor gene p53 contribute to the development of up to half of 
all human cancers (Harris CC, 1993); Greenblatt MS et al, 1994).    A high degree of p53 
expression has been reported in several human cancers (Lipponen P et al, 1993; Joypaul BV 
et al, 1994; Auvinen A et al, 1994; Hardwick RH et al, 1997).  The correlation between p53 
expression and prognosis however varies in different studies and in different forms of cancer.  
In pancreatic cancer, a high level of p53 expression has been demonstrated in up to 75% of 
tumours (Barton et al 1991; Zhang et, 1994; Rozenblum et al, 1997; Apple SK et al, 1999).   
Results of p53 overexpression in pancreatic tumours are conflicting.  Lundin et al (1997) 
found no association between p53 overexpression and tumour stage, histology, age, sex or 
survival in a study of 133 patients with pancreatic cancer.   Other studies have demonstrated 
similar results (Zhang et al, 1994; Dergham et al, 1997a; Ruggeri et al, 1997; Makinen et al, 
1998).   Three small studies have reported reduced survival (Yokohama et al, 1994; Weyrer 
et al, 1996; Linder et al, 1997; Sessa F et al, 1998).   Yokohama et al (1994) reported a 
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marginally significant association in 69 patients.  DiGiuseppe et al (1994) in a study of 48 
patients reported an association with poor prognosis although it was not significant and in the 
study by Linder et al (1997), a different cut off level of 1% p53 immunoreactivity was used.  
In a study of both p53 and Bcl-2 in the same patients, Bold et al, (1999) found that patients 
whose tumours stained positive for p53 and Bcl-2 had a longer survival period when 
compared to tumours that stained negative for both markers.   Two studies investigated 58 
patients of whom 28 had surgery alone and the other 30 had adjuvant chemotherapy.  Patients 
with p53 positive tumours (shown by immunostaining) who had chemotherapy had a 
significantly better survival times than those who did not (Nio Y et al, 1998).  This is 
probably a reflection of the fact that tumours containing a mutated p53 are usually radio 
resistant and/or chemo resistant (Dergham St et al, 1998).   Patients with combined p53 
positive and p21 negative tumours had significantly poorer survival and those of this group 
who had chemotherapy had a non-significant trend for improved survival (Nio Y et al, 1999).  
Immunhistochemistry has been used to examine premalignant lesions for p53 inactivation.   
DiGiuseppe et al found immunoreactivity in 12% of 17 cases of histologically high grade 
lesions (carcinomas in situ) while lower-grade lesions did not show immunoreactivity to p53 
(DiGiuseppe JA et, 1994).  This suggests that p53 gene inactivation is a late event in genetic 
progression in pancreatic ducts.  The wide variation in p53 status seen with IHC can be 
partially explained by methodology; fresh specimens will give a more accurate picture than 
specimens that have had a long delay between extraction and processing.  A more accurate 
approach is the use of microdissection to obtain samples containing only cancerous cells, 
followed by direct sequencing.  Rozenblum et al (1997) for example found p53 mutation in 
31 out of 41 (76%) samples.  Apple et al, 1999 used IHC on 15 cases of PDAC and found 
that 13 out of 15 (87%) invasive carcinomas stained for p53, compared to 3 out of 15 (20%) 
dysplastic areas.  Only one out of 50 samples showed positive p53 staining in normal or 
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hyperplastic cells.  In contrast, 11 out of 15 (73%) dysplastic areas stained positive for the 
mutant K-RAS gene product p21.  p53 mutation therefore represents a later genetic event in 
PDAC than K-RAS mutation (Apple SK, 1999). 
 
 
 
 
 
4.2.2  p16 
Approximately 85% of all pancreatic cancers have mutated or deleted p16 gene (Caldas C et 
al, 1994; Liu Q et al, 1995; Naumann M et al, 1996).    The p16 gene has been shown to be 
genetically mutated or its expression abrogated in duct lesions (Wilentz RE et al, 1998; 
Moskaluk CA et al, 1997).  Its inactivation can be detected occasionally as early on in flat 
intraductal neoplasia (including PanIN-1-A).  Wilentz et al (1998), using 
immunohistochemistry for the p16 gene product, showed that 30% of flat duct lesions 
without significant atypia, 55% of papillary duct lesions without significant atypia, and 71% 
of papillary duct lesions with significant atypia had loss of expression of the p16 gene 
product.   Bartsch D et al (1996) reported that the survival of patients whose tumours 
contained CDKN2 mutations was significantly less than that of patients whose tumours 
contained no mutations (median survival times of 8.5 months and 17.0 months respectively; 
p<0.01).   Naka T et al (1998) in an immunohistochemical study of 32 cases of pancreatic 
cancer, found that 19 out of 32 (59%) stained positive for p16 protein and there was a 
significant correlation between p16 negativity and poor prognosis.   
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4.2.3  p21 
p21 overexpression is an early event in the development of pancreatic intraepithelial 
neoplasia (Biankin AV et al, 2001).  In a study of 451 Pan IN lesions present in the pancreas 
of 60 patients, p21 overexpression was found in 9% of normal ducts 9%, in 16% of patients 
with Pan IN-A lesions, 32% in Pan IN-B lesions, 56% with PanIN-2 lesions, 80% in patients 
with PanIN-3 and 85% of patients with invasive carcinoma (p<0.01).  In the same study, p53 
and cyclin D1 occurred predominantly in PanIN-3 lesions (Biankin AV et al, 2001).   p21 
overexpression was found to be independent of p53 and DPC4/Smad4 expression within 
invasive carcinoma and PanIN-3 lesions demonstrating that it is an early event in the 
development of Pan IN appearing before aberrations in p53, cyclin D1 and DPC4/Smad4 
expression.  This may possibly be explained by increased Ras activity either through 
activating K-ras mutations or by c-erbb-2 overexpression (Biankin AV et al, 2001).   Previous 
work by Coppola D et al (1998) observed a lack of correlation between p53 alterations and 
p21WAF1 expression in human pancreatic cancer, a finding that is consistent with the reported 
TGF-ß1 induction of p21WAF1 through a p53-independent mechanism (Coppola D et al, 
1998).   Published studies so far have not shown any prognostic value in p21 expression as 
demonstrated with immunohistochemistry (Okada N et al, 1995; Coppola D et al, 1998; 
Ruggeri BA et al, 1997). A study of 75 cases by Dergham et al (1997) however reported a 
better survival of patients with an earlier clinical stage who overexpressed the p21 protein.  
They also reported that there was improved survival with adjuvant treatment in tumours that 
were p21 positive and p53 negative (Dergham ST et al, 1997).   The role of chemotherapy in 
these patients may be important; in one study using immunostaining patients with a 
combination of p53 positive (implying the presence of mutant p53) and p21 negative tumours 
demonstrated poorer survival following resection and adjuvant chemotherapy (Nio Y et al, 
1999).   In another study median survival in patients with resected pancreatic cancer who 
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received adjuvant chemo radiation with p21WAF1 positive tumours was significantly longer 
than those with negative staining (25 months versus 11 months p=0.01) (Ahrendt SA et al, 
2000). 
 
4.2.4  BRCA2 
Carriers of this mutation have a ten-fold higher risk of developing pancreatic cancer than the 
general population (Bretnall TA et al, 2000).  The penetrance of the mutation seems to be low 
and there are likely environmental factors involved resulting in a rather late onset of the 
disease.  In addition, the exact incidence of BRACA2 germline mutations in the general 
population has not yet been determined and any screening programme needs more 
information in order to be cost effective.  Mutations appear to occur often in Ashkenazi Jews 
(617delT).  The estimated risk of acquiring pancreatic cancer by the age of 75 is 7% in the 
carriers as compared to 0.85% in the general population (Ozcelik H et al, 1997).  Mutation 
analysis of different grades of precursor lesions [pancreatic intraepithelial neoplasia (Pan IN)] 
for allelic imbalance in germline BRCA2 mutations in carriers with pancreatic cancer 
revealed loss of heterozygosity in one grade 3 Pan IN and in none of 13 grade 1 Pan IN 
lesions.  These findings indicate that LOH at the BRCA2 gene locus is not likely to be an 
early event in tumourigenesis unlike several other genes in inherited cancer syndromes [for 
instance APC gene in familial adenomatous polyposis (Goggins M et al, 2000)].   
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4.3  Oncogenes 
4.3.1  cyclin D1 
A study of 82 pancreatic cancers demonstrated overexpression (by immunostaining) of cyclin 
D1 in 65% of tumours and this was associated with shorter survival for these patients, but not 
independently of tumour stage and grade (Gansauge F et al, 1998).  In another study (n=16 
patients) a median survival of 6.5 months was reported in patients with higher levels of cyclin 
D1 compared to 15.5 months in those with low expression (Kornmann M et al, 1998).  In a 
more recent study of 129 patients, there was no correlation between cyclin D1 overexpression 
and survival (Biankin AV et al, 2002). Cyclin D1 and DPC4 /SMAD4 overexpression or loss 
was seen in 85% of invasive carcinomas but in only 14% of PanIN-2 lesions.  With respect to 
adjuvant treatment, the inhibition of cyclin D1 in addition to suppressing the growth of 
pancreatic cancer cells enhances their responsiveness to cisplatinum and this could possibly 
be due to the altered expression of several chemo resistance genes (Kornmann M et al, 1999). 
 
4.3.2  K-ras 
Kras mutations have been reported to occur with a very high frequency in pancreatic cancer 
with point mutations found in 70-90% of cases, the most common of which result in the 
substitution of the wild type glycine residue (codon 12) by cysteine, arginine, valine or 
aspartic acid (Smit et al, 1998; Lemoine NR et al, 1992a; Finkelstein et al, 1994). This high 
frequency of mutations is not found in other tumours. Mutated K-ras is present in both 
invasive and the earlier non-invasive cells.  Evidence for this comes from a number of 
studies.  Sugioe et al performed microdissection from tissue adjacent to areas of unequivocal 
malignancy and were able to demonstrate  K-ras mutations in all of the  17 carcinoma-in – 
situ lesions, and 19 out of 21 (90%) of the atypical hyperplasia lesions (Sugio K et al, 1997). 
Additional evidence for this came from a larger study on operative specimens in which a 
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third of early ductal lesions were found to have a K-ras mutation (Luttges J et al, 1999).  
These two studies are also supported by work done using a hamster model of experimental 
PDAC using N-nitroso-bis (2-oxopropyl) amine (BOP) (Fujii H et al, 1990; Cerny WL et al, 
1992).  BOP induces pancreatic cancer characterized by a transition at codon 12 of K- RAS 
(GGT to GAT), causing a substitution of aspartate for glycine.  This is the most frequently 
occurring K-ras mutation in human PDAC and furthermore the same experimental model 
gives rise to K-ras mutation in early lesions (described in the report as hyperplasia, papillary 
hyperplasia and carcinoma – in- situ).   A number of investigators have micro dissected the 
duct lesions of the pancreas and analysed them for K-ras mutations (Yanagisawa A et al, 
1993; Caldas C et al, 1994; Wilentz RE et al, 1998).  The first genetic evidence for a 
progression model for these duct lesions was provided by Caldas et al (Caldas C et al, 1994; 
Yanagisawa A et al, 1993).  They noted that activating point mutations in codon 12 of the K-
ras gene occur in about half of the non papillary duct lesions, but were present in the vast 
majority of papillary and more advanced lesions.  It is this progression in K-ras mutational 
frequency that suggests that K-ras is not necessarily the first change, or gatekeeper required 
for pancreatic ductal neoplasia (Kinzler KW et al, 1997).   
The presence or the type of K-ras mutations in pancreatic tumours has not been shown to be 
associated with patient survival (Hruban RH et al, 1999; Dergham ST et al, 1997).  Hruban et 
al (1999) studied 82 cancers and found mutations in 63 (83%).  There was a higher 
prevalence of mutations in 72 patients (88%) who had smoked cigarettes at some time in their 
life; 67 patients (86%) in current smokers and 78 patients (89%) in ex-smokers.  The 
presence of mutations did not correlate with survival (Hruban RH et al, 1999).   Scarpa 
(1994) reported differences in the pattern of Kras mutations seen in the Japanese as compared 
to Europeans and also regional variations  (Scarpa A et al, 1994), raising the possibility of 
ethnic or environmental differences. K-ras mutation analysis in Europeans showed 
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differences amongst countries; all mutations in an Italian population (80.5%) involved the 
second base and were G to A transitions or G to T transversions while in a Spanish 
population (73%) different bases were involved (Scarpa A et al, 1994).  In a study of 51 
Japanese and 34 Chinese patients, K-ras point mutations were found in 94% and 71% 
respectively and in addition the patterns of mutations was different (Song et al, 2000).  The 
GAT mutation appeared more in the Japanese and there was also a higher ratio of transitions 
to transversions as compared to the Chinese.  It is likely that environmental and social factors 
may contribute to these differences (Song et al, 2000). Given that the risk of pancreatic 
cancer is significantly elevated in patients with chronic pancreatitis, a study was carried out 
to determine the frequency of K-ras mutations in chronic pancreatitis.  DNA samples from 21 
normal pancreatic tissues, 26 chronic pancreatitis tissues and 24 pancreatic cancers were 
analysed for K-ras mutations.  None of the DNA samples from normal or chronic pancreatitis 
exhibited a K-ras mutation at codons 12 or 13.  In contrast 17 of the 24 pancreatic cancer 
were found to have a K-ras mutation (Hsiang D et al, 1997). DNA from the pancreas of 
intraoperative resected specimens of 60 patients with chronic pancreatitis and 11 patients 
with histologically confirmed pancreatic cancer was evaluated by PCR amplification.  In 
none of the 60 samples of chronic pancreatitis (CP) could K-ras mutations be found (Ort M et 
al, 1998).  Boadas however found K-ras mutations in 8 of 49 cases (16%) of CP studied 
(Boadas J et al, 2001).  Mutant K-ras was detected in pancreatic juice from 20 out of 54 
patients (37%) with CP and on long term follow up (mean 78 months) there was no evidence 
of the development of PDAC (Furuya N et al, 1997).  Even more surprisingly some reports 
also suggest the presence of mt K-ras in patients with no pancreatic disease at all (Luttges J et 
al, 1999).  This undermines the use of mt K-ras alone as a marker of pancreatic pathology.  
Moreover, it implies that the pancreas is in some way resistant to K-ras mutation that would 
normally induce death or that there may be another, as yet unknown, pre-existing genetic 
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event that allows K-ras mutation to be tolerated.  The simplest method of detecting K-ras 
mutations is to amplify K-ras DNA using the polymerase chain reaction (PCR) and then 
sequence the product.  However, neoplastic cells will normally comprise only 25% of the 
pancreatic tumour mass, the remainder being composed of the desmoplastic response.  Hence 
microdissection of suspected tumour tissue is essential for accurate genetic analysis.  To 
improve sensitivity various techniques have been developed to enrich mutant sequences e.g. 
restriction fragment length polymorphism (RFLP) and the amplification refractory mutation 
system (ARMS) based on mutation specific primers in combination with PCR.  Clinical trials 
using vaccinations against mutant K-Ras protein are in progress (Z’graggen Z et al, 2000).   
Vaccinations using either directly injected peptides corresponding to the mutant codon 12 or 
through insertion of mini-gene cassettes that express mutant K-RAS peptides that reflect the 
mutation found in host cells (Gjertsen MK et al, 1995; Khleif SN et al, 1999). 
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4.4  Growth factor receptors 
4.4.1  c-erbB-2 
The c-erbB-2 proto-oncogene has been reported to be overexpressed in a number of human 
tumours (Yokota J et al, 1986; Gullick WJ et al, 1987; Scorilas A et al, 1995; Hardwick RH 
et al, 1997; Morote J et al, 1999). Few studies exist on c-erbB-2 overexpression and survival 
in pancreatic cancer.  C-erbB-2 is overexpressed in about 20% of invasive pancreatic cancers 
and this is usually attributed to gene amplification.  .  In precursor lesions c-erbB-2 has been 
reported to be expressed in flat duct lesions, papillary duct lesions without atypia and atypical 
duct lesions in 82%, 86% and 92% of cases respectively (Day et al, 1996).  Hall reported c-
erbb-2 overexpression in 17 (19%) of 87 cases of pancreatic cancer studied (Hall PA, 1990).  
In a series of 79 pancreatic tumours Dugan MC et al (1997) studied c-erbB-2 expression and 
correlated this to histological grade and survival.  They found a lower expression of c-erbB-2 
in poorly differentiated parts of the tumour as compared to the well differentiated and poorly 
differentiated areas but no difference in survival.   In a recent study of 154 patients with 
pancreatic cancer, Safran H et al (2001) reported that thirty patients (21%) demonstrated 
cerbB-2 overexpression by immunohistochemistry but this did not correlate with survival.  
Similar results have been found by Novotny J et al (2001) in 57 cases studied.  In contrast, 
Lei S et al (1995) in a small series of 21 pancreatic cancers found c-erbB-2 overexpression in 
10 (47.6%) of cases and this was closely and inversely related to survival.   This study was 
supported by Okada et al (1995) who found a correlation between survival and serum levels 
of c-erbB-2.  
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 4.4.2  c-erbB-3 
The c-erbB-3 gene has no known natural ligand but shares a similar structure to EGF receptor 
and c-erbB-2.  In normal pancreas c-erbb-3 is only seen in the islets of Langerhans but has 
been detected in up to 90% of pancreatic and ampullary cancers (Lemoine NR et al, 1992).  
Freiss et al (1995) found the c-erbB-3 overexpression in 47% (27 of 58) cases and these were 
found to correlate with decreased patient survival.   
 
4.4.3  TGFBs and TGFB receptors 
The three isoforms of TGF have been shown to be overexpressed in pancreatic cancer. 
Survival data from 60 patients with pancreatic cancer showed a significantly decreased 
survival time with overexpression of these isoforms (Friess H et al, 1993; Lu Z et al, 1997).  
In a more recent study however, TGF-1, which was expressed in 31%, was not significantly 
associated with survival (Coppola D et al, 1998).  The TGF receptors are all found in 
normal pancreas but in cancer there is an overexpression of TGF-2 receptor only (Friess et 
al, 1993b) 
 
 
 
4.4.4  Fibroblast growth factors 
Both αFGF and βFGF are overexpressed in pancreatic cancer tissue at the mRNA and protein 
levels (Yamanaka Y et al, 1993; Vickers SM, 1999). Expression of βFGF and FGFR but not 
αFGF is associated with poor prognosis (Yamanaka Y et al, Ohta T et al, 1995). 
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4.5  Apoptotic factors 
Several recent studies have looked at these factors in pancreatic cancer.  In a study of 60 
patients tumour expression of bax immunostaining was associated with significantly longer 
survival compared with patients who had negatively staining tumours (Friess H et al, 1998).  
Bcl-2 also has prognostic significance (Friess H et al, 1998) but several studies have shown 
that expression of the bcl-xL is significantly associated with poor survival (Friess H et al, 
1998; Miyamoto Y et al, 1999; Evans JD et al, 2001).  This is surprising since bcl-xL inhibits 
apoptosis and suggests reduced anti-apoptosis by heterodimerization. 
 
4.5.1   Vascular Endothelial Growth Factor (VEGF) Platelet derived Endothelial 
Cell Growth Factor (PD ECGF) 
VEGF and PD-ECGF are frequently co-expressed in human cancers. Intratumoural micro 
vessel density (MVD) is a prognostic marker in several tumour types including breast cancer. 
Two studies in pancreatic cancer (a relatively hypovascular tumour) did not show prognostic 
value for MVD; the expression of PD-ECGF however was associated with a significantly 
reduced survival (Fujimoto K et al, 1998; Ellis LM et al, 1998).  These latter studies also 
showed no prognostic value for VEGF expressing tumours but a third study found a 
significantly shorter survival for those patients with VEGF positive tumours (Ikeda N et al, 
1999). 
 
4.5.2   SMAD4 (DPC4-deleted in pancreatic carcinoma, locus 4) 
Immunohistochemical labelling for the SMAD4 gene product has been reported to correlate 
with gene expression (Wilentz et al, 2000).  Loss of DPC4/Smadd4 expression cosegregated 
with resectability (p<0.0001) and was associated with improved survival after resection 
(p<0.0001), whereas resection did not improve survival in patients whose tumour expressed 
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DPC4/SMAD4 (p=5).  They concluded that preoperative assessment of this gene has a 
potential as a prognostic maker in patients with pancreatic cancer given that resection did not 
benefit those patients whose cancers expressed DPC4/Smad4.   
 
 
4.6     E-cadherins and matrix metalloproteinases (MMPs) 
The expression of metalloproteinases has been shown to directly correlate with invasion and 
metastasis in pancreatic cancer. A recent study assessed the expression of E-cadherin and 
MMP-2 and MMP-9 using in-situ hybridisation in pancreatic cancer (Kuniyasi H et al, 1999).  
Expression of E-cadherin in pancreatic cancer was inversely correlated with tumour 
progression and the development of metastases.  Patients with cancers that had an expression 
ratio of MMP: E-cad 3 had a significantly better prognosis than those with ratio of 3.  
Inactivation of the adenomatous polyposis coli (APC) is observed at early stages of intestinal 
tumour formation, whereas loss of E-cadherin is usually associated with tumour progression.  
Smit has demonstrated in an Apc mouse model that because both proteins compete for the 
binding to beta-catenin, an essential component of the Wnt signalling pathway, and a 
reduction of E-cadherin levels could influence both tumour initiation and progression (Smits 
R et al, 2000).  In addition the loss or reduced function of E-cadherin may affect tumour 
formation by altering its cell-adhesiveness.   
   
4.7  DNA Mismatch Repair Genes 
In a small series of nine pancreatic carcinomas Han H-J et al (1993) found microsatellite 
instability in six pancreatic ductal adenocarcinomas.  
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4.8  DNA Ploidy and cell proliferation 
The content of DNA in the nuclei of tumour cells has been correlated with survival in 
pancreatic cancer.  There seems to be agreement that diploid tumours have slightly better 
survival than aneuploidy tumours, but there is no real effect on survival (Linder S et al, 1994; 
Takada T et al, 1995; Berczi C et al, 1999). Correlation with liver metastases in pancreatic 
cancer has been reported with increased levels of Ki-67, a marker of proliferating tumour 
cells (Ferrara C et al, 1999).    
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Table 4.1.   Immunohistochemical studies of molecular factors in pancreatic cancer 
 
Study  Year No Factor  Expression Survival       P   value 
        Median 5year 
        (mths)  (%) 
Gansauge et al 1998 82 cyclin D  +  10  - 
      -  18  - <0.01 
Friess et al 1998 60 bax  +  12  - 
      -  5  - <0.04 
Friess et al 1998 74 bcL-xL  +  5  - 
        12  - <0.05 
Evans et al 1998 24 bcL-xL  +  6  -  
      -  20  - <0.002 
Dong et al  1998 57 EGF+R  +  10  - 
      -  17  - <0.002 
Lei et al  1995 21 c-erbB-2  +  7  - 
      -  19  - <0.01 
Friess et al 1995 58 c-erbB-3  +  9  - 
      -  13   <0.04 
Friess et al 1995 60 TGFβ-1  +  9  - 
      _  12  - <0.05 
    TGFβ-2  +  7  - 
      -  13  - <0.001 
    TGFβ-3  +  7  - 
      -  12   <0.01 
Coppola et al 1998 42 TGFβ-1  +  13  23 
      -  5  4 <0.05 
Yamanaka et al 1993 78 βFGF  +  9  - 
      -  16  - <0.001 
Bramhall et al 1996 50 MMP-2 –3 & timp1    +  50   <0.0001 
Seo Y et al  2000 142 vegf  +  132  
      -  10   < 0.0001 
 
 
EGFR+R=epidermal growth factor and receptor; TGFß = transforming growth factor beta; 
bFGF=basic fibroblast growth factor.  
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4.9   Summary 
 
The molecular alterations found in pancreatic cancer, loss of control at key points in the cell 
cycle together with the over expression of growth factors help to explain the poor prognosis 
associated with this tumour.  In addition angiogenic factors and apoptotic genes have 
significant correlations with survival and/or treatment responsiveness in pancreatic cancer.  
The effect of oncogene mutations and tumour suppressor gene loss on the biology of 
pancreatic cancer is very complex and is still not fully understood in pancreatic cancer.  
There is now the potential to repair the genetic defects and to develop pharmacological agents 
that counter the resulting changes.  Pancreatic cancer is the only gastrointestinal malignancy 
with a consistent genetic profile and this places scientists in a position to take advantage of 
the recent advances in molecular biology techniques to improve diagnosis and treatment.  
Given the inadequate staging systems available at present, the genetic changes in pancreatic 
cancer may provide a basis for prognostic markers.  
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4.10  Research aims 
 
Previous studies of molecular prognostic markers following resection for exocrine pancreatic 
cancer have produced conflicting results.  The aim of this project was to undertake a 
comprehensive analysis of potentially useful molecular markers in a large, multicentre patient 
population and to compare these markers with standard pathological prognostic variables.  
Formalin-fixed, paraffin-embedded specimens of pancreatic ductal adenocarcinoma were 
analyzed from 157 patients who had undergone pancreatectomy in the United Kingdom and 
Sweden.  Immunohistochemistry was used to detect expression of p16INK4, p53, p21WAF1, 
cyclin D1, erbB-2 and erbB-3.  Mutations in p53 and K-ras were detected using Sequence 
Specific Conformational Polymorphism (K-ras only) and sequencing following DNA 
extraction and amplification by PCR. 
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CHAPTER 5: IMMUNOHISTOCHEMICAL STUDIES      
 
 
5.0   Immunohistochemistry 
 
The aim of this part of the study was to employ immunohistochemistry to study the 
significance of growth factor overexpression including receptors (c-erbB-2 and c-erbB-3), 
p53, p21 and cyclin D1 overexpression and p16 loss in resected ductal pancreatic 
adenocarcinoma using formalin-fixed paraffin-embedded glass slides.  The data produced 
was analysed in conjunction with the Union International Contre Le Cancer system using 
univariate and multivariate analysis.  Immunohistochemistry is an inexpensive method to 
detect altered protein products.  Many investigators use IHC as a screening test prior to DNA 
sequencing, and staining is often considered a surrogate marker for gene mutation in the 
absence of confirmatory DNA studies.  Other methods for screening tumours to identify those 
likely to contain mutations involve detection of altered electrophoretic mobility patterns of 
DNA sequences containing point mutations e.g. Sequence Specific Conformational 
Polymorphism (SSCP).   
 
5.1  Introduction 
 
Recent molecular studies have identified a high frequency of genetic abnormalities in growth 
factor regulation (e.g. c-erbB-2 and 3), inactivation of tumour suppressor genes (e.g. p53, 
p21, p16) and activation of dominant oncogenes (e.g. cyclin D1) in pancreatic cancer 
formation.  Currently used staging systems are poor at predicting the biological behaviour of 
pancreatic cancer, particularly with “small” or “early” pancreatic tumours.  Therefore 
accurate prognostic systems are required to assess the outcome of different forms of 
treatment currently under investigation. Previous immunohistochemical studies of molecular 
markers in pancreatic cancer are few with small numbers of patients and usually studying 
expression of a single gene.  Immunohistochemistry is a method where localisation and 
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visualisation of cellular or tissue components (antigen) in situ by use of specific antibody: 
antigen reactions and has become important in the diagnosis of tumours.   As well as being 
important diagnostically, the expression of several antigens expressed by 
immunohistochemistry correlates with the prognosis of a number of cancers and may 
influence treatment (Gaskell DJ et al, 1989).  The principle of the method was first described 
by Marrack (1934).    The avidin biotin complex (ABC) technique and the similar 
streptavidin biotin complex (StrepABC) were the most commonly used methods. The 
principle of the ABC method is based upon the high affinity that Streptavidin, a large 
bacterial protein has for biotin, a low molecular weight vitamin found in egg yolk   
 
5.2  Avidin-biotin indirect  
 
The high affinity of avidin for biotin is exploited in immunohistochemistry.  Avidin has four 
binding sites for biotin although the molecular orientation of these binding sites is such that 
fewer than four molecules will actually bind.  A secondary antibody that contains a 
covalently attached biotin molecule is able to occupy these unbound sites, hence allowing 
attachment of the avidin-biotin complex.  Labelling of the avidin-biotin complex with a 
peroxidase molecule enables the use of a chromagen reaction, involving hydrogen 
peroxidase, to complete the immuno-labelling process.  If the primary antibody used in this 
method is derived from mouse or rabbit, the secondary antibody must be directed against 
mouse or rabbit immunoglogulins respectively.  The third step involves the application of a 
pre-formed avidin-biotin complex labelled with horseradish peroxidase.  This complex binds 
to the biotinylated secondary antibody, which in turn is bound to the primary antibody.  A 
substrate-chromagen solution containing 3, 3’- diaminobenzidine tetrahydrochloride (DAB) 
and hydrogen peroxide is then applied to the sections for eight minutes.  As a result of these 
steps, the staining patterns in the section reflect the presence or absence of the antigen of 
interest. 
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Figure 5.1:  Avidin- Biotin Complex. 
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5.3  Patients  
 
Three centres contributed archival pathological specimens from one hundred and fifty seven 
patients who had undergone resection for pancreatic ductal carcinoma with curative intent.  
There were 69 patients from the University Hospital of Lund, Lund Sweden operated upon 
between 1969-1984; 66 patients who had undergone resection between 1984 and 1995 at the 
Queen Elizabeth Hospital, Birmingham, UK; and 22 patients who had undergone resection 
between 1990 and 1997 at the Royal Liverpool University Hospital, Liverpool, UK.  Thirteen 
patients (8%) had adjuvant treatment as part of the ESPAC trial (Neoptolemos JP et al, 2001).  
Archival formalin fixed paraffin embedded blocks were retrieved from the respective 
pathological departments.  Survival and clinico-pathological data were obtained from hospital 
records, cancer registries and in a few cases by contact with the general practitioner of the 
patient.  
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Table 5.1 Swedish clinical data   
 
Case Age Clear 
margins 
Grade Stage Tumor 
size (cm) 
Lymph node Adjuvant 
treatment 
Survival (Days) 
1 70 Yes Poor 3 2.5 Yes None 7 
2 60 Yes Poor 3 3.5  None 135 
3 60 Yes Moderate 2 2.0  None 420 
4 73 Yes Moderate 3 4.5  None 161 
5 46 Yes Well 1 2.0  Dxt 269 
6 59 Yes Poor 3 3.0  None 0 
7 47 Yes Moderate 3 3.5  None 104 
8 38 Yes Moderate 3 4.0  None 154 
9 56 Yes Poor 3 4.0 Yes None 327 
10 48 Yes Poor 3 3.0  Dxt 473 
11 65 Yes Poor 3 2.0  None 461 
12 77 Yes Poor 3 3.0  None 670 
13 65 Yes Poor 1 5.0  None 402 
14 59 Yes Poor 1 3.0  None 389 
15 46 Yes Poor 1 2.0  None 498 
16 45 Yes Poor 3 3.0  None 390 
17 67 Yes Poor 1 4.0  None 53 
18 60 Yes Moderate 3 2.5  None 131 
19 68 Yes Well 1 5.5  None 120 
20 58 Yes Moderate 2 2.0 No None 252 
21 72 Yes Poor 3 4.5 Yes None 206 
22 64 Yes Moderate 3 4.0 Yes None 511 
23 53 Yes Poor 1 4.0 No None 637 
24 56 Yes Moderate 2 2.0 No None 210 
25 68 Yes Moderate  3.5  None 210 
26 62 Yes Moderate 1 1.5 No None 390 
27 61 Yes Poor 2 5.0 No None 210 
28 56 Yes Poor 1 3.0 No None 533 
29 59 Yes Moderate 2 3.0 No None 13 
30 71 Yes Poor 3 4.0 Yes None 342 
31 72 Yes Moderate 1 3.0 No None 1120 
32 70 Yes Poor 1 3.5 No None 716 
33 75 Yes Moderate 2 6.0 No None 403 
34 56 Yes Poor 3 5.0 Yes None 210 
35 46 Yes Moderate 3 4.0 Yes None 137 
36 66 Yes Moderate 2 3.0 No None 60 
37 64 Yes Poor 3 3.5 Yes None 29 
38 53 Yes Moderate 3 3.5 Yes None 204 
39 69 Yes Poor 3 2.0 Yes None 210 
40 68 Yes Poor 3 4.0 Yes None 112 
41 73 Yes Poor 2 4.0 No None 30 
42 58 Yes Moderate 3 2.0 Yes None 92 
43 67 Yes Moderate 3 4.0 Yes None 347 
44 49 Yes Well 1 3.0 No None 1308 
45 65 Yes Poor 1 3.5 No None 454 
46 76 Yes Poor 2 2.5 No None 219 
47 56 Yes Moderate 3 3.0 Yes None 440 
48 54 Yes Poor 2 4.0 No None 181 
49 77 Yes Moderate 2 1.5 No None 337 
50 59 Yes Moderate 1 4.0 No None 150 
51 71 Yes Moderate 1 2.0 No None 1769 
52 55 Yes Well 3 1.0 Yes None 234 
53 68 Yes Well 3 6.0 Yes None 125 
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54 51 Yes Moderate 3 4.0 Yes None 798 
55 63 Yes Moderate 1 2.0 No None 458 
56 74 Yes Well 3 5.0 Yes None 157 
57 59 Yes Moderate 3 2.0 Yes None 316 
58 67 Yes Well  5.0  None 157 
59 61 Yes Poor 3 5.0 Yes None 150 
60 65 Yes Moderate 3 4.0 Yes None 195 
61 72 Yes Moderate 3 4.0 Yes None 37 
62 74 Yes Poor 1 5.0 No None 1278 
63 60 Yes Moderate 2 5.0 No None 330 
64 49 Yes Moderate 3 5.0 Yes None 267 
65 43 Yes Poor 3 8.0 Yes None 90 
66 65 Yes Poor 2 2.5 No None 900 
67 65 Yes Poor 3 2.0 Yes None 240 
68 76 Yes Moderate 3 2.0 Yes None 77 
69 66 Yes Moderate 1 4.0 No None 330 
 
 
 
 Blank spaces indicate that data was not available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 103 
Table 5.2 United Kingdom clinical data 
 
Case Age Clear 
margins 
Grade Stage Tumour Size 
(cm) 
Lymph node  Adjuvant 
treatment 
Survival (Days) 
70 47 Yes Poor 3 4.0  None 367 
71 60 No Well 3 7.0  None 63 
72 42 Yes Moderate 3 3.0  None 305 
73 54 Yes Moderate 1 1.0  None 451 
74 61 Yes Moderate 3 3.0  Dxt/Chem 450 
75 48 Yes Poor 3 2.0  None 34 
76 63 Yes Moderate 2 1.5  None 197 
77 74 Yes Moderate 2 3.5  Dxt/Chem 393 
78 71 Yes Poor 2 3.4  Dxt 293 
79 50 Yes Moderate 3 3.0  None 118 
80 65 Yes Well 3 2.0  Dxt/Chem 313 
81 51 Yes Moderate 2 3.1  Dxt/Chem 1827 
82 74 Yes Moderate 3 1.0  Dxt/Chem 190 
83 48 Yes Poor 2 2.0  None 760 
84 49 Yes Moderate 3 3.0  Dxt/Chem 229 
85 46 Yes Poor 3 2.5  Dxt/Chem 300 
86 48 Yes Well 2 1.0  Dxt 1060 
87 68 Yes Well 2 5.0  None 2485 
88 74 Yes Moderate 3 3.0  None 1206 
89 64 Yes Moderate 2 2.0  None 170 
90 40 Yes Moderate 1 1.0  - 353 
91 60 Yes Moderate 2 2.0  None 924 
92 60 Yes Poor 3 3.0  Dx 106 
93 69 Yes Well 2 2.0  Dxt/Chem 1113 
94 45 Yes Poor 2  No None  
 104 
95 65 Yes Moderate 3  Yes None 767 
96 48 Yes Moderate 3  Yes None 88 
97 55 Yes Poor 1  No None 509 
98 52 Yes Poor 2  No None 103 
99 53 Yes Well 3  No None 193 
100 69 Yes Moderate 3  Yes None 167 
101 57 Yes Moderate 3  No None 23 
102 65 Yes Poor 2  No None 450 
103 63 Yes Moderate 3  No None 245 
104 53 Yes Moderate 3  Yes None 493 
105 63 Yes Poor 1  No None 475 
106 65 Yes Moderate 3  Yes None 568 
107 51 Yes  3  Yes None 50 
108 59 Yes Moderate 3  Yes None 443 
109 62 Yes Moderate 2  No None 547 
110 71 Yes Well 2  No None 915 
111 73 Yes Well 1  No None 398 
112 68 Yes Well 2  No None 822 
113 68 Yes Well 2  No None 9 
114 56 Yes Poor 3  Yes None 155 
115 55 Yes Moderate 2  No None 323 
116 64 Yes Moderate 2  No None 260 
117 62 Yes Poor 3  No None 257 
118 64 Yes Poor 3  Yes None 225 
119 61 Yes Poor 3 3.0 No None 205 
120 50 no Poor 3 2.0 Yes None 162 
121 66  Moderate 3  No None  
122 69  Moderate 1  No None 357 
123 36  Well 1 4.5 No None 138 
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124 71  Well 3 2.0 No None 912 
125 53  Moderate 1  Yes None 489 
126 73  Well 1 5.0 No None 24 
127 76  Moderate 1  No None 569 
128 45  Poor 1 4.0 No None 540 
129 48  Moderate 1  No None 229 
130 45  Moderate 1 1.2 no None 353 
131 61  Poor 1  No None 393 
132 56  Moderate 1 3.0 No None 259 
133 57  Moderate 1  No None 171 
134 62  Poor 1 5.0 No None 132 
135 58   1  no None 78 
136 51  Poor 1 3.0 No None 314 
137 60  Well 1 0.7 No None 235 
138 53  Moderate 1 2.5 No None 598 
139 58  Poor 1 3.0 No None 236 
140 59   1  no None 16 
141 58  Moderate 1 3.5 Yes None 1366 
142 59  Well 1 2.8 No None 1465 
143 50 No Moderate 3  Yes Dxt/Chem. 114 
144 63 Yes Poor 1 2.0 No Chem. 798 
145  Yes Poor 3 4.0 Yes Chem 212 
146 62 - Moderate   No Chem 722 
147 30 No Poor 3 2.5 Yes Dxt 180 
148 66 Yes Poor 3 2.5 Yes Dxt 33 
149 51 Yes Moderate  2.0  Chem 249 
150 53 Yes Poor 3 6.0 No None 241 
151 64 No Moderate   Yes Dxt 191 
152  Yes - 3 3.5 No None 1055 
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153 60 No Poor 3 3.5 Yes None 187 
154 58 Yes Moderate 3 3.5  None 167 
155 56 Yes Moderate 3 2.5  Chemo  
156 51 No Moderate 3 - Yes Chem  
157 60 No Poor 3 5.0 yes Chem  
 
 
 
Table 5.3  Swedish Immunohistochemical data  
 
 
Case P53 P16 P21 C-erbB-2 C-erbB-3 Cyclin D1 Survival (Days) 
1 Neg Neg Neg Neg Pos Pos 7 
2 Neg Neg Pos Neg Neg Pos 135 
3 Neg Neg Neg Pos Neg Pos 420 
4 Pos Pos Neg Pos Neg Pos 161 
5 Neg Neg Neg Neg Pos Pos 269 
6 Pos Neg Neg Neg Neg Neg 0 
7 Pos Neg Neg Pos Neg Pos 104 
8 Neg Neg Pos Neg Neg Neg 154 
9 Neg Neg Neg Neg Neg Pos 327 
10 Neg Neg Neg Neg Pos Pos 473 
11 Neg Neg Pos Neg Pos Pos 461 
12 Neg Neg Pos Pos Pos Pos 670 
13 Neg Pos Neg Neg Pos Pos 402 
14 Neg Neg Neg Neg Pos Pos 389 
15 Neg Neg Neg Neg Neg Pos 498 
16 Neg Neg Pos Neg Pos Neg 390 
17 Neg Neg Neg Pos Pos Pos 53 
18 Pos Neg Neg Neg Neg Neg 131 
19 Pos Neg Neg Neg Pos Pos 120 
20 Neg Pos Neg Neg Neg Pos 252 
21 Pos Neg Neg Neg Neg Pos 206 
22 Pos Neg Neg Neg Pos Pos 511 
23 Neg Neg Pos Pos Neg Pos 637 
24 Neg Neg Neg Neg Pos Neg 210 
25 Neg Neg Neg Neg Neg Pos 210 
26 Neg Neg Neg Neg Pos Pos 390 
27 Pos Neg Pos Neg Pos Pos 210 
28 Pos Neg Neg Neg Pos Neg 533 
29 Pos Neg Neg Neg Neg Neg 13 
30 Neg Neg Neg Pos Neg Neg 342 
31 Pos neg Neg Neg Pos Pos 1120 
32 Pos pos Neg Neg Pos Pos 716 
33 Neg Neg Neg Neg Neg Neg 403 
34 Pos Neg Neg Neg Neg Pos 210 
35 Pos Neg Pos Pos Pos Pos 137 
36 Neg Neg Neg Pos Neg Pos 60 
37 Neg Neg Neg Pos Neg Pos 29 
38 Neg Pos Neg Pos Neg Pos 204 
39 Neg Neg Neg  Pos Neg 210 
40 Neg Neg Neg Pos Pos Pos 112 
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41 Neg Neg Neg  Pos Pos 30 
42 Pos Neg Neg Pos Pos Pos 92 
43 Pos Neg Neg Pos Pos Pos 347 
44 Neg Neg Neg  Pos Pos 1308 
45 Neg Neg Pos Pos Neg Neg 454 
46 Pos Neg Neg Pos Pos Pos 219 
47 Pos Neg Neg Pos Pos Neg 440 
48 Neg Neg Neg Neg Pos Pos 181 
49 Neg Neg Neg Neg Pos Pos 337 
50 Neg Neg Neg Neg Neg Pos 150 
51 Pos Neg Neg Neg Neg Pos 1769 
52 Pos Neg Neg Neg Neg Pos 234 
53 Neg Neg Neg Neg Neg Pos 125 
54 Neg Pos Neg Neg Pos Pos 798 
55 Neg Neg Neg Neg Neg Neg 458 
56 Neg Pos Pos Pos Pos Pos 157 
57 Pos Neg Neg Pos Pos Pos 316 
58 Neg Neg Neg Neg Neg Neg 157 
59 Neg Neg Neg Neg Pos Pos 150 
60 Neg Neg Neg Neg Pos Pos 195 
61 Neg Neg Neg Pos Pos Pos 37 
62 Neg Pos Neg Neg Neg Pos 1278 
63 Pos Pos Neg Neg Pos Pos 330 
64 Neg Neg Neg Pos Pos Pos 267 
65 Neg Neg Neg Neg Neg Pos 90 
66 Neg Neg Neg Neg Neg Neg 900 
67 Neg Neg Pos Neg Neg Pos 240 
68 Pos Pos Neg Neg Neg Pos 77 
69 Neg Neg Neg Neg Pos Pos 330 
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Table 5.4  United Kingdom immunohistochemistry data  
 
Case P53 P16 P21 c-erbB-2 c-erbB-3 Cyclin D1 survival 
70 Pos Neg Neg Pos Neg Pos 367 
71 Neg Neg Neg Neg Pos Pos 63 
72 Neg Neg Neg Neg Pos Pos 305 
73 Pos Neg Neg Neg Pos Pos 451 
74 Pos Neg Neg Neg Pos Pos 450 
75 Pos Neg Neg Neg Pos Neg 34 
76 Neg Neg Neg Neg Neg Neg 197 
77 Pos Neg Pos Neg Neg Pos 393 
78 Neg Pos Neg Neg Pos Neg 293 
79 Neg Neg Neg Neg Neg Pos 118 
80 Neg Neg Neg Neg Pos Pos 313 
81 Neg Neg Neg Neg Pos Neg 1827 
82 Pos Neg Neg Neg Pos Pos 190 
83 Pos Neg Neg Neg Pos Neg 760 
84 Neg Neg Neg Pos Neg Pos 229 
85 Neg Neg Neg Neg Pos Pos 300 
86 Pos Neg Neg pos Pos Pos 1060 
87 Neg Neg Neg Neg Pos Pos 2485 
88 Pos Neg Neg Neg Neg Pos 1206 
89 Neg Neg Neg Neg Neg Pos 170 
90 Neg Neg Neg Neg Neg Pos 353 
91 Neg Neg Neg Neg Pos Pos 924 
92 Neg Neg Neg Neg Pos Pos 106 
93 Neg Neg Neg Neg Neg Pos 1113 
94 Pos Neg Neg Neg Pos Neg  
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95 Neg Neg Pos Pos Neg Pos 767 
96 Neg Neg Neg Pos Pos Neg 88 
97 pos Neg Neg Neg Pos Neg 509 
98 Pos Neg Neg Neg Pos Neg 103 
99 Pos Neg Neg Pos Pos Neg 193 
100 Neg Neg Neg Neg Neg Neg 167 
101 Neg Neg Neg Neg Pos Pos 23 
102 Neg Pos Pos Pos Neg Pos 450 
103 Pos Neg Neg Pos Pos Pos 245 
104 Pos Neg Pos Pos Pos Pos 493 
105 Pos Neg Neg Pos Neg Pos 475 
106 Neg Neg Pos Neg Neg Pos 568 
107 Neg Pos Neg Neg Neg Neg 50 
108 Pos Neg Pos Neg Neg Pos 443 
109 Pos Pos Neg Neg Pos Pos 547 
110 Pos Neg Pos Neg Neg Pos 915 
111 Neg Neg Pos Neg Pos Pos 398 
112 Neg Pos Pos Neg Neg Pos 822 
113 Neg Neg Neg Neg Pos Neg 9 
114 Neg Neg Pos Neg Pos Pos 155 
115 Pos Neg Pos Pos Neg Pos 323 
116 Pos Neg Pos Neg Pos Pos 260 
117 Pos Neg Neg Pos Pos Pos 257 
118 Neg Neg Neg Neg Neg Pos 225 
119 Pos Neg Pos Pos Neg Pos 205 
120 Pos Pos Pos Pos Neg Pos 162 
121 Pos Neg Pos Pos Pos Neg 265 
122 Neg Neg Neg Pos Pos Pos 357 
123 Neg Neg Pos Pos Neg Neg 138 
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124 Neg Neg Neg Neg Pos Neg 912 
125 Pos Neg Neg Neg Neg Neg 489 
126 Neg Neg Neg Pos Pos pos 24 
127 Pos Pos Pos Pos Neg Neg 569 
128 Neg Neg Neg Neg Neg Pos 540 
129 Neg Neg Neg neg Pos Neg 229 
130 Neg Neg Neg Neg Neg Neg 353 
131 Neg Neg Neg Neg Pos Pos 393 
132 Neg Neg Neg Neg Pos Neg 259 
133 Pos Neg Neg Pos Neg Neg 171 
134 Neg Neg Neg Neg Pos Pos 132 
135 Neg Neg Pos Pos Pos Neg 78 
136 Neg Neg Neg Neg Neg Pos 314 
137 Neg Neg Neg Neg Pos Pos 235 
138 Pos Neg Neg Neg Pos Neg 598 
139 Neg Neg Neg Neg Neg Neg 236 
140 Pos Neg Pos neg neg Pos 16 
141 Pos Pos Neg Pos Neg Neg 1366 
142 Pos Neg Pos Pos Pos Pos 1465 
143 Pos Neg Neg Pos Pos Neg 114 
144 Neg Pos Neg Pos Pos Pos 798 
145 Pos Pos Pos Pos Pos Pos 212 
146 Neg Neg Neg Pos Pos Pos 722 
147 Pos Neg Pos Neg Pos Pos 180 
148 Pos Neg Neg Pos Neg Pos 33 
149 Neg Neg Neg Neg Pos Pos 249 
150 Neg Pos Neg Neg Neg Pos 241 
151 Pos Neg Neg Neg Pos Pos 191 
152 Neg Neg Neg Neg Neg Neg 1055 
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153 Neg Neg Neg Pos Pos Pos 187 
154 Pos Pos Neg Neg Pos Neg 167 
155 Pos Neg Neg Neg Pos Pos 229 
156 Pos Neg Pos Pos Pos Pos 249 
157 Pos Neg Pos Pos Pos Pos 267 
 
 
 
 
 
5.4  Tissue Specimens 
 Histological examination was performed by two pathologists (Professor NR Lemoine and Dr 
F Campbell) on haematoxylin and eosin (H&E) stained sections of all the blocks which were 
previously fixed in buffered formaldehyde and then paraffin embedded.  Neither the 
pathologist nor the author were aware of either the previous histology or the clinical outcome 
of the patient.  Only resected ductal adenocarcinoma of the pancreas cases were selected.  
Appropriate blocks for study were then selected and 5 µm sections cut and mounted on poly-
Lysine coated glass slides (Merck Ltd, Lutterwoth, Leics).  These were then dried for 12-24 
hours at 37°C. They were then labelled with the pathology number of the tumour sample.  
Tumour grading was evaluated as previously described and staging was according to the 
UICC (Kloppel et al, 1996).  Specimens of normal pancreatic tissue were obtained from 
healthy organ transplant donors following informed consent from the relatives.  Positive 
control specimens were obtained from the same pathology departments.  These were selected 
if staining with the appropriate antibodies was strong and homogenous. 
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5.7  Antibodies 
 
The primary antibodies used were all monoclonal and obtained within the United Kingdom.  
They were refrigerated immediately upon arrival in the laboratory.  The c-erbB-3 monoclonal 
antibody was a generous gift from Professor W. Gullick at the Hammersmith Hospital, 
London, UK. 
 
 
 
 
 
 
 
 
 
TABLE   5.5     Function and dilution of antibodies 
antibody function dilution 
p53 (NCL-p53-DO7) recognises wild type and mutant p53 protein. 1:300 
c-erbB-2 (NCL-CB11) recognises the internal and external domains of 
c-erbB-2 
1:40 
c-erbB-3 (NCL c-erbB-3) 
Clone RTJ1 
recognises an epitope in the cytoplasmic 
domain of the human c-erbB-3 oncoprotein 
1:10 
p21  detects p21 protein 1:100 
p16  detects human p16 protein 1:100 
cyclin D1 detects cyclin D1 protein 1:100 
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Table 5.6 Positive controls 
 
P53 
 
Gastric cancer 
P21 
 
Normal colon 
P16 
 
Breast cancer 
c-erbB-2 
 
Breast cancer 
c-erbB-3 
 
Colon cancer 
Cyclin D1 
 
Breast cancer 
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5.6  Immunohistochemical method 
   
5 μm sections on glass slides (Merck Ltd, Leics) were loaded onto a metal rack and then 
immersed in two changes of xylene of ten minutes each to remove the wax.  The sections 
were then rehydrated through graded solutions of ethanol (University of Liverpool stores) in 
concentrations of (100, 100, 90, 90, and 70%) for 5 minutes each.  Endogenous peroxidase 
(Sigma Chemical Co, Poole, and Dorset) was blocked by immersing the sections in methanol 
and hydrogen peroxide (3% v/v) for 15 minutes.  After washing in running tap water for five 
minutes the sections were subjected to an antigen retrieval step by being immersed in 10mM 
EDTA (Sigma, Chemical Co, Poole, Dorset) (pH 7.0) and then placed in a microwave oven 
(Creda Ltd, Blythe  Bridge, Stoke on Trent) at 850watts for 15 minutes.  The sections were 
then allowed to cool to room temperature for 15 minutes and then washed in running tap 
water for 5 minutes to avoid precipitation of the citrate salts.  Following this, the slides were 
transferred in R.O (reverse osmosis) water for a few minutes and then mounted onto plastic 
cover plates and secured into a sequenza rack.  The sequenza racks were filled with Tris 
buffered saline [TBS (BDH/Merck Chemicals Ltd, Lutterwoth, Leics)] to confirm correct 
positioning of slides and then 5% bovine serum albumin [1gBSA in 20cc TBS  (Sigma, 
University of Liverpool stores)] added to each well.  The primary antibodies (p53 at 1:300; 
p21 and cyclin D1 at 1:100; c-erbB-2 at 1:40 and c-erbB-3 at 1:10) were diluted in 5% 
Bovine Serum Albumin (BSA) and then added into each of the wells, excluding the negative 
control slides on which 5%BSA only was added.  Slides were incubated for one hour at room 
temperature.  The sections were then washed with TBS for 5 minutes three times and were 
then incubated with the 100μL of biotinylated rabbit anti-mouse secondary antibody 
(Amersham Life Sciences, Bucks, UK) for 45 minutes at room temperature.  The slides were 
again rinsed in TBS as before and 100µL of streptavidin-biotin complex (DAKO Ltd, Bucks, 
UK) containing 10mL/mL of streptavidin and 9mL/mL of biotinylated horseradish peroxidas 
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(ABC) made up at least 30 minute before use, was then added onto the slides.  After 20 
minutes the slides were again rinsed with TBS.  The peroxidase staining was visualised using 
0.5% (w/v) 3,3 diaminobenzidine HCL (DAB), (Dako Ltd, Bucks, UK) containing 0.03% 
(w/v) hydrogen peroxide for 7 minutes and then rinsed in running tap water for three minutes.  
The slides were then lightly stained with Meyers haematoxylin (BDH/Merck chemicals Ltd) 
for 15 seconds followed by a brief wash and dunking in acid alcohol to remove the excess 
haematoxylin.  A further wash followed by soaking in Scott’s tap water (20.0g magnesium 
sulphate, 3.5g sodium hydrogen carbonate in 1 litre tap water then one crystal of thymol 
preservative; store at 4°C) which stains the sections blue followed by a final wash.  The slides 
were then dehydrated through graded alcohol solutions followed by immersion in two 
changes of xylene for 30 seconds before mounting them onto coverslips with DPX mountant 
BDH/Merck chemicals Ltd, Lutterworth, Leics).  Specificity of immunostaining was 
established using a negative control for each section, missing out the primary antibody and 
using 100µL of the diluent alone.  Also included in each batch of sections was a known 
positive control as shown. 
 
5.7  Haematoxylin and eosin staining of tissue sections 
 
Prior to use the haematoxylin was filtered.  The paraffin embedded slides were then dewaxed 
in two changes of xylene (University of Liverpool stores) for 10 minutes followed by 
dehydration in absolute alcohol (University of Liverpool stores) for 3 minutes and 1 minute 
in 70% alcohol.  The slides were then washed in running tap water and then immersed in 
haematoxylin (BDH/Merck chemicals Ltd, Leics) for 5 minutes followed by washing in tap 
water for two minutes.  Following 10 dips in 0.5% acid alcohol (University of Liverpool 
stores) the slides were immediately plunged into tap water and washed well.  They were then 
put in Scott’s tap water for 30 seconds, washed and then immersed in eosin for 1-2 minutes 
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and washed in tap water.  Finally the sections were dehydrated in absolute alcohol and put 
through 3 changes of xylene.  The slides were then mounted on slides with DPX.  
 
5.8  Scoring of slides 
 
The stained sections were examined using a standard light microscope.   Staining results were 
interpreted independently by the author, two gastrointestinal pathologists (Professor NR 
Lemoine, Hammersmith, London and Dr F Campbell, Royal Liverpool Hospital, Liverpool) 
and another independent observer unaware of the clinical outcome of the patients under 
study.   The aim was to arrive at reproducible interpretation of staining.  There was agreement 
on the significance of nuclear, diffuse cytoplasmic or membrane staining.  Most antibodies 
either localise (functionally) in the nucleus for example p53, p16, p21 and cyclin D1.  Others 
localise in the cell membrane or in the cytoplasm for example c-erbB-2 and c-erb-B-3.  
Staining patterns not typical of the antibody were ignored and in some cases experiments 
were repeated.  The staining was assessed in tumour areas and in all cases this was with the 
agreement of the pathologist.  A percentage expression was then estimated, again with the 
full agreement of the pathologist.  Following this a quantitative assessment of the staining 
was made.  Areas of necrosis, giant cell infiltration and neural invasion were noted because 
this would influence future microdissection for gene sequencing.  The background of the 
slides were then assessed looking for mucinous metaplasia, dysplasia and acini cytoplasmic 
staining.  Nuclear expression was scored by arbitrary division into widespread nuclear 
staining if present in >75% of cells within the section, focal if there were <25% of cells 
displaying nuclear staining and absent if there was no nuclear staining.  Tumours displaying 
membranous staining were scored as positive and similarly with cytoplasmic staining. When 
samples from more than one site of the tumour were available, the mean percentage of 
positive staining was considered as representative of the tumour. Agreement in scoring was at 
least 95% in all cases.  Specimens were considered to be positive when more than 5% of the 
 117 
tissue components were unequivocally immunoreactive in the appropriate cellular 
compartment.  Attempts to grade scoring was not easy.  The problems ranged from the use of 
different antibodies, different controls subject to availability and some slides were very old 
and fixed differently at the time.  The actual number of stained cells was not done.  With 
respect to the p16 gene, there was no work to compare with at the time and therefore not easy 
to determine the quality of staining required.  P21 posed similar problems, with very few 
reliable publications.  Inspite of all these problems, it was still important to bear in mind that 
negative staining did not necessarily mean absence of a mutation.  This is because for 
example a large deletion within a gene may not show a positive result.  Additionally, some 
protein products are involved in coupling thus not exposing the epitopes needed for an 
antigen –antibody reaction. 
 
5.9   Statistical analysis 
 
The Chi-squared or Fisher's exact test were used for categorical data.  Overall survival was 
calculated by the Kaplan-Meier method and for differences in survival curves the log rank 
test was used.  The log rank test is a non-parametric means of testing the null hypothesis that 
no difference exists in the survival experience of the groups.  Median survival times were 
calculated for negative and positive staining groups.  In the Kaplan Meier method, censored 
observations are patients who were alive at last follow up or who were lost to follow-up but 
who did not die during the follow-up period.  Variables were first subjected to univariate 
analysis and after confirmation that the log-plots did not deviate from the proportional 
hazards assumption, the significant variables were then entered into multivariate analysis 
using the Cox regression model.  Cox regression is used to study the relationship between 
time to an event and a set of variables.  All deaths were due to pancreatic cancer.  A p value 
of <0.05 as was accepted as statistically significant.  Stat view (version 4.53) for windows 
was the statistical package used. 
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6.0 Results of  Immunohistochemistry 
 
6.1  Clinicopathological  parameters and survival 
A total of 157 patients were studied with a median (range) follow up of 1.8 (0.3-7) years.  
The overall median survival was 33.9 months (95% confidence interval:  28.48 – 39.32) 
(Table 6.1).   
 
6.2.  Overall analysis of clinocopathological factors 
 
Significant prognostic markers were TNM stage of disease and lymph node involvement 
(Table 6.2).  There were no significant correlations between survival and gender, 
differentiation of tumour, size of tumour, resection margin status and the use of adjuvant 
therapy.  Multivariate analysis showed no significant difference in survival between patients 
from the UK and Sweden once lymph node status had been taken into account.   
 
6.3 Immunohistochemical Results 
 
 
6.3.1  p53 results 
 
The slides were scored as positive if there was brown nuclear staining in tumour areas.  The 
level of immunoreactivity was then expressed as a percentage of areas of tumour.  Staining 
outside tumour areas was disregarded but noted.  There was predominantly nuclear 
immunoreactivity of p53 in the tumour specimens graded as positive (although intensity 
varied between cases) and there was no nuclear reactivity with normal pancreas.  Faint 
cytoplasmic staining without nuclear staining was considered negative.  41 % (n=64) of cases 
showed immunoreactivity. 18 (90%) out of 20 tumours that were more than 5cm in diameter 
were negative for p53 immunostaining.  There was no correlation with patient survival (Table 
6.5).  
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6.3.2  p21  results 
 
p21 WAF1 nuclear immunostaining in tumours was found in 25% (n=39) cases.  Almost 100% 
positive nuclear activity was seen in normal pancreas.  There was no correlation with survival 
between those cases that were positive for p21 staining and those that were negative.   
 
6.3.3.  p16  results 
 
The loss of p16 expression was found in 87% (n=136) of cases.  No correlation was found 
between p16 expression or loss with survival. 
 
6.3.4 c-erbB-2 results 
 
Membranous and some cytoplasmic staining were seen with the c-erbB-2 antibody in 
pancreatic tumour samples.  33% (n=33) of pancreatic cancer cases showed membranous or 
cytoplasmic staining.    Normal pancreas demonstrated non-specific background 
immunoreactivity.   
 
6.3.5  c-erbB-3 results 
  
Cytoplasmic staining was seen in pancreatic tumour samples.  Normal pancreas demonstrated 
non-specific background immunoreactivity.  c-erbB-3 immunoreactivity was in 56% (n=89) 
of pancreatic cancer cases. 
 
 
 
6.3.6  cyclin D1 results 
 
Nuclear immunoreactivity was found in 72% of pancreatic cancer cases (n=113).  Normal 
pancreas did not show any staining (0%).  There was no correlation between cyclin D1 
staining or absence of staining with survival.   
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6.3.7.  multivariate analysis 
Further analyses of particular patient subsets were performed.  This was done to see if 
different combinations of various markers would give any prognostic information.  There was 
no significant in survival between patients with p53 positive, p21 negative and cyclin D1 
positive tumours and the others.  Patients with combined c-erbB-2 and c-erbB-3 positive 
tumours also demonstrated no difference in survival compared with other patients.  Patients 
with five marker abnormalities in any combination did not demonstrate a significant decrease 
with survival (Table 6.6).    
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Table 6.1.  Clinical parameters of 157 patients who underwent pancreatectomy from 
the UK and Sweden 
 
 
Clinical parameter     Number  Not Known  % 
 
Country    UK   88     56 
    Sweden   69     44 
 
Median age years (range)  60  (30-77) 
Gender    Male   100     64 
    Female   57     36 
Histology   Ductal   157 
    adenocarcinoma       
Grade    Well   21     13 
    Moderate  77     49 
    Poor   59     38 
Stage    I   45  4   30 
    II   32     20 
    III   76     50 
Lymph node   Positive   71  2   45 
    Negative  84     55 
Resection margins  Involved  12  13   8 
    Not involved  122     92 
Tumour size   <2cm   38  15   27 
    2-5cm   84     59 
    >5cm   20     14 
Adjuvant therapy   Yes   13     8 
    No   144     92 
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Table 6.2.   Univariate analysis of clinical parameters and survival in 157 patients 
who have undergone pancreatoduodenectomy 
 
Parameter   Median survival   95% CI  2            P Value 
    (months) 
 
All patients   33.90   28.48- 39.32 
UK    39.14  30.91 – 47.37  4.66  0.03* 
Sweden    28.29  21.63  - 34.95      
 
Male    33.72  27.18 – 40.26  0.24  0.87 
Female    33.97  24.43 – 43.51    
 
Differentiation  well  45.95  30.24 – 61.66  4.24  0.11 
  moderate 32.91  24.94 – 40.88     
  poor  29.67  21.60 – 37.74     
Stage I    44.31  33.32 –55.30  16.04  0.0003* 
          II    41.19  26.77 – 55.61     
          III    23.70  18.61 -  28.79     
 
Lymph  node positive  24.23  16.38 – 32.08  14.3  0.008* 
Lymph node negative  37.34  29.21 – 45.52     
 
Resection margins positive 37.60  17.91 – 57.29  0.01  0.92 
Resection margins negative 33.61  27.38 – 39.84     
 
Tumour size <2cm  8.9  22.51 – 41.13  0.03  0.98 
  2-5cm  8.6  26.74 – 42.44     
  >5cm  8.6  19.19 – 30.47    
 
     
 
*Statistically significant value 
 
CI  -  confidence interval 
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Figure 6.1: Kaplan Meier plot showing gender vs. survival. 
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Figure 6.2: Kaplan Meier plot showing stage vs. survival – this was statistically 
significant. 
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Figure 6.3: Kaplan Meier plot showing lymph node status vs. survival. 
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Figure 6.4: Kaplan Meier plot showing differentiation vs. survival. 
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Figure 6.5: Kaplan Meier plot showing resection margins vs. survival. 
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Figure 6.6: Kaplan Meier plot showing tumour size vs. survival.  Tumour size was 
divided into three groups; less than and equal to 2cm, between 2-5cm and 
more than 5cm. 
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Figure 6.7:  P53 nuclear immunostaining in ductal pancreatic cancer with DO7 
antibody (low power) 
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Figure 6.8: P53 negative nuclear staining  (control pancreatic cancer slide) 
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Figure 6.9:  Kaplan Meier plot showing p53  immunostaining versus survival. 
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Figure 6.10: p21 nuclear immunoreactivity in ductal pancreatic cancer. 
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Figure 6.11:  p21 Kaplan Meier plot -  no statistical significance with positive staining 
with survival. 
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Figure 6.12:   P16   nuclear immunoreactivity in ductal pancreatic cancer. 
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Figure 6.13:  Kaplan Meier plot showing p16 staining Vs survival.  
% survival  
 136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14:   c-erbB-2 membranous staining. 
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Figure 6.15: Kaplan Meier plot showing c-erbB-2 and survival. 
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Figure 6.16: c-erbB-3 cytoplasmic  staining in ductal pancreatic cancer. 
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Figure 6.17:  Kaplan Meier plot showing c-erbB-3 and survival. 
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Figure 6.18:  cyclin D1 nuclear   staining in ductal pancreatic cancer. 
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Figure 6.19:  Survival of patients in relation to cyclin D1 immunostaining.  
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Table 6.3.   Overall immuno-staining rates for 157 cases of pancreatic 
adenocarcinoma 
 
 
Antibody  Positive 
   N  % 
p53   64/157  41 
p21WAFI  39/157  25 
p16INK4  21/157  13 
cyclin D1  113/157 72 
c-erbB-2  51/157  33 
c-erbB-3  89/157  57 
 
 
 
N = number 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 143 
 
 
 
 
 
Table 6.4.    A correlation matrix for each antibody and clinical parameters 
 
 
Clinical 
parameter 
p53 
 
p21 p16 cyclin D1 c-erbB-2 c-erbB-3 
gender P=0.44 
 
P=0.91 P=0.56 P=0.24 P=0.65 P=0.27 
stage P=0.54 
 
P=0.64 P=0.44 P=0.28 P=0.61 P=0.74 
differentiation P=0.30 
 
P=0.77 P=0.42 P=0.47 P=0.42 P=0.57 
tumour size P=0.01* 
 
P=0.70 P=0.58 P=0.51 P=0.19 P=0.99 
lymph node 
status 
P=0.30 P=0.34 P=0.64 P=0.05 P=0.16 P=0.81 
resection 
margins 
 
P=0.21 P=0.44 P=0.68 P=0.55 P=0.05 P=0.20 
 
* Statistically significant 
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Table 6.5. Univariate analysis of the relationship of immunohistochemical staining 
to patient survival 
 
 
Molecular N  Median     95% CI    p value 
marker  
    survival  
    (months) 
 
 
p53+  64  34.72  26.30 – 43.14  0.29  0.86 
p53-  93  33.38  26.21 -  40.39 
 
p21WAFI+ 39  32.83  23.76 – 41.90  3.26  0.98 
p21WAFI-  118  21.58  13.35 – 29.81 
 
p16 INK4I+ 21  40.16  24.50 – 55.81  0.75  0.38 
p16INK4- 136  32.86  27.10 – 38.62 
 
cyclin D1+ 113  35.79  29.13 – 42.45  1.67  0.19 
cyclinD1- 44  29.03  20.06 – 38.00 
 
c-erbB-2+ 51  30.73  22.46 – 39.00  0.05  0.83 
c-erbB-2- 106  35.36  28.37 – 42.35 
 
c-erbB-3+ 89  32. 89  25.92 – 39.86  0.13  0.71 
c-erbB-3- 68  35.22  26.56 – 43.88 
 
  
 
+ = positive immunostaining, -  = negative immunostaining, N = number 
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Table 6.6.   Correlation of patient subgroup immunostaining and survival 
 
 
 
Immunostaining  N  Immunostaining  N    p value  
  
subgroup    subgroup       
             
         
                         
 
p53+p21-  45 p53-p21+  18  0.03  0.85  
             
             
      
p53+p21-  45 rest   112  0.12  0.72 
 
p53+p21-cyclinD1+ 28 p53-p21+cyclinD1-  5  2.13  0.14  
             
     
p53+p21-cyclin D1+ 28 rest   129  0.49  0.48 
 
ErbB2+erbB3+  29 ErbB2-erbB3-  45  0.02  0.89 
 
ErbB2+ebB3+  29 rest   128  0.07  0.79 
 
p53+p21-cyclin D1+ 7 rest   150  0.13  0.72 
erbB+erbB-3+ 
 
 
 
 
 
+ = positive immunostaining, - = negative immunostaining, N= number 
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 6.4 Summary of immunohistochemical staining results 
 
1) The overall median survival survival was 33.9 months (CI – 28.48 – 39.32) in this 
study population 
2)  Significant prognostic factors were TNM stage and lymph node involvement 
3) There were no significant correlations between survival and gender, differentiation, 
size of tumour, resection margin status and the use of adjuvant therapy 
4) Multivariate analysis showed no significant difference in survival between patients 
from the UK and Sweden once lymph node status was taken into account. 
5) The pattern of expression of p53, p21WAF1, p16INK4, cyclin D1, c-erbB-2 and c-
erbB-3 did not significantly correlate with patient survival 
6) Correlation between immunohistochemistry and clinical parameters showed a 
significant association between size of tumour and p53 immunoreactivity (p< 0.01) 
7) There were no significant differences in survival between patients with combined p53 
positive, p21 negative and cyclin D1 positive tumours with the other markers 
8) Patients with combined c-erbB-2 and c-erbB-3 positive tumours also demonstrated no 
difference in survival when compared with other markers 
9) Patients with abnormalities in all the markers did not demonstrate a significant 
decrease in survival when compared with the rest 
6.5 Conclusions  
 
The molecular markers studied occur with significant frequencies in pancreatic cancer but do not 
correlate with survival in resected ductal pancreatic cancer either independently or in 
combination. 
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7.0   p53 mutation analysis 
 
7.1    Introduction 
Studies of p53 alterations at the genomic and protein level show that overexpression of the p53 
protein correlates significantly with allelic loss (El Diery WS et al, 1997) and missense mutation 
in exons 5-9 (Kupryjanczykk J et al, 1993; McManus D et al, 1994).  But nonsense mutations, 
splice site mutations and most deletions do not result in protein accumulation (Kupryjanczykk J 
et al, 1993; Righetti SC et al, 1996).   At least 50% of pancreatic cancers show allelic loss 
(deletion of one copy of the gene) at the p53 locus (Berrozpe G et al, 1994; Redston MS et al 
1994; Rozenblum E et al, 1997).   Most studies of mutations in the p53 tumour suppressor gene 
in tumours have examined mainly exons 5-8, the so called  mutational   “hot-spot” region.   In 
one study, up to 30% of p53 mutated pancreatic cancers were negative for p53 
immunohistochemical staining (Scarpa A et al, 1993) since intragenic deletions associated with 
the loss of the normal allele prevented protein synthesis.   Also, the few large studies that have 
examined the entire coding region of the p53 gene suggest that 10% to 25% of all mutations 
occur outside exons 5-8 (Hartmann A et al, 1995).   It is important therefore that mutational 
analysis of the p53 gene is performed in conjunction with immunohistochemical analysis so that 
the relationship between mutation, expression, treatment and prognosis can be more fully 
understood.  The aim of this part of the work was to confirm the findings of p53 positive and 
negative staining immunohistochemistry by mutation analysis in a selected group of the cases 
that were either p53 positive or negative.   Microdissected pancreatic cancer specimens were 
processed using a new multiplex PCR system and then sequenced.   
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7.2.  Mutation detection methods 
The number of methods that are available for mutation detection vary in their complexity, costs, 
labour-intensiveness and type of mutations detected.  There are two main approaches for 
mutation detection; scanning and diagnostic.  Scanning methods detect both known and 
unknown mutations and are more frequently used when large numbers of samples and/or large 
genes are being investigated.  By contrast diagnostic methods are generally applied to the 
detection of a single base pair changes within single genes.  A summary of the main techniques 
used for mutation detection is shown in Table 7.1.  
Microdissection of paraffin-embedded formalin-fixed samples used for routine diagnosis allows 
analysis of DNA from normal and diseased microscopic lesions.  The problem with archival 
formalin-fixed paraffin-embedded tissue is that extracted DNA is often fragmented because of 
fixation; this restricts the size of the product that can be amplified.  Therefore to cover the entire 
1.8-kb of p53 coding region and splice sites, multiple products need to be generated.  
Unfortunately the limited amount of material generated from microdissection makes it difficult 
to perform multiple amplification reactions.  Multiplex polymerase chain reaction (PCR) is one 
method that can be used to amplify multiple loci in one reaction (Henegariu O et al, 1997; 
Angelopoulou K et al, 1998; Thompson-Hehir J et al, 2000).  Used in conjunction with nested 
PCR, multiple specific products can then be generated on which mutational analysis can be 
performed. 
Previous work by Thompson-Hehir J et al, (2000) has suggested that multiplex PCR followed by 
a second PCR to amplify individual products, could potentially reduce the amount of clinical 
material used by up to 95%.   The rationale behind this was that single exon amplification 
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requires 2ųL for each exon in the first round, whereas only 2ųL of the same micro dissected 
material would be required for multiplex PCR to amplify all exons.  
 
 
Table 7.1.   Summary of current methods used for mutation detection. 
Technique Scanning/Diagnostic Known/Unknown 
mutation detection 
Sensitivity 
% 
Fragment 
length 
SSCP 
HA 
DGGE 
NIRCA 
CCM 
EMC 
ASO 
PASA/ARM 
DNA chips 
Sequencing 
Scanning 
Scanning 
Scanning 
Diagnostic 
Diagnostic 
Diagnostic 
Diagnostic 
Diagnostic 
Diagnostic 
Both 
Both 
Both 
Both 
Both 
Both 
Both 
Known 
Known 
Known 
Both 
80-90% 
80% 
99% 
95% 
90-95% 
>98% 
N/a 
N/a 
99% 
95% 
300bp 
200-600bp  
<1000bp 
1000bp 
1400bp 
1300bp 
N/a 
N/a 
N/a 
<700bp 
 
Single Strand Conformational Polymorphism (SSCP), Heteroduplex Analysis (HA), 
Denaturing Gradient Gel Electrophoresis (DGGE), Non-Isotopic Rnase Cleavage Assay 
(NIRCA), Chemical Cleavage Mismatch (CCM), Enzyme Mismatch Cleavage (EMC), 
Allele Specific Oligonucleotides (ASO), Amplification of Specific Alleles  (PASA/ARMS 
PCR). 
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7.3.  DNA sequencing 
DNA sequencing provides information about the position and type of mutation whether the 
mutation is known or unknown. The most commonly used method is chain termination 
dideoxysequencing (Sanger F et al, 1977).   Dideoxynucleotides which, when incorporated into 
the growing DNA strand by a DNA polymerase cause termination of elongation.  By using 
appropriate concentrations of both deoxynucleotides and dideoxynucleotides in a sequencing 
reaction, a chain termination event is generated for each base position in the piece of DNA being 
sequenced.  Originally DNA sequencing used the Klenow fragment from DNA polymerase to 
generate the sequencing reaction products and radionucleotides for product detection.  Generally 
DNA sequencing is now carried out by cycle sequencing using thermostable DNA polymerases 
and fluorescent nucleotides or primers for product analysis and automated data collection and 
analysis. 
The other methods used for mutation detection have their advantages and disadvantages and 
these will be discussed briefly.  SSCP enables a large number of samples to be processed, 
especially if the method is multiplexed.  CCM has a detection rate nearing 100% but has the 
disadvantage of using toxic chemicals.  DGGE has one of the highest reported mutation 
detection rates but requires customized primers and specialised equipment.  Although DNA 
sequencing can be time consuming and expensive it does provide both the position and type of 
nucleotide change for a given fragment of DNA.   
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7.4    Materials and methods 
 
7.4.1  Source of clinical samples  
Formalin-fixed, paraffin-embedded pancreatic cancer samples were obtained from the pathology 
archives of the department of pathology at the Royal Liverpool University hospital, Liverpool, 
United Kingdom.  Human Placental Genomic DNA (Sigma, UK) was used throughout as 
controls. 
 
7.4.2   Preparation of slides for microdissection 
For cases chosen for mutation analysis, formalin fixed paraffin-embedded tissue blocks were 
retrieved from archives.  A 5µm section was cut followed by six serial 10µm sections and a 5µm 
section, all of which were then prepared on labelled slides.  To avoid cross contamination 
between cases a disposable microtome blade was used and cleaned with xylene after each tissue 
block.  Before cutting from each tissue block a few sections were cut from a blank paraffin 
block.  Slides for microdissection were stored in a plastic container until ready for use.  The first 
5µm section was stained with haematoxylin and eosin and reviewed by a pathologist to select 
tissue regions for microdissection.  Appropriate areas were marked on these slides with a marker 
pen.  The slides were dewaxed by soaking in xylene (heated to 37°C), for 20 min followed 
respectively by a 2x10min, soak in xylene (at room temperature), 5 min, soak in absolute 
ethanol, 5min, soak in 75% ethanol, 5 min soak in 25% ethanol and a final 5 min soak in sterile 
distilled water.  The slides were stained using 0.1% toluidine blue (30second soak) and washed 3 
times using distilled water (Liverpool University Stores). 
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7.5  Microdissection 
After staining with 0.1% toluidine blue the slides were washed twice in fresh distilled water and 
held in water prior to microdissection. Slides were then mounted on the microscope stage and a 
pool of microdissecting buffer (10mM EDTA, 1mM Tris-HCl, 10mM Tris base) was placed over 
the slide with a disposable pipette, a deep pool of microdissecting buffer was dropped on to the 
slide to cover the entire section.   Microdissection of the ducts with tumour was carried out using 
a stereodissecting microscope and an electrolytically polished tungsten needle replaced between 
slides and controlled by a micromanipulator (Leitz mechanical manipulator) as described 
previously (Going et al, 1996).  Siliconised tips with ends cut off at an angle to give a wide flat 
mouth were held with the cut edge parallel to the slide to facilitate removal of the tissue 
specimens.  Tissue fragments of tumour cells were microdissected avoiding were possible blood 
vessels and regions of necrosis.  These fragments within the same low power field (x50) were 
collected in 12.5µl buffer (10mM Tris HCL pH 8.0, 1mM EDTA) and stored in sterile 0.5mL 
polypropylene micro centrifuge tubes.  Control samples from normal pancreas from each case 
were preserved.  Digitised computer images were archived before and after microdissection as 
shown in Figure7.1.  These images and haematoxylin and eosin stains of the microdissected 
sections and serial sections were used for subsequent pathological review. 
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Figure 7.1:  Video capture images of pre and post microdissection, top and bottom 
respectively.   A malignant duct (A) and microdissected malignant duct (B) are shown by 
arrows. 
A 
B 
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7.6  DNA extraction from microdissected tissues 
 All subsequent manipulations of microdissected tissue were carried out in a class 11 laminar 
flow cabinet.  An equal volume of Proteinase K digestion buffer [(20mg/mL proteinase K 
(Sigma), 0.2% Tween 20 (Sigma)] and microdissection buffer was added to the microdissected 
tissue and the sample incubated at 37oC for 48 hours.  The Proteinase K was inactivated by 
incubation in a boiling water bath for 15 minutes. The proteinase K digestion buffer stock used 
was made up as follows: 
880ml microdissection buffer 
20µl Tween-20 (polyoexyethylene Sorbitan Monolaurate) 
100ųl proteinase k (@20mg/ml) 
 
7.7.   Oligonucleotide primers 
Primer sequences were selected from p53 genomic sequence (GenBank accession number 
U94788) using Oligo software version 5.  Oligonucleotides were purchased from Oswel DNA 
services (Southamptom, UK) and from Gnosys (Cambridge, UK) and arrived as a freeze-dried 
pellet.  To each primer, 100µL of sterile water was added and they were incubated at 4°C either 
for 4 hours or overnight to allow primer resuspension.  To prevent contamination and repeated 
freeze thawing of the oligonucleotides a system was designed for primer storage.  The 
concentration of each oligonucleotides in 100µL of water was determined.  The appropriate 
volume of stock oligonucleotide to prepare a 500µL, 50µM aliquot was then dispersed into a 
series of sterile, labelled micro centrifuge tubes.  The tubes were labelled with the primer name 
and the amount of water required to be added to make the oligonucleotide to 50ğM e.g. 
1NF1/247µL, 3R1/329µL.  These stocks were stored at minus 20° C until required. 
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7.8     Polymerase Chain Reaction 
Polymerase chain reactions (PCR) were either multiplex or single product.  Amplification of p53 
products using the multiplex method employed two rounds of PCR, the first being multiplex and 
the second being hemi-nested amplification of specific p53 products from the first round mix.  
Single product amplification, employed one or two rounds of amplification, with second the 
round being hemi-nested amplification of specific products.  First round reactions contained 
1xPCR buffer П (Perkin Elmer), 1.5-3.0mM MgCl2, 200ųM dNTPs, 0.025µl-1 Amplitaq Gold 
and 1x Multiplex primer mix.  Second round or single exon reactions were prepared as for first-
round reactions except both forward and reverse primers were included at 1µM. When first 
round amplified product was used as a target in second round PCR the first round reaction was 
diluted to 1:16 prior to the addition to second round reactions.  First round PCR cycling 
conditions were 94oC for 10 min, then 94oC 30 sec, 30oC for 60sec, 72oC for 60sec for 8 cycles, 
followed by 36 cycles of 94oC, 60oC for 30sec and 72oC for 30 sec, followed by 72oC for 10min 
and finally 4°C hold.  Second round and single exon PCR cycling conditions were 94oC for 
10min, and then 42 cycles at 94oC for 30sec, 72oC for 30sec followed by 72oC for 10min and 
finally 4oC hold.  All reactions were carried out in foil sealed 96 well Thermofast plates 
(Advanced Biotechnologies, UK) and cycled in a Perkin Elmer 9600 thermal cycler 
(Biosystems).   
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7.9     Agarose gel electrophoresis 
All gels were an equal volume of 3% Seakem LE (FMC Bioproducts) and 3% Nusieve 
(Flowgen, Staffordshire) agarose in 1xTAE (Tris-acetate-EDTA buffer) containing ethidium 
bromide (0.5ug.ml-1).  Sample volume loaded was variable but contained loading dye (40% 
sucrose, 0.025%(v/v) bromophenol blue, and 0.025% xylene cyanol) at 1/6th to 1/10th of the 
sample.  Following electrophoresis the gels were scanned using a Fluorimager SI (Molecular 
Dynamics, Chesham, Bucks) with Image quant software (Molecular Dynamics).  
 
 
7.10    Drying of PCR products 
Where there was judged to be low sample/product yield, the samples were dried down using a 
standard Gyrovap vacuum drier and resuspended in an appropriate volume of sterile water. 
 
7.11     Clean up of PCR Products 
Prior to sequencing the reaction components e.g. dNTPs and primers which would interfere with 
the sequencing were removed using Qiaquick tm 96 well PCR purification kit (Quiagen, West 
Sussex, UK) according to the manufacturer's instruction.  Samples were eluted in 60µL of sterile 
water and 4µL of product was anaylsed by electrophoresis.  Eluates were dried down by 
overnight incubation at 37°C and samples were resuspended in the appropriate amount of sterile 
water to give a concentration within the range recommended for cycling sequencing.  
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7.12    DNA sequencing 
 ABPI PRISM dRhodamine Dye Terminator Ready Reaction Cycle Sequencing kits (Perkin 
Elmer) with AmpliTaq DNA Polymerase FS (Perkin Elmer) were used for direct sequencing of 
PCR products.  The sequencing kits were used as instructed except volumes of ready mix added 
were reduced by 50%.  The reaction mixtures consisted of 4µL of DNA template (15ng-45ng), 
2ųL of forward or reverse primer at 0.8pmoles µl-1 and 4µL of ready reaction mix.  Reactions 
were set up using 96 well Thermofast plates (Advanced Biotechnologies).  The cycling 
parameters were 96°C for 2 min, and then 25 cycles at 96° C for 10sec, 50°C  for 5sec and 60°C   
for 4min and finally 4°C   hold. 
 
7.13  Ethanol precipitation in micro centrifuge tubes 
Each sequencing reaction was transferred to a labelled, sterile micro centrifuge 0.5mL tube and 
25uL of a 24:1 96% (v/v) ethanol/3M sodium acetate (pH5.2) stock was added to each tube, 
vortexed briefly and incubated at room temperature for 20min.  Samples were then centrifuged in 
a micro centrifuge at full speed for 30 min and the supernatant discarded.  125ųL of 70%(v/v) 
ethanol was added to each tube, the samples were vortexed briefly and centrifuged as before for 
15 min.  The supernatant was discarded and the tubes left to dry at 37oC for 10-15min.  Samples 
were either stored at minus 20oC or re-suspended in 2ųL sequencing loading dye (de-ionsed 
formamide and 25mM EDTA-containing 50mg/mL blue dextran, in a ratio of 1:5) and used 
immediately.  1.5ųl of the sample was loaded on a 55 polyacrylamide gel (Long Ranger) and 
electrophoresed on a 377 automated flourescent sequencer (PE Biosystems) for 3-6 hours. 
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 7.14   Analysis of sequencing data. 
Analysis was carried out blind without knowledge of the p53 status of the specimens.  Sequence 
data was analysed using Factura and sequence Navigator software (PE Biosystems).  Sequence 
variations detected manually in both forward and reverse directions were confirmed by further 
analysis of a second independent PCR amplified product from the same tissue extract. Both 
forward and reverse directions were confirmed by further analysis of a second independent PCR 
amplified product from the same tissue extract.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 159 
Chapter 8      Results of   p53 mutation analysis 
 
8.1  DNA extraction from microdissected samples 
17 cases were chosen for mutation detection and of these 12 (70%) yielded detectable DNA (See 
Table5). Of these 12 cases, seven were negative for p53 nuclear staining while the remaining 
five were p53 positive.  The author was blinded as to the p53 status of the samples until after 
sequencing results were verified with an independent observer.  A pathologist (Dr F Campbell, 
Royal Liverpool Hospital) had previously selected tumour areas for microdissection.  In the p53 
positive staining group at least 60% of the tumour areas showed widespread p53 nuclear 
staining.  
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Table 8.1.   Clinical information on micro dissected sample 
CASE BACKGROUND P53 STAINING % STAINING DIFFERENTIATION 
3 mucinous metaplasia positive 70% well to moderate 
4 normal negative absent mod.focal poor 
5 normal negative absent poor to moderate 
6 mucinous metaplasia positive 90% poor 
10 mucinous metaplasia positive 60% well to moderate 
11 normal positive 75% moderate 
12 normal negative absent poor.  perineural 
13 normal negative absent mod. Giant cells 
14 mucinous metaplasia positive 80% mod. To poor 
15 mucinous metaplasia negative absent moderate 
16 normal negative absent poor.giant cells 
17 Mucinous metaplasia  positive 100% Poor. Huge nerve 
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Figure 8.1:    Agarose gel electrophoresis of duplicate second round polymerase chain 
reaction products from micro dissected pancreatic cancer showing 
amplification of exons 1 – 11. 
 
  
3 4c 8 
1 2 9 11 
4d 4a 
6 10 7 
5b 5a 
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TABLE 8.2.  p53 primers nested, second-round primers are highlighted in bold 
 
 
PRODUCTS 
 
 
FORWARD 
PRIMER 
 
 
SEQUENCE (5’-3’) 
 
REVERSE 
PRIMER 
 
 
SEQUENCE (5’-3’) 
 
First-Round 
 
1F 
 
TTTGTGCCAGGAGCCTCGCA 
 
1R 
 
CCCAGCCCCAGCGATTTTCCCGAGCTGAA
A 
 
Second-Round 
1N  
GGAGCCTCGCAGGGGTTGATG 
 
1R 
 
as above 
 
First-Round 
 
2F 
 
CAGGGTTGGAAGCGTCTCAT 
 
2R 
 
TCTCTGCTAGGGGGCTGGGGT 
 
Second-Round 
 
2N 
 
TGGAAGCGTCTCATGCTGGA 
 
2R 
 
as above 
 
First Round 
 
3F 
 
CCCTAGCAGAGACCTGTGGG 
 
3R 
 
CGGCAAGGGGGACTGTAGAT 
 
Second-Round 
 
3F 
 
as above 
 
3N 
 
AGCAGTCAGAGGACCAGGTCCTCA 
 
First-Round 
 
4AF 
 
TCTGGTAAGGACAAGGGTTG 
 
4AR 
 
GGAGCAGCCTCTGGCATTCTGGGAGC 
 
Second-Round 
 
4AF 
 
as above 
 
4AN 
 
CATCTGGACCTGGGTCTTCA 
 
First-Round 
 
4BF 
 
CTGAAAACAACGTTCTGGTAAGG 
 
4BR 
 
TGCAGGGGCCGCCGGTGTA 
 
Second-Round 
 
4BN 
 
CTGACTGCTCTTTTCACCCATC 
 
4BR 
 
as above 
 
First-Round 
 
4CF 
 
GCAATGGATGATTTGATGCTGT 
 
4CR 
 
CCGTAGCTGCCCTGGTAGGT 
 
Second-Round 
 
4CN 
 
ATTTGATGCTGTCCCCGGAC 
 
4CR 
 
as above 
 
First-Round 
 
4DF 
 
GCACCAGCAGCTCCTACA 
 
4DR 
 
CAAACAAAAGAAATGCAGGGGGAT 
 
Second-Round 
 
4DF 
 
as above 
4DN  
AAATGCAGGGGGATACGG 
 
First-Round 
 
5AF 
 
TTCCAGTTGCTTTATCTGTTCA 
 
5AR 
 
CGCTCATGGTGGGGGCAG 
 
Second-Round 
 
5AF 
 
as above 
 
5AN 
 
GGCAGCGCCTCACAACCT 
 
First-Round 
 
5BF 
 
GCCAAGACCTGCCCTGTG 
 
5BR 
 
AAGAGCAATCAGTGAGGAATCAGA 
 
Second-Round 
 
5BF 
 
as above 
 
5BN 
 
GGCAACCAGCCCTGTCGTC 
 
First-Round 
 
6F 
 
AGACGACAGGGCTGGTTG 
 
6R 
 
CTCACCCGGAGGGCCACTGA 
 
Second-Round 
 
6N 
 
CTGGTTGCCCAGGGTCCCCA 
 
6R 
 
as above 
 
First-Round 
 
7F 
 
GGCCTCCCCTTGCTTGCCACA 
 
7R 
 
GGCCCAGGGGTCAGCGGCAA 
 
Second-Round 
 
7N 
 
CCCCTGCTTGCCACAGGTCT 
 
7R 
 
as above 
 
First-Round 
 
8F 
 
GTTTTTTAAATGGGACAGGTAGG
A 
 
8R 
 
GGTGATAAAAGTGAATCTGAGGCATAAC 
 
Second-Round 
 
8N 
 
GGGACAGGTAGGACCTGATTTCC
T 
 
8R 
 
as above 
 
First-Round 
 
9F 
 
CAAGAAGCGGTGGAGGAGACCA
AGGGT 
 
9R 
 
CCCCCTGATGGCAAATGCCCCAA 
 
Second-Round 
 
9F 
 
as above 
 
9N 
 
GCCCCAATTGCAGGTAAAACAGTCA 
 
First-Round 
 
10F 
 
CAATTGTAACTTGAACCATCTTTT
AACT 
 
10R 
 
TGAGAATGGAATCCTATGGCTTTC 
 
Second-Round 
 
10F 
 
as above 
 
10N 
 
GGAATCCTATGGCTTTCCAACCTA 
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First-Round 
 
11F 
 
GGGCACAGACCCTCTCAC 
 
11R 
 
GTTCAAAGACCCAAAACCCA 
 
Second-Round 
 
11F 
 
as above 
 
11N 
 
CCCAAAACCCAAAATGGC 
1with reference to Genbank accession number U94788 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amplicon Positions Within p53 Gene 
(GenBank Accession Number U94788) 
First-Round/ 
Second-Round 
Primers 
 
1a 
 
 
 
 
 
291/282 
 
2 
 
 
 
 
 
213/207 
 
3 
 
 
 
 
 
193/163 
 
4a 
 
 
 
 
 
213/185 
 
4b 
 
 
 
 
 
272/189 
 
4c 
 
 
 
 
 
209/199 
 
4d 
 
 
 
 
 
224/214 
 
5a 
 
 
 
 
 
233/220 
 
5b 
 
 
 
 
 
227/188 
 
6 
 
 
 
 
 
242/231 
non-coding 
1R 
10
40 
75
9 1N 75
0 1F 
84
3 
94
8 
1-24 
11
64
2 2F 
2R 
11
85
4 
11
68
9 
11
79
0 
11
64
8 2N 
3R 
12
03
2 
11
84
0 3F 
3N 
12
00
2 
11
90
6 
11
92
7 
24-32 
4AN 
12
10
8 
11
92
4 4AF 
4AR 
12
13
6 
12
02
1 
33-54 
11
99
4 4BN 
11
91
1 4BF 
4BR 
12
18
2 
12
02
1 
33-80 
12
03
9 4CF 
4CR 
12
24
7 
43-100 
4DR 
12
37
3 
12
15
0 4DF 
4DN 
12
36
3 
12
29
9 
76-125 
5AR 
13
22
1 
12
98
9 5AF 
5AN 
13
20
8 
13
05
5 
126-175 
5BR 
13
31
7 
13
09
1 5BF 
5BN 
13
27
8 
13
23
8 
144-186 
13
25
9 6F 
6R 
13
50
0 
13
32
0 
13
43
2 
187-224 
13
93
5 7N 
13
93
0 7F 
7R 
14
18
2 
14
00
0 
14
10
9 
225-261 
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7 
 
 
 
 
 
253/248 
 
8 
 
 
 
 
 
280/269 
 
9 
 
 
 
 
 
263/247 
 
10 
 
 
 
 
 
257/250 
 
11 
 
 
 
 
 
226/217 
 
Table 8.3:  Primers used to generate each amplicon including localisation of 5’ends. Nucleotide positions in brackets represent 
the position of the 5’end of the nested second-round primer. Coding sequence is shown in black and intron sequence 
in grey. aExon 1 is non-coding; the region shown in black forms part of the primary transcript 
. 
 
8.2    Analysis of sequence variations in archival tumour samples 
Most of the cases studied produced good sequence data but not in all exons exons (See Table 
8.4). Human placental genomic DNA (Sigma, Dorset, UK) were used as controls for sequence 
analysis and mutation detection.  Sequence data was considered complete when there was bi-
directional read for the full coding sequence transcribed region for exon 1 and 10 bases upstream 
and downstream of the coding region for each product.   
 
 
 
 
 
 
 
 
 
14
39
2 8NF 
14
38
1 8F 
8R 
14
66
0 
14
45
2 
14
58
8 
261-307 
9R 
14
86
5 
14
60
3 9F 
9N 
14
84
9 
14
68
1 
14
75
4 
307-331 
14
75
4 
17
49
7 10F 
10R 
17
75
3 
10N 
17
74
6 
14
68
1 
332-367 
18
53
9 11F 
11R 
18
76
4 
11N 
18
75
5 
18
59
9 
367-393 
18
68
0 
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Table 8.4.  Summary of sequencing yield from exons 
Exon Case3 4 5 6 10 11 12 13 14 15 16 17 Total/12 % 
1 p p p g p g g g g g p g 7 58 
2 g g g g g g g g g g g g 12 100 
3 p p p p p g g g g g g g 7 58 
4a p p g p g g p g g g g g 9 75 
4b p g g g g g p g g g g g 10 83 
4c p g p p p g p p g p g g 7 58 
4d g g g g g g p g g g g g 11 91 
5a g g g g g g g g p p g g 10 83 
5b g g p g g p p p g g g g 9 75 
6 g g g g g g g g g g g g 12 100 
7 g g g g g g g g g g g g 12 100 
8 g g p g g g g g p g g g 11 89 
9 p p g p g g g g p g g g 9 75 
10 g g g g p p p p g g g g 8 66 
11 g g g g g g g g g g g g 12 100 
total/15 9 11 11 12 11 13 11 12 12 13 14 15 146/180 81 
% yield 60 73 73 80 73 86 73 80 80 86 93 100   
 
g = good sequence 
p = poor sequence 
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Table 8.5.   Summary of sequence variations detected in pancreatic cancer samples.  
Sample Region Variation Type p53 Grade 
3 exon 5b mutation Base change G-A@113 positive well/mod 
10 exon5b mutation Base change G-T@103 positive well/mod 
10 exon 7 polymorphism G-T base change positive well/mod 
11 exon2 polymorphism C-insertion@173,174,177 positive moderate 
12 exon2 polymorphism C-insertion@173,174,177 negative poor 
13 exon2 polymorphism C-insertion@173,174,177 negative mod 
14 exon3 polymorphism C-insertion @32 positive poor 
15 exon3 polymorphism C-insertion@32 negative mod 
16 exon3 polymorphism C-insertion@32 negative poor 
17 exon4a polymorphism G-T@ 208 positive poor 
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Figure 8.2:  Electrophoregram showing mutation as a base change between G-A@133base 
Exon  5b in case 3 (p53 positive).  Sequence variants detected in both forward and reverse 
directions in duplicate.  The experiments were repeated by analysis of independent PCR 
products amplified from the same tissue extract.  When PCR products from the same 
sample shared the base change, it was defined as a “confirmed variant”. 
 
 
 
forward 
reverse 
forward 
reverse 
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Figure 8.3:  Electrophoregram showing polymorphisms in Cases 11, 12, 13 in Exon 2 
@173,174,177 in codon 21.  Case 11 was p53 positive while cases 12 and 13 
were p53 negative.   
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Figure 8.4:  Gel image from an ABI 377 DNA sequencer 96 gel lane format. 
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8.3.   Summary of results 
 
1) Confirmed p53 mutations were found in cases 3 and 10 in Exon 5b (See Figure 8.3).  These 
samples were previously p53 positive on immunostaining 
2)  We detected a C-insertion at base positions 173, 174 and 177(Figure 8.4) in intron 2, and a  
G-T change at position 14168 in intron 7 (See Figure. 8.4).  These variations had previously 
been deposited in Genbank (U94788).  
3)  There were 10 taq polymerase errors (Case 14; Ex3 bases 90, 96, 108; case 15 and 16, exon 3 
base 90, 96, 108; case 17, exon 4a at base 52 found in sequencing.  These were genetic variants 
found from PCR-induced errors. Distinction was made between true sequence variants (genetic 
variants or mutations) and sequence variants resulting from PCR-induced errors, with the former 
being defined as being present in multiple independent PCR products.  
 
8.4. Conclusion from this study 
 
The entire p53 gene was sequenced successfully using a multiplex PCR system.   Mutations were 
confirmed in two of six cases that were previously positive for p53 on immunostaining.  There 
were no mutations found in the p53 negative staining cases.   A number of polymorphisms 
previously unreported to Genebank were found but more work is needed to correlate this with 
clinical parameters.     
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Chapter 9 K-ras  mutation  studies 
 
 
9.1   Introduction and aims 
 
In ductal adenocarcinoma of the pancreas point mutations in codon 12 of the K-ras gene are 
amongst the most common genetic abnormality found (Hruban RH et al, 1993).  In previous 
studies the presence or the type of K-ras mutations in pancreatic tumours has not been shown to 
significantly correlate with patient survival (Dergham ST et al, 1997; Hruban RH et al, 1999).    
The aim of this part of the  study was to analyse K-ras mutations using microdissected samples 
and correlate the findings with survival.  This work was carried out in collaboration with the 
department of  Molecular Medicine at Haukeland University, Norway. 
 
  9.2  Single Strand conformation polymorphism (SSCP) 
 This is a rapid and simple method of studying mutations.  The electrophoretic mobility of a particle 
in a gel is sensitive to both its shape and size.  In the absence of denaturing, single stranded DNA 
has a three folded structure that is determined by intramolecular interactions and therefore by its 
sequence.  In SSCP analysis, a mutated sequence is detected as a change of mobility in 
polyacrylamide gel electrophoresis caused by its altered folded structure.  The target sequence is 
first labelled and amplified simultaneously by the PCR of the genomic DNA or cDNA using 
labelled substrates.  The PCR product is then denatured and resolved by polyacrylamide gel 
electrophoresis and mutations are detected as altered mobility of separated single strands in the 
autoradiogram.  Further characterisation of the mutation can be done by eluting the mutated allele 
from the gel used for autoradiography and amplifying again for sequence determination. 
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9.3   Methods 
9.3.1   Patients  
143 clinical samples from patients in the  immunohistochemical study were used.  The clinical 
details are shown in Table 9.1.   The samples were selected by myself and the work was carried 
out with collaborators in Norway who had no knowledge of clinical details of patients until 
completion of study. 
 
 9.3.2  Extraction of DNA 
Tissue blocks or tumour specimens which had been formalin-fixed, paraffin- embedded and slide 
mounted were used to prepare the DNA for analysis.   Two methods were then used to extract 
DNA.  Tissue sections were mixed with 100µL of buffer [(10mM Tris- HCL ph 8.0 and 5% 
Chelex (Biorad)] and the tubes were heated to 95°C for 5 minutes.  After centrifugation for 
30seconds, 5µL of the supernatant was immediately added to separate PCR reactions mixes.  
Alternatively 5µL tumour areas were scraped off microscopic slides and paraffin was removed 
with 1ml xylene  incubation at 50°C for 30 minutes.  The samples were then washed twice with 
96% ethanol, centrifuged and allowed to dry at room temperature.  DNA was extracted using the 
Puregene kit.  500µL of lysis buffer was added to the sample with 10uL of 10mg/ml proteinase 
K, incubated overnight at 50°C and then cooled.  A 100µL aliquot of protein precipitation 
solution was added followed by a short centrifugation.  The supernatant was removed and DNA 
precipited using isopropanol.  Pellets were centrifuged for ten minutes at 12,000 revolutions then 
washed with 70% ethanol.  Once the pellets were dry the DNA was dissolved in 50µL of TE  
(10mM Tris-HCl,  1mM EDTA, pH 8.0). 
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9.4 PCR Amplification 
 
 
9.4.1    primers 
 
 Oligonucleotide primers 5”- AACCTTATGTGTGACATGTTAAT-3” and 5”- 
AATGGTCCTGCACCAGTAAT-3” were designed to target K-ras exon 1 to produce a 
221 base pair (bp) product.  
 
9.4.2  PCR Amplification 
 A 2-5 µ1 of sample DNA was added to a PCR reaction mix consisting of 10mM Tris-HCl 
ph 9.0, 50mM KCl, 1.5mM MgCl2, 0.01% (w/v) gelatin, 0.1% Triton, 125 mM dNTP, 
0.5M of each primer and 0.2 units of  Taq polymerase (Supertaq, HT Biotechnology Ltd, 
UK) in a total volume of 100µL.  PCR conditions were 94oC for 2 minutes, then 40 cycles 
at 94oC for 15 seconds and then at 60oC for 30 seconds, followed by 72oC for 2 minutes 
using a Perkin Elmer TC 1 thermocycler.   
 
  
9.5  Single Strand conformation polymorphism (SSCP) analysis 
 
 A 4µ1 aliquot of PCR product was denatured by mixing with an equal volume of deionised 
formamide and incubated briefly at 80oC.  The samples were then applied to a 20% 
homogeneous polyacrylamide gel (Phast gel, Pharmacia, Sweden) with buffer strips 
containing 0.88 M L-Alanine, 0.25M Tris pH 8.8 and run on the Pharmacia Phast system 
automatic electrophoresis and development unit.  The programme used was pre run: 400V, 
10mAA, 2.5W, 100Vh, loading: 400V, 1mA, 2.5W, 3 Vh, separation: 400V, 10mA, 2.5W, 
300Vh.  After electrophoresis the gels were silver stained.  This method has the ability to 
identify all the mutations so far reported in exon 1 of K-ras (Ulvik A et al, 1995).  A 
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minimum of three separate analyses was performed for each sample to  eliminate the 
possibility of PCR artefact. 
 
 9.6 Sequence analysis 
 
 PCR products were directly sequenced (standard Sequenanse kit, Amersham Life Science, 
Little Chalfont, Buckinghamshire, UK) to confirm the above mutations.  Standard reagents 
other than those specified were purchased from BDH Laboratory Supplies Ltd, Poole, 
Dorset, UK. 
 
 9.7  Statistical analysis       
  
 Chi-squared or Fisher's exact test were used for categorical data.  Survival data were 
analysed using the Kaplan-Meier method and statistical significance of the difference in 
survival between the two groups was calculated using the log rank test.  Multivariate 
analysis was used to test for independent significance.  Statistical significance was set at 
P<0.05. 
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9.8    Results of K-Ras mutation  analysis 
 
The clinical data on all patients studied is shown in tables 9.1 and 9.2.   Case numbers that were 
used in immunohistochemistry were retained.  From 143 cases   DNA was obtained in 93 cases 
and of these 73 (75%) were found to have mutations 
 
Table 9.1.  Clinical data for K-ras analysis in Swedish cases. 
 
Case TISS PCR SSCP SSCP1 Survival (Days) 
1 N- + wild type (GGT GGC) GGTGGC 7 
2 ¥ ¥  ¥ 135 
3 N++ ----- wild type (GGT GGC) GGTGGC 420 
4 N- + GGT GGC > GaT GGC GaTGGC 161 
5 N + wild type (GGT GGC) GGTGGC 269 
6 N- + GGT GGC > GcT GGC GcTGGC 0 
7 N- ----- wild type (GGT GGC) GGTGGC 104 
8 N- ----- wild type (GGT GGC) GGTGGC 154 
9 N++ ----- GGT GGC > GaT GGC GaTGGC 327 
10 N- ----- GGT GGC > GtT GGC GtTGGC 473 
11 N- + wild type (GGT GGC) GGTGGC 461 
12 N++ + GGT GGC > aGT GGC aGTGGC 670 
13 N++ + GGT GGC > GaT GGC GaTGGC 402 
14 N++ (+) wild type (GGT GGC) GGTGGC 389 
15 N- OK wild type (GGT GGC) GGTGGC 498 
16 N OK GGT GGC > GGT GaC GGTGaC 390 
17 N- ----- wild type (GGT GGC) GGTGGC 53 
18 N- (+) wild type (GGT GGC) GGTGGC 131 
19 N OK GGT GGC > GaT GGC GaTGGC 120 
20 N- + wild type (GGT GGC) GGTGGC 252 
21 N- + GGT GGC > GtT GGC GtTGGC 206 
22 N++ + GGT GGC > aGT GGC aGTGGC 511 
23 N OK GGT GGC > GaT GGC GaTGGC 637 
24 N+ (-) GGT GGC > GtT GGC GtTGGC 210 
25 N - GGT GGC > GtT GGC GtTGGC 210 
26 N- (+) wild type (GGT GGC) GGTGGC 390 
27 N ----- - ¥ 210 
28 N- + GGT GGC > GtT GCC GtTGGC 533 
29 N- + wild type (GGT GGC) GGTGGC 13 
30 N (+) wild type (GGT GGC) GGTGGC 342 
31 N+ + GGT GGC > GaT GGC GaTGGC 1120 
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32 N- + wild type (GGT GGC) GGTGGC 716 
33 N+ + wild type (GGT GGC) GGTGGC 403 
34 N ----- GGT GGC > GaT GGC GaTGGC 210 
35 N- (+) GGT GGC > GaT GGC GaTGGC 137 
36 N+ + GGT GGC > cGT GGC cGTGGC 60 
37 N- + GGT GGC > GaT GGC GaTGGC 29 
38 N- (+) wild type (GGT GGC) GGTGGC 204 
39 N- + wild type (GGT GGC) GGTGGC 210 
40 N (+) wild type (GGT GGC) GGTGGC 112 
41 N- (+) wild type (GGT GGC) GGTGGC 30 
42 N+ ----- wild type (GGT GGC) GGTGGC 92 
43 N-- + wild type (GGT GGC) GGTGGC 347 
44 N + GGT GGC > aGT GGC aGTGGC 1308 
45 N + GGT GGC > GtT GGC GtTGGC 454 
46 N + GGT GGC > GtT GGC GtTGGC 219 
47 N+ ----- GGT GGC > GtT GGC GtTGGC 440 
48 N- + GGT GGC > cGT GGC cGTGGC 181 
49 N + GGT GGC > GaT GGC GaTGGC 337 
50 N OK GGT GGC > GtT GGC GtTGGC 150 
51 - (+) GGT GGC > GtT GGC GtTGGC 1769 
52 N- ----- - ¥ 234 
53 N + GGT GGC > GaT GGC GaTGGC 125 
54 N- ----- GGT GGC > GtT GGC GtTGGC 798 
55 - ----- - ¥ 458 
56 - ----- GGT GGC > GaT GGC GaTGGC 157 
57 N+ (+) GGT GGC > GaT GGC GaTGGC 316 
58 N+ ----- wild type GGT GGC GGTGGC 157 
59 N + wild type GGT GGC GGTGGC 150 
60 N- + GGT GGC > GcT GGC GcTGGC 195 
61 N + GGT GGC > GaT GGC GaTGGC 37 
62 N- + wild type GGT GGC GGTGGC 1278 
63 - ----- GGT GGC > GtT GGC GtTGGC 330 
64 N- OK GGT GGC > GaT GGC GaTGGC 267 
65 N+ ----- GGT GGC > GtT GGC GtTGGC 90 
66 N-- + wild type GGT GGC GGTGGC 900 
67 N + wild type GGT GGC GGTGGC 240 
68 N ----- wild type GGT GGC GGTGGC 77 
69 N ----- wild type GGT GGC GGTGGC 330 
 
 
 
¥   absent 
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Table 9.2. Clinical data for  K-ras analysis in United Kingdom cases. 
Case TISS PCR SSCP SSCP1 Survival (days) 
70 
N + 
wild type 
GGT GGC GGTGGC 
367 
71 
¥ ¥  ¥ 
63 
72 
N ----- - ¥ 
305 
73 
N++ ----- - ¥ 
451 
74 
N- ----- - ¥ 
450 
75 
N OK 
GGT GGC > 
GaT GGC GaTGGC 
34 
76 
N++ + 
GGT GGC > 
GaT GGC GaTGGC 
197 
77 
N- ----- 
GGT GGC > 
GtT GGC GtTGGC 
393 
78 
N- + 
GGT GGC > 
GtT GGC GtTGGC 
293 
79 
N+ OK 
GGT GGC > 
GaT GGC GaTGGC 
118 
80 
- ----- - ¥ 
313 
81 
¥ ¥  ¥ 
1827 
82 
N+ (+) 
GGT GGC > 
GAT GGC GaTGGC 
190 
83 
N++ + 
GGT GGC > 
GaT GGC GaTGGC 
760 
84 
N++ ----- 
wild type 
GGT GGC GGTGGC 
229 
85 
N OK 
GGT GGC > 
cGT GGC cGTGGC 
300 
86 
N + 
GGT GGC > 
GaT GGC GaTGGC 
1060 
87 
N+ + 
GGT GGC > 
GaT GGC GaTGGC 
2485 
88 
¥ ¥  ¥ 
1206 
89 
N- ----- 
wild type 
GGT GGC GGTGGC 
170 
90 
N OK 
GGT GGC > 
cGT GGC cGTGGC 
353 
91 
¥ ¥  ¥ 
924 
92 
N- ----- 
wild type 
GGT GGC GGTGGC 
106 
93 
N ----- 
wild type 
GGT GGC GGTGGC 
1113 
94 
N+ ----- 
wild type 
GGT GGC GGTGGC 
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95 
N- + 
GGT GGC > 
GaT GGC GaTGGC 
767 
96 
N- + 
GGT GGC > 
GaT GGC GaTGGC 
88 
97 
N+ + 
wild type 
GGT GGC GGTGGC 
509 
98 
N (+) 
wild type 
GGT GGC GGTGGC 
103 
99 
N- + 
GGT GGC > 
GaT GGC GaTGGC 
193 
100 
N + 
wild type 
GGT GGC GGTGGC 
167 
101 
N- + 
wild type 
GGT GGC GGTGGC 
23 
102 
N + 
GGT GGC > 
cGT GGC ¥ 
450 
103 
N- + 
GGT GGC > 
GtT GGC GtTGGC 
245 
104 
N++ + 
GGT GGC > 
GaT GGC GaTGGC 
493 
105 
N + 
GGT GGC > 
GtT GGC GtTGGC 
475 
106 
N+ + 
GGT GGC > 
GGT GaC GGTGaC 
568 
107 
N++ + 
wild type 
GGT GGC GGTGGC 
50 
108 
N++ + 
GGT GGC > 
cGT GGC cGTGGC 
443 
109 
N++ + 
GGT GGC > 
GtT GGC GtTGGC 
547 
110 
N++ + 
GGT GGC > 
GtT GGC GtTGGC 
915 
111 
¥ ¥  ¥ 
398 
112 
N + 
GGT GGC > 
GaT GGT GaTGGC 
822 
113 
¥ ¥  ¥ 
9 
114 
N++ ----- 
GGT GGC > 
GtT GGC GtTGGC 
155 
115 
N- + 
wild type 
GGT GGC GGTGGC 
323 
116 
N+ + 
wild type 
GGT GGC GGTGGC 
260 
117 
N+ + 
GGT GGC > 
GtT GGC GtTGGC 
257 
118 
N++ + 
GGT GGC > 
GtT GGC GtTGGC 
225 
119 
N++ + 
GGT GGC > 
GtT GGC GtTGGC 
205 
120 
N++ + 
GGT GGC > 
GtT GGC GtTGGC 
162 
121 
N++ + 
GGT GGC > 
GaT GGC GaTGGC 
 
 179 
122 
N + 
wild type 
GGT GGC GGTGGC 
357 
123 
N- + 
wild type 
GGT GGC GGTGGC 
138 
124 
¥ ¥  ¥ 
912 
125 
¥ ¥  ¥ 
489 
126 
N- + 
wild type 
GGT GGC GGTGGC 
24 
127 
N + 
GGT GGC > 
GtT GGC GtTGGC 
569 
128 
N+ (+) 
wild type 
GGT GGC GGTGGC 
540 
129 
N+ + 
wild type 
GGT GGC GGTGGC 
229 
130 
N-- (+) 
wild type 
GGT GGC GGTGGC 
353 
131 
N + 
wild type 
GGT GGC GGTGGC 
393 
132 
N++ + 
GGT GGC > 
GaT GGC GaTGGC 
259 
133 
N+ ----- 
wild type 
GGT GGC GGTGGC 
171 
134 
N + 
GGT GGC > 
GaT GGC GaTGGC 
132 
135 
N + 
GGT GGC > 
GaT GGC GaTGGC 
78 
136 
N-- - 
GGT GGC > 
GtT GGC GtTGGC 
314 
137 
N+ ----- 
wild type 
GGT GGC GGTGGC 
235 
138 
N - 
GGT GGC > 
GtT GGC GtTGGC 
598 
139 
N- (+) 
wild type 
GGT GGC GGTGGC 
236 
140 
N + 
GGT GGC > 
GtT GGC GtTGGC 
16 
141 
N++ ----- 
GGT GGC > 
GtT GGC GtTGGC 
1366 
142 
N+ + 
wild type 
GGT GGC GGTGGC 
1465 
143 
N + 
wild type 
GGT GGC GGTGGC 
114 
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9.6.1     SSCP and mutation analysis 
 
DNA extraction, PCR and SSC was successful in 97 specimens of pancreatic adenocarcinoma 
and 73 (75%) were found to have a K-ras mutation (Table 9.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1:    1: Wild type K-ras codon 12 GGT 
   2: Samples heterozygous for wild type and GTT 
    3: Samples heterozygous for wild type and GTT (less wild type tissue than in lane 2) 
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 9.10    K-ras mutation and clinicopathological parameters 
 There were no significant associations between K-ras mutation status or mutation subtype with 
gender, stage, grade, tumour size and resection margin status (Table 9.3).  There was a 
significant association between the subtype of mutation and lymph node involvement (p<0.04).  
75% of GtT tumours were lymph node negative, 100% of aGT and GcT tumours were lymph 
node positive.  Survival analyses revealed no significant correlation between the presence or 
absence of K-ras mutation and patient survival, but there was improved survival by analysis of 
mutation subtypes.  
 
Table 9.3.   Incidence of K-ras mutations in pancreatic adenocarcinoma 
Authors and year Number of patients Mutation frequency (%) 
Almoguerra et al, 1988 22 95 
Smit et al, 1988 30 93 
Grunewald et al, 1989 65 75 
Mariyama et al, 1989 13 77 
Tada et al, 1990 18 100 
Shibata et, 1990 27 74 
Motojima et al, 1991 18 100 
Lemoine et al, 1992 16 75 
Hruban et al, 1993 82 83 
Pellegata et al, 1994 35 71 
Dergham et al 1997 76 84 
Kubrusly et al, 1999 11 100 
Luttges et al, 1999 35 100 
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Table 9.4.   Correlation between K-ras mutation status and single mutation subtype 
(GaT  GtT   cGT   aGT   Gct or GaC) and clinical parameters and survival 
 
 
    
Parameter wild type vs. mutations wildtype vs each mutation   mutation subtype only 
      subtype(Gat GtT cGT Gct or Gac)   (Gat GtT cGT aGT Gct or GaC) 
 
 
   X2  p value  X2 P value   X2 P value 
 
 
Gender   0.084  0.81  5.07 0.54   5.04 0.41 
Grade of tumour 4.87  0.08  8.60 0.74   4.05 0.95 
Stage of tumour 1.71  0.43  14.33 0.28   12.69 0.24 
Tumour size 0.05  0.98  14.3 0.28   14.46 0.15 
Lymph node status  0.29  0.59  12.27 0.06   11.86 0.04 
Resection margins 0.25  0.62  0.70 0.99   0.53 0.99 
Adjuvant therapy 0.7  0.41  1.73 0.94   1.54 0.91 
Survival  2.15  0.14  23.4 0.0007   17.59 0.0004 
 
 
 
 
 Statistically significant value. 
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Table 9.5.   Frequency of K-ras codon 12 and 13 mutations detected by SSCP in 97 
tumour samples and median survival    
 
 
K-ras     Codon  Number % Median survival            95% CI 
Mutation   (months)  
subtype       
           
  
GGT  (wild type) -  24  25  31.15  23.45 – 38.85 
             
GaT   (ASP)  12  31  31  29.20  17.93 – 40.47 
             
GtT  (VAL)  12  29  29  31.41  20.18 – 42.64 
             
cGT  (ARG)  12  6  6  15.81  4.25 – 27.37 
            
aGT  (SER)  12  3  3  42.43  27.23 – 57.63 
             
GcT  (ALA)  12  2  2  8.75  1.40- 16.10 
             
GaC  (ASP)  13  2  2  36.04  29.11 – 42.97 
            
 
 
ASP=aspartic acid; VAL= valine; ARG=arginine; SER=serine; ALA=alanine 
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9.11    Summary 
 
a)  DNA extraction, PCR and SSCP was successful in 97 specimens of pancreatic 
adenocarcinoma 
 
b) 73 cases (75%) were found to have a K-ras mutation 
c) The were no significant associations between K-ras mutation status or mutation      subtype 
with gender, stage, grade, tumour size and resection margin status 
d) There was no significant association between the subtype of mutation and lymph node 
involvement (p<0.04) 
e)  75% of GtT tumours were lymph node negative 
f)  All (100%) of aGT and GcT tumours were lymph node positive 
g) Survival analyses revealed no significant correlation between the presence or absence of 
mutation subtype 
h) There was improved survival by analysis of mutation subtypes (p =0.0004) 
 
 
 
 
 
 
 
 
 
9.12   Conclusion from this study 
 
 Survival analyses revealed no significant correlation between the presence or 
absence of K-ras mutation and patient survival but there was improved survival 
by analysis of mutation subtypes. 
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CHAPTER 10 Discussion 
 10.1   Introduction 
A comprehensive analysis of potentially useful  prognostic molecular markers in ductal 
pancreatic cancer has been carried out in a large series of clinical specimens from a multicentre 
population to clarify previous conflicting reports.  Previous studies on molecular prognostic 
markers were small, usually involving the study of a single gene and reported conflicting 
survival outcomes.  Our study has addressed these concerns and we have found that these 
molecular markers occur with high frequency in ductal pancreatic cancer, although no 
correlation with survival was found except in particular subsets of K-ras mutations.   Following 
an apparently curative resection for ductal pancreatic cancer, most patients develop local 
recurrence within the resection bed as well as liver metastases (Andren-Sandberg A et al, 1997).  
Thus present surgical procedures are inadequate for cure except in a few cases and, where 
adjuvant treatment is used it must be effective not only against systemic spread of the disease but 
also against local recurrence.  Staging of pancreatic cancer has become critical given that there is 
now a better understanding of its pathogenesis and the obvious improvements in surgical care.  
Currently there are two main staging systems in use, the UICC (TNM systems) and that of the 
Japanese Pancreas Society.  These two systems are fundamentally different and have wide 
confidence intervals (Zerbi A et al, 1994) making them unsuitable for clinical decision making.   
The recent explosion in knowledge of molecular biology has generated an interest in the possible 
use of altered gene products as possible prognostic markers, particulary in cancer treatment.  
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10.2  Clinical Characteristics   
We were fortunate to have available resected pancreatic cancer specimens from three different 
centres with very good clinical data.. A significant difference in survival between British and 
Swedish patients (p=0.01) on univariate analysis was found but this disappeared following 
multivariate analysis, the reasons for this was unclear.  The only significant prognostic factors 
were TNM stage for disease (p=0.002) and lymph node involvement (p=0.0002).  We found 
lymph node involvement in 70 (45%) of cases and this is in agreement with other reports of up to 
70% resected pancreatic cancers (Cameron JL et al, 1991; Bassi C et al, 1995; Yeo CJ et al, 
1995; Delcore R et al, 1996).  There is however an uncertain relationship between lymph node 
involvement and survival in pancreatic cancer.  Therefore lymph node status does not influence 
adjuvant treatment as it does in other malignancies. Those who favour extended 
lymphadenectomy during pancreatic resections argue that potential foci are removed and also 
that there is interruption of lymphatic tumour spread.  Some have even suggested removing the 
retroperitoneal tissue, including the coeliac plexus (Nagakawa T et al, 1993; Beger HG et al, 
2002) but this has not gained wide acceptance (Osaki H et al, 1998).   In a prospective 
multicentre randomised trial, 83 patients were randomised to traditional or extended 
lymphadenectomy (Pedrazzoli S et al, 1998).  The overall survival was the same in the two 
groups (p<0.05).   Although there was a correlation between stage and survival, there is still a 
problem of “stage migration” given the differences in the available staging systems.  There also 
remains the problem of identifying patients whose disease is likely to progress rapidly or those 
with a better prognosis.  In our study there were no significant correlations between survival and 
gender (p=0.87), differentiation  (p=0.07), tumour size (p=0.98), resection margin status 
(p=0.92) and the use of adjuvant treatment (p=0.67).   Only 13 patients (8%) had adjuvant 
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treatment via the UKPACA and ESPAC trial.   Some studies have reported tumour size to be a 
significant prognostic factor by both univariate (Allison DC et al, 1991; Geer RJ and Brennan 
MF, 1993) and multivariate analyses (Allison DC et al, 1991; Geer RJ and Brennan MF, 1993: 
Yeo CJ et al, 1995).    Tumour size also correlates with peripancreatic (e.g. retro perineal or 
portal vein) invasion, which has also been found to be a strong prognostic factor (Kobari M et al, 
1996).  Our results do not agree with this, and this could possibly be due to the subjective nature 
of the interpretation of size of a tumour and in 15 of our cases there was no comment by the 
reporting pathologist on the size.  Recently, Neoptolemos et al (2001) have reported on the 
largest randomised adjuvant study to date where they examined the influence of resection 
margins on survival in 541 patients.  About 20% of patients had positive resection margins (R1).  
The patients had either chemo radiation or chemotherapy and the median follow up was 10 
months.  Resection margin status was found to be a significant prognostic factor with a median 
survival of 10.9 months for R1 as compared to 16.9 months for R0 margins.  There was a 
survival benefit for chemotherapy (19.7 months) but not for chemo radiation (14.0 months) 
irrespective of resection margin status.  Those patients with RO margins who received 
chemotherapy had a longer survival compared with those who did not.   
 
10.3  Results of immunostaining  
Reports of p53 overexpression in pancreatic cancer have been small and with conflicting results. 
Previous studies of p53 abnormalities in paraffin sections, frozen material and in pancreatic 
cancer cell lines have revealed similar p53 nuclear expression (van den Berg FM et al, 1993).  
The immunohistochemical data in this study revealed p53 immunoreactivity  in 41% of the 
cases.  These findings are in general agreement with previous studies reporting overexpression 
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rates of between 30 – 75% (Barton CM et al, 1991b; Zhang et al, 1994; Lundin et al, 1996; 
Rozenblum et al, 1997).  Similar results have been reported in metastatic pancreatic lesions both 
regional and distant (Ruggeri BA et al, 1997). The presence of p53 overexpression and 
or/mutations has been shown to correlate with survival in a number of human malignancies 
(Lane DP et al, 1991; Hollstein M et al, 1994).    In agreement with three other studies, p53 
expression, in this study did not correlate with survival (Lundin et al, 1996; Dergham et al, 
1997a; Ruggeri et al, 1997).  In contrast some smaller studies have reported reduced survival 
(Yokoham et al, 1994; Weyrer et al, 1996; Linder et al, 1997).   In addition there was no 
significant association between p53 and the pathological parameters studied, although a trend 
toward a higher histologic grade (more poorly differentiated tumour) was observed.  Two 
previous studies have investigated expression of p53 and p21 as predictors of survival associated 
with resectional adjuvant chemotherapy.  One study found that patients with tumours 
overexpressing p53 and given adjuvant treatment had significantly longer survival (Nio et al, 
1998) but in another study improved survival of patients was found only in those cases in which 
tumours overexpressed p53 and did not express p21 (Nio et al, 1999). Also there was no 
correlation on multivariate analysis with any of the other prognostic markers studied.  Even if an 
association with survival was found in other studies it is obvious that the correlation is not 
sufficiently strong enough on which to base decision making.  Given the central role of p53 in 
the cell cycle the lack of prognostic significance is unclear.   It has been suggested that p53 
mutation is a relatively late event in the progression of pancreatic cancer (Hruban RH et al, 
2000) and therefore would not influence survival.  Another explanation is that 
immunohistochemical staining does not always correlate with mutation status.  In the p53 
negative staining cases it is possible that the p53 had a very large deletion or had a nonsense 
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mutation. p53 protein stability depends not only on mutation but on binding to mdm-2 (Lane DP 
and Hall PA, 1997).   Mdm2 overexpression may affect p53 function as previously discussed.  
The stability of the p53 protein is affected by different fixation methods and this particularly 
applies to weak staining.  Using frozen tissue and a panel of anti-p53 antibodies, Barton et al 
(1991) found an overexpression of mutant p53 protein in 60% of cases of pancreatic cancer but 
only 20-25% nuclear immunoreactivity in paraffin embedded tissue.  This difference in p53 
immunoreactivity was probably because the epitope recognised by the antiserum is only partially 
resistant to formalin fixation Barton CM et al (1991).   Negative staining does not necessarily 
mean that there is no abnormality in the p53 gene and conversely positive staining does not 
always indicate mutant protein.  Fisher et al (1994) showed that some fixatives appear to 
preserve antigenicity of the p53 protein better than others particularly to tumours showing only 
weak nuclear staining.  They concluded that formal saline is a good preservative for antigenicity.  
Tissue fixation in this way has a good morphology and fixation is rapid and gives excellent 
preservation of DNA for use in flow cytometry and in analyses using the polymerase chain 
reaction technique (Fisher CJ et al, 1994).    The fact that p53 is commonly altered in cancer does 
not necessarily imply that it is a good prognostic marker, on the contrary a genetic change 
present in a majority of the specimens of a particular tumour type is unlikely to be predictive of 
diverse outcomes.  A second assumption often made about p53 alteration is that it is a binary 
event, with p53 alteration being either normal or altered in a tumour.  It is important when 
considering p53 in tumours to remember that different mutations are variable in their phenotype.  
Some mutations are recessive “loss of function” whereas others are dominant “gain-of function” 
mutations more typical of dominant oncogenes (Steele RJ et al 1998).  Further various assays 
used to study p53 have differing levels of sensitivity for the various forms of p53 alteration.  The 
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recently suggested progression model for pancreatic cancer shows that p53 mutation is a 
relatively late event in the progression of pancreatic cancer.   It is possible that mutations of other 
oncogenes or tumour suppressor genes are more critical in promoting progression of pancreatic 
tumours.  Inspite of the correlation with survival, p53 occurs at significant frequency in 
pancreatic cancer and it may still be important to study the different types of p53 mutations and 
correlate this with survival.  
The overall rates of p21 positivity conform with previous reports (Ruggeri B et al, 1997; Coppla 
D et al, 1998).  p21 overexpression was not found to correlate with any of the clinicopathological 
variables studied and is in keeping with the few reports in the literature (Okada N et al, 1995; 
Coppola D et al, 1998; Ruggeri BA et al, 1997).  Mutation analysis studies of p21 in some 
malignancies has revealed few somatic mutations (Ruggeri BA et al, 1997) leaving its tumour 
suppressor role unresolved.  Further, p21WAF1 null mice do not exhibit a higher frequency of 
spontaneous tumours as do p53 null mice (Ruggeri et al, 1997).   Most recent studies have failed 
to show a correlation between p21 expression and p53 suggesting that in addition to the p53 
dependent pathway for p21 induction other mechanisms exist.    Correlation between p21 
immunoreactivity and the clinical parameters studied was not statistically significant.  
Multivariate analysis with other prognostic markers did not show any correlation.  In the normal 
colon positive control p21 immunoreactivity was found in the nuclei of crypts as previously 
reported (Yasui W et al, 1997). There was no correlation with patient survival, which contradicts 
previous smaller studies, which have postulated a link between p16 inactivation and survival 
(Naka et al, 1998).  A multivariate analysis of p16 overexpression with other prognostic markers 
did not show any statistical significance.   The overall rates of positivity of c-erbB-2 were similar 
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to those published, but unlike the smaller studies by Friess et al (1995) and Lei et al (1995) there 
was no relationship with prognosis  
C-erbB-2 overexpression was not associated with survival in this study.  This is in contrast with 
two previous smaller studies (Friess H et al, 1995; Lei SZ et al, 1995).   Lei et al (1995) studied 
21 cases of pancreatic cancer using the monoclonal antibody (Mab) CB11 and found 
overexpression in 10 cases (47.6%).  Overexpression of c-erbB-2 was closely and inversely 
related to survival; 19.1 +/- 11.7 months for those that were negative for c-erbB-2 and 7+/- 3.8 
months for those that were positive (p<0.01).   In a recent study by Jacobs et al (2000) looking at 
interlaboratory agreement in assessing overexpression of c-erbB-2 in breast cancer, they found 
the agreement in interpreting cases as positive or negative was 97%.  This was remarkable given 
that although the same polyclonal antibody was used they employed different automated 
immunostainers, detection systems, and methods of scoring were used.  The success of clinical 
trials using Herceptin (trastuzumab, a humanised anti-erbB-2 antibody) as therapy for patients 
with advanced breast cancer (Pegram MD et al, 1998) has generated further interest in this 
oncoprotein.  The minority of patients who had significant improvement expressed very high 
levels of c-erbB-2.  Currently the Hercep Test kit (Dako, Carpinteria, CA) has become popular.  
It has the advantage of being easy to use and promotes reproducibility because it contains 
comprehensive standardised reagents.  (Roche PC et al, 1999).  An ideal scoring system should 
report the percentage or proportion of positive or negative cells and their intensity as merely 
reporting positive or negative can be misleading because there are many assays in use.   There 
are a limited number of studies with the c-erbB-3 oncoprotein but our findings agree with those 
by Friess et al (1995) and Lei et al (1995).  Multivariate analysis with other clinical parameters 
as well as with other prognostic factors did not show any correlation. 
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 The levels of immunoreactivity of cyclin D1 (72%) was similar to previous reports and 
overexpression did not correlate with survival in this study in agreement with other studies 
(Ruggeri D et al, 1997; Coppola D et al, 1998).  The high expression rate suggests that cyclin D1 
is involved in the pathogenesis of pancreatic cancer.  In a study of 75 patients with transitional 
cell carcinoma of the bladder, Shin et al (1997) found that overexpression was not associated 
with reduced survival.  The loss of   p16 expression in 87% cases was consistent with the high 
frequency of p16 mutation in pancreatic cancer found in other studies (Caldas C et al, 1994; 
Naumann M et al, 1996).  No correlation was found with survival and this is in conflict with 
recent small studies  (Naka T et al, 1998).  In a study of 32 patients with pancreatic cancer, 
nineteen cases (59%) were positive for p16 and were associated with poor survival (Naka T et al, 
1998). 
Multivariate analysis was carried out between all the molecular markers.   This was done because 
it is becoming clear that pancreatic cancer formation is associated with multiple cancer related 
genes, including K-ras, p53, p16 and DPC4 genes that occur at high frequencies (Rozenblum E 
et al, 1997).  The change from a benign to a malignant condition is not regulated by a single gene 
but by multiple mutations in a single cell.  There was no correlation with survival however 
between the different combination markers.  This was not surprising given that those individual 
markers did not independently show any correlation  
 
10.4  Immunohistochemistry 
Immunohistochemistry is a useful laboratory method; however it has limitations with respect to 
quantitation and reproducibility.  Problems include threshold for detection of antigen (varying 
factors such as antibody concentration will alter staining), interpretation of staining (what is 
 193 
positive and negative) and specificity of antibodies.    Most laboratories routinely fix material in 
some variant of formaldehyde which gives good morphology.  However this introduces problems 
of sensitivity in the detection of a significant number of antigens due to a phenomenon known as 
masking of epitopes in fixed tissues.  Immunoreactivity for many antigens is lost or reduced and 
this appears to be proportionate to the length of fixation. The exact mechanism by which 
formaldehyde acts in fixing tissues is not fully understood, but it involves cross-linking of 
reactive sites within the same protein and different proteins via methylene bridges (Fox CH et al, 
1985; Mason JT et al, 1991).  To optimise staining results several techniques exist for unmasking 
or retrieving antigens based firstly on treating sections with proteolytic enzymes and more 
recently on heating sections at high temperature in water or a variety of solutions prior to 
immunostaining (Taylor CR et al, 1996).  Recent evidence suggests that release of calcium ions 
from tissues may play a role in unmasking epitopes and for this reason chelating agents e.g. 
EDTA were used in the antigen retrieval step in my experiments.    For example, there is an 
increase in positive staining for the p53 protein in some tumours with antigen retrieval and 
different results with different antibodies (Lambkin HA et al, 1994).  
 
 
10.5  p53 mutation analysis 
 This part of the study was done to confirm the results of immunohistochemistry. The limitations 
of immunohistochemistry have been discussed previously in this thesis. We sort to study 
mutations in all exons (1 –11) of the p53 gene.  By limiting analysis to the DNA binding domain 
of the p53 protein most studies that only look at the so called “hot spot’ regions, up to 25% of 
mutations can be overlooked (Hartmann A et al, 1995).  Successful microdissection of pancreatic 
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tumour samples and subsequent multiplex PCR of the DNA obtained, followed by sequencing 
was undertaken in 12 cases.  Microdissection was performed by using a polished tungsten needle 
with no contamination.  This shows that it is possible to carry out complex genetic analysis with 
inexpensive equipment.  Multiplex PCR is an economical method of utilising scarce DNA 
specimens (e.g. pancreatic cancer).    We were able to analyse the full coding sequence, splice 
sites, and polymorphisms from one 2µL aliquot of  5 micron tissue section clinical sample. All 
the exons in all 12 cases chosen for study were successfully sequenced.  p53 mutations were 
found in 2 (33%) of the 6 cases that showed p53 positive nuclear staining.  There were no 
mutations in the other six cases that were p53 negative.   Previous work has reported mutation 
rates of up to 75% in pancreatic cancer (Rozenblum et al, 1997).  The mutational yield was lower 
than expected and the most likely explanation for this was the small numbers studied.  In a 
number of cases where poor sequence was obtained we cannot be certain that mutations were 
missed.  It is possible that fixation of tumours from old specimens could contribute. For example, 
microdissection could only be done if tumour cells actually seen  clearly on slides. The other 
problem was possibly the difficulties we encountered with alcohol and gel electrophoresis.  This 
made it difficult to confirm presence of tumour products. 
For each sequence variation detected, validation was made by further sequencing of additional 
independent PCR products.  This allowed us to determine whether the changes seen were PCR-
induced errors or were genuine sequence variations.  The G-T change within intron 7 seen in 
cases 10 and 17 was not identified in a search of the GenBank database.  Analysis of these 
products with an alternative sequencing chemistry may help to validate these findings, although 
the presence of a T at this nucleotide in those samples would imply that the p53 sequence 
U94788 either contained a sequencing artifact at that position or that the source represented a 
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polymorphic variant.  The PCR method described was designed to amplify low-copy number, 
fragmented DNA from microdissected archival tumour samples.  This mutational analysis study 
was carried out at a time when the multiplex PCR system was being optimised in the laboratory 
where I carried out the experiments. It was unknown at the time whether a multiplex system 
would work for microdissected pancreatic tissue although this had been shown in ovarian and 
brain tissue in the same laboratory (Clatterbridge, Wirral, Liverpool, UK).   It was found during 
the course of the experiments that minute amounts of alcohol carried over from the DNA 
purification stage interfered with sequencing reactions. This led to experiments being repeated 
under different conditions several times until the cause of the poor sequencing was found.  This  
of course cannot be an explanation for the lower mutation frequency but is worth noting given 
that alcohol is routinely used in these experiments.    A further drying out process was 
subsequently included in the purification stage and this resulted in good sequencing yield.  In 
spite of the fact that the risk of PCR induced errors is increased when amplifying from the small 
amounts of amplifiable DNA available when working with microdissected tissue, we were able 
to satisfactorily eradicate false mutations by repeat PCR from the same sample.  For the 
amplicons shown, each aliquot from the pancreatic cancer samples contained amplifiable 
material but amplification from duplicate samples did not always produce detectable PCR 
product.  The fact that not all genomic DNA products amplified with equal intensity in the 
second-round amplification may reflect this. 
 
  10.6  K-ras mutation analysis 
 
  Our results of the frequency and types of K-ras mutations were very similar to previous large 
series (Hruban et al, 1993; Dergham et al, 1997b).  There was no correlation between survival 
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and the presence or absence of K-ras mutations in agreement with previous reports (Hruban et al, 
1993; Dergham et al, 1997b).  Hruban et al (1993) studied 82 resected formalin-fixed paraffin-
embedded pancreatic adenocarcinomas for the presence of point mutations at codon 12.  
Mutations were found in sixty-eight (83%) of cases and of these 33(49%) were guanine to 
cytosine transversions, 27 (39%) were guanine to thymine transversions and eight (12%) were 
guanine to cytosine transversions.  The prevalence of mutations was higher in ex-smokers (89%) 
and current smokers (86%) when compared to those who had never smoked (68% p=0.046).  
There was no correlation however with survival.  In a more recent study, Dergham et al (1997) 
extracted DNA from 81 patients with pancreatic cancer and studied K-ras muations in them by 
SSCP.  The incidence of K-ras mutation was 83% but there was no correlation with survival 
(Dergham ST et al, 1997).  The association of K-ras mutations and survival with adjuvant chemo 
radiation was demonstrated in one recent study.  Patients with pancreatic cancer and K-ras 
positive nodal micro metastases (pathologically classified as stage 1 disease) were shown to 
demonstrate better survival with adjuvant therapy compared to patients with nodal micro 
metastases who underwent surgery alone (Demeure et al, 1998).  Analysis of the K-ras mutation 
subtype revealed significant associations with patient survival.  All of the mutations identified 
have been shown to contribute to malignant transformation but whether there are differences in 
K-ras downstream signalling by certain mutations is unclear. Previous studies in colorectal 
cancer have demonstrated that patients with G to A transitions and G to C transversions tend to 
have a worse prognosis than those with G (T transversions (Span et al, 1996).  In addition codon 
13 mutated tumours were less likely to progress to local or distant metastases (Finkelstein et al, 
1993).  Our results agree with this, as patients with K-ras mutations GaT, cGT and GcT 
demonstrated shorter median survival times when compared with other mutations. There have 
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been reports of differences in the pattern of K-ras mutations between Europeans (Scarpa A et al, 
1994).  Differences in the site of the mutation and in the ratio of transitions to transversions were 
observed between an Italian and Spanish population.  Dong et al (1998) has reported differences 
in the substitution of K-ras mutations between the western population compared to the Chinese 
and Japanese.     The implied ethnic or environmental differences may be important because the 
pathogenesis of the tumour may implicate geographical genotoxic substances.  If a causal 
relationship were to be found , this could go a long way in the understanding of this aggressive 
tumour.  
 
 
10.7  Conclusions from present study 
 
This study represents the largest bank of pancreatic ductal adenocarcinoma that has been 
examined for molecular prognostic markers at the same time and with identical methods.  The 
molecular markers (p53, p16INK4, p21WAF1, cyclin D1, c-erbB-2 and c-erbB-3) studied by 
immunohistochemistry occur in significant proportions in pancreatic cancer but do not correlate 
with survival.   Mutations were confirmed in a small number of p53 positively staining cases 
using an economical method of DNA amplification.  The presence of K-ras mutation alone did 
not correlate with survival but there were significant differences in survival according to the type 
of K-ras mutation (p=0.0004).    
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10.8  Future studies 
Further studies of specific p53 and K-ras mutations as prognostic and treatment response 
markers are needed.  It is possible that different types of these mutations may have important 
epidemiological, prognostic or therapeutic implications in pancreatic cancer.  Recently, p53 
mutations have been reported to be helpful in predicting response of adjuvant treatment in some 
tumours (Berns EM et al, 2000).  With regard to K-ras mutations, future studies looking at 
adjuvant treatment data for mutation subtype will be important.  This would possibly help to 
explain whether mutation subtype could predict response to adjuvant treatment or whether 
patients have a poor outcome because they did not respond to chemotherapy.  This study could 
not address this problem because of the limited data on adjuvant treatment.   Most recently, there 
has been more work on  complete sequencing of the pancreatic cancer genome (Niki, A et al, 
2011).  This breakthrough will no doubtful provide an opportunity to exploit this knowledge for 
developing treatment methods such as gene therapy.  
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APPENDICES 
  Appendix 1   
 
Suppliers of chemicals and reagents  (Immunohisochemistry - IHC) 
 
    Chemicals and Reagents   Supplier  
 
Avidin biotin complex   DAKO Ltd, High Wycombe, Bucks 
                                                                                                 
    Biotinylated sheep secondary antibody  Amersham LIFE SCIENCE,  Buck  
 
 Citric acid     Sigma Chemical Co, Poole, Dorset 
  
DAB      Sigma Chemical Co, Poole, Dorset 
   (3-diaminobenzidinetetra- 
 Hydrochloride) 
  
DPX mountant    BDH/Merck chemicals Ltd, Leics. 
         
 EDTA      Sigma Chemical Co, Poole, Dorset 
  
Eosin      Sigma Chemical Co, Poole, Dorset 
   
Ethanol     University of Liverpool stores 
  
 Foetal calf serum    ICN  Biomedicals Ltd, Irvine, Scotland 
         
 Harris Haematoxylin    BDH/Merck  chemicals  Ltd, Leics 
        
 Horseradish peroxidase labelled anti-  Sigma Chemical Co, Poole 
               mouse secondary IgG (Goat)       
  
Hydrochloric acid    BDH/Merck chemicals  Ltd 
       Lutterworth, Leics. 
 Hydrogen peroxide solution (30%)  Sigma Chemical Co, Poole, Dorset 
                
 Poly-L-lysine     Sigma Chemical Co, Poole, Dorset 
  
R.O (Reverse osmosis) water 15 mega ohms University of Liverpool stores 
 
 Sodium chloride     BDH/Merck chemicals Ltd 
       Lutterworth, Leics. 
 Sodium hydroxide pellets    BDH/Merck chemicals Ltd 
       Lutterworth, Leics. 
 Tris (Tris (hydroxymethyl) methalamine/ 
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 HCl)      BDH/Merck chemicals Ltd, 
       Lutterworth, Leics. 
 Xylene      University of Liverpool stores 
 
 Methanol     Diagnostic Developments,  Lancs., UK 
 
 
 
 
 
    
Appendix 2 (IHC) 
 
Suppliers of equipment 
            Equipment              Supplier 
  
Centrifuge     Hereaus Equipment Ltd, Brentwood, Essex 
   
Eppendorf tubes (0.5&1.0)   Sarstedt Ltd, Beaument Leys, Leics 
  
Filter paper     BioRad Laboratories 
  
 Gilson pipette tips    Sarstedt Ltd, Beaument Leys, Leics 
  
Microscope slides    Merck Ltd, Lutterworth, Leics. 
  
Microwave oven    Creda Ltd, Blythe Bridge, Stoke-on- Trent 
      
Shandon Sequenza Life Sciences International (UK) Ltd, Hants 
        
 Universal tubes    Sterilin Ltd, Hounslow, Middlesex 
   
 Silicon tips     Sigma 
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 Appendix 3 (IHC) 
 
 Preparation of solutions  
 
          Solution      Method  
 
Acid  Alcohol      Make up a 70% methanol solution 
       Using distilled water.     Add   1% 
          Hydrochloric acid to this solution 
and 
       store at room temperature 
 
Citrate buffer (0.01) Dissolve 10.5g citric acid powder in  
5 L distilled water. Adjust pH to 6.0 
       with HCL 
 
DAB (0.05%) Dissolve 10 g DAB in 100mL TBS.  
(3- diaminobenzidinetetra- Measure out  2 ml aliquots and store  
Hydrochloride)                                     at –20C. When required, take 2ml 
        aliquot and dissolve in 400ml TBS 
  
Ethanol solutions (300ml)    100% = 300ml ethanol 
        90%=270 ml ethanol + 30ml water 
        70%= 210ml ethanol + 90ml water 
  
Hydrogen peroxide solution (3%)   30ml of 30% hydrogen peroxide 
  were added to 300ml of distilled 
water.     
  
Scotts' Tap Water Dissolve 20.0 g magnesium sulphate, 
and 3.5 g sodium hydrogen 
carbonate 
        in 1 litre of tap water.  Add one  
crystal of thymol (preservative) and 
store at 4ºC  
 
 Bovine serum albumin    1g BSA in 20mLs TBS 
 
 Tris- Hcl 50mM, pH 7.6 (TBS)   Dissolve 40.85 g sodium chloride 
and 30.3 g Tris in 1 Litre of distilled 
water.  Make up to 5L with distilled  
        water. Adjust pH to 7.6 with HCL. 
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Appendix 4 Materials  (Mutation analysis) 
PCR reagents        Supplier 
10x PCR buffer II        Perkin Elmer 
100 mM deoxynucleotides (dNTP’s)      Pharmacia 
25mM Magnesium Chloride       Perkin Elmer 
Sterile filtered distilled water       Sigma 
Amplitaq Gold (5µ/ µL)       Perkin Elmer 
Taq polymerase           Supertaq, HT        
Primers         Oswel 
Agarose gel Electrophoresis  
Nusieve 3:1 Agarose        Flowgen 
10x TAE buffer:         
1210g Tris base         Sigma 
 500ml of 0.5M EDTA (ph 8.0)      Clatterbridge  (UK) 
285.5ml glacial acetic acid       Fisons 
214.5 ml distilled water       Sigma 
Gel loading buffer  (w/v) bromophenol blue, 30% (v/v) glycerol 
Vistra green         Amersham 
Ethidium Bromide (0.5µg/ml)      Sigma 
Marker VI and IX (0.5 – 1.0 µg)      Boehringer  
Purification 
QIAquick PCR purification kit      Qiagen 
QIAquick 96 purification kit      Qiagen 
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Appendix 5 Classification of pancreatic intraepithelial neoplasia 
The normal duct and ductular epithelium is a cuboidal to low-columnar epithelium with 
amphophilic cytoplasm.  Mucinous cytoplasm, nuclear crowding, and atypia are not seen. 
 
Squamous (transitional) metaplasia 
A process in which the normal cuboidal ductal epithelium is replaced by mature stratified 
squamous or pseudostratified transitional epithelium without atypia. 
 
PanIN-1A (pancreatic intraepithelial neoplasia 1-A) 
These are flat epithelial lesions composed of tall columnar cells with basally located nuclei and 
abundant supranuclear mucin.  The nuclei are small and round to oval in shape.  When oval, the 
nuclei are oriented perpendicular to the basement membrane.  It is recognised that there may be 
considerable histologic  overlap between non-neoplastic flat hyperplastic lesions and flat 
neoplastic lesions without atypia.  Therefore, some may choose to designate these entities with 
the modifier term “lesion” (PanIN/L-1A) to acknowledge that the neoplastic nature of many 
cases of PanIN-1A has not been unambiguously established.  
 
PanIN-1-B (pancreatic intraepithelial neoplasia 1-B) 
These epithelial lesions have a papillary, micropapillary, or basally pseudostratified architecture 
but are otherwise identical to PanIN-1A. 
 
PanIN-2 (pancreatic intraepithelial neoplasia 2) 
Architecturally these mucinous epithelial lesions may be flat but are mostly papillary.  
Cytologically, by definition, these lesions must have some nuclear abnormalities.  These 
abnormalities may include some loss of polarity, nuclear crowding, enlarged nuclei, pseudo-
stratification and hyperchromatism.  These nuclear abnormalities fall short of those seen in 
PanIN-3.  Mitoses are rare, but when present are nonluminal (not apical) and are not atypical.  
True cribriform structures with luminal necrosis and marked cytologic abnormalities are 
generally not seen and, when present, should suggest the diagnosis of PanIN-3.  
 
 
PanIN-3 (pancreatic intraepithelial neoplasia 3) 
Architecturally, these lesions are usually papillary or micropapillary; however, they may rarely 
be flat.  True cribriforming, the appearance of “budding off” of small clusters of epithelial cells 
into the lumen, and luminal necrosis should all suggest the diagnosis of PanIN-3.  Cytologically, 
these lesions are characterised by a loss of nuclear polarity, dystrophic goblet cells (goblet cells 
with nuclei oriented toward the lumen and mucinous cytoplasm oriented toward the basement 
membrane), mitoses that may occasionally be abnormal, nuclear irregularities, and prominent 
(macro) nucleoli.  The lesions resemble carcinoma at the cytonuclear level, but invasion through 
the basement membrane is absent.  
 
Adapted from R.H Hruban et al (2001) Am J Surg Pathol. 25(5), 2001. 
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Appendix 6   PTNM pathological classification 
The pT, pN and pM categories correspond to the T, N and M categories.  pN0 Histological 
examination of the regional lymphadenectomy specimen will ordinarily include 10 or more 
lymph nodes 
1 = peripancreatic tissues include the surrounding retroperitoneal fat (retro peritoneal soft    
tissue or retro peritoneal space), including mesentery (mesenteric fat), mesoclon, greater and 
lesser omentum and peritoneum.  Direct invasion to bile ducts and duodenum includes 
involvement of ampulla of Vater. 
2 = adjacent large vessels are the portal vein, celiac artery, and superior mesenteric and 
common hepatic arteries and veins (not splenic vessels) 
 
The classification system applies only to carcinomas of the exocrine pancreas.  There should be 
histological or cytological confirmation of the disease.  The following are the procedures for 
assessing T, N, and M categories: 
 
 T categories Physical examination, imaging, and/or surgical exploration 
 
 N categories Physical examination, imaging, and/or surgical exploration 
 
 M categories  Physical examination, imaging, and/or surgical exploration 
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